



1 4 February 2019  
2 EMA/CVMP/CHMP/682198/2017  
3 Committee for Medicinal Products for Veterinary use (CVMP)  
4 Committee for Medicinal Products for Human Use (CHMP)

5 **Answer to the request from the European Commission for**  
6 **updating the scientific advice on the impact on public**  
7 **health and animal health of the use of antibiotics in**  
8 **animals - Categorisation of antimicrobials**  
9 **Draft**

Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG)	29 October 2018
Adopted by the CVMP for release for consultation	24 January 2019
Adopted by the CHMP for release for consultation	31 January 2019
Start of public consultation	5 February 2019
End of consultation (deadline for comments)	30 April 2019

10

Comments should be provided using this [template](#). The completed comments form should be sent to [vet-guidelines@ema.europa.eu](mailto:vet-guidelines@ema.europa.eu)

11

Keywords	antimicrobials, antimicrobial resistance, categorisation
----------	--

12



13 Answer to the request from the European Commission for  
14 updating the scientific advice on the impact on public  
15 health and animal health of the use of antibiotics in  
16 animals - Categorisation of antimicrobials  
17

18 **Table of Contents**

19 **1. Summary assessment and recommendations ..... 3**

20 **2. Introduction ..... 6**

21 2.1. Background .....6

22 2.2. Scope of the response.....7

23 **3. Considerations for the response ..... 7**

24 3.1. Risk to public health .....7

25 3.2. Consideration of other recent work on classification of antimicrobials and pathogens ....8

26 3.2.1. WHO .....8

27 3.2.2. WHO essential substances ..... 10

28 3.2.3. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and  
29 development of new antibiotics..... 11

30 3.2.4. OIE List of Antimicrobials of Veterinary Importance ..... 12

31 3.3. Refinement of AMEG criteria ..... 13

32 3.3.1. Impact of the route of administration on antimicrobial resistance ..... 15

33 3.4. Transmission of antimicrobial-resistant bacteria or resistance determinants between  
34 animals and man ..... 17

35 3.4.1. Consideration of AM classes not taken into account in AMEG 1 advice and those given  
36 further consideration ..... 21

37 3.4.2. Mechanisms for transfer of resistance genes and resistant bacteria..... 27

38 **4. Categorisation ..... 36**

39 Risk management measures to be applied to each category ..... 37

40 4.1. Category A: "Avoid" ..... 37

41 4.2. Category B: "Restrict" ..... 38

42 4.3. Category C: "Caution" ..... 38

43 4.4. Category D: "Prudence" ..... 38

44 **5. Use of AMEG Categorisation ..... 49**

45 **Annex 1 - The WHO list in an EU perspective..... 50**

46 **Annex 2 - ATC and ATCvet codes ..... 53**

47 **Annex 3 – References..... 55**

48

49

## 50 **1. Summary assessment and recommendations**

51 The first Antimicrobial Advice *ad hoc* Expert Group (AMEG) categorisation considered the risk to public  
52 health from antimicrobial resistance (AMR) due to the use of antimicrobials in veterinary medicine. The  
53 work focussed on antimicrobials included in the World Health Organisation's (WHO) list of critically  
54 important antimicrobials<sup>1</sup> (CIAs). The categorisation was based primarily on the need for a particular  
55 antimicrobial (sub)class in human medicine, and the risk for spread of resistance from animals to  
56 humans.

57 The categorisation was published in 2014 (EMA/AMEG, 2014) wherein the AMEG proposed to classify  
58 the antimicrobials from the WHO CIA list in three different categories:

- 59 • Category 1 as antimicrobials used in veterinary medicine where the risk for public health is  
60 estimated as low or limited,
- 61 • Category 2 as antimicrobials used in veterinary medicine where the risk for public health is  
62 estimated higher and
- 63 • Category 3 as antimicrobials not approved for use in veterinary medicine.

64 The categorisation for colistin was reviewed in an updated advice published by the European Medicines  
65 Agency (EMA) in 2016 (EMA/AMEG, 2016).

66 In July 2017, the European Commission (EC) asked the EMA to update its 2014 advice regarding the  
67 categorisation of antimicrobials to take account of experience gained, in particular the reflection papers  
68 recently published by the EMA on the use of aminoglycosides and aminopenicillins in animals in the  
69 European Union, the risk of resistance development associated with their use and potential  
70 consequential impacts on human and animal health.

71 During this review, the AMEG considered additional criteria that could be taken into account for the  
72 categorisation of antimicrobials. Hence in the updated categorisation proposal, more emphasis is  
73 placed on the availability of alternative antimicrobials in veterinary medicine. In addition, the ranking  
74 has been refined with the addition of a further (fourth) category. To harmonise with other lists, the  
75 order of the categories, in terms of level of risk, has been reversed compared to the first AMEG report.  
76 Further, those antimicrobial classes which were not considered in the 2014 AMEG advice have been  
77 considered in this updated advice, and ranked according to the updated categorisation proposal.

78 A separate listing is provided which suggests routes of administration and types of formulation which,  
79 in general, are preferred in terms of their estimated impact on the selection of AMR.

80 The AMEG proposes to classify the antimicrobials in four different categories, from A to D. For  
81 communication purposes, key action words have been attributed for each category.

82 **Category A** ("Avoid") corresponds to Category 3 in the first AMEG report, and includes antimicrobial  
83 classes not currently authorised in veterinary medicine in the EU. In the absence of established  
84 maximum residue limits for foodstuff of animal origin, use of these classes of AM in food-producing  
85 animals is prohibited and they may only be administered to individual companion animals  
86 exceptionally, in compliance with the prescribing "cascade".

87 **Category B** ("Restrict") corresponds to Category 2 in the first AMEG report, including the substances  
88 listed as highest priority CIAs (HPCIA) by the WHO with the exception of macrolides and those classes

---

<sup>1</sup> For this document "antimicrobials" is defined as "active substance of synthetic or natural origin which destroys microorganisms, suppresses their growth or their ability to reproduce in animals or humans". In this context, antivirals, antiparasitics and disinfectants are excluded from the definition.

89 included in Category A. Thus, this category includes quinolones, 3<sup>rd</sup>- and 4<sup>th</sup>-generation cephalosporins  
90 and polymyxins. For these antimicrobials, the risk to public health resulting from veterinary use needs  
91 to be mitigated by specific restrictions.

92 These restricted antimicrobials should only be used for the treatment of clinical conditions when there  
93 are no alternative antimicrobials in a lower category that could be effective. Especially for this  
94 category, use should be based on the results of antimicrobial susceptibility testing, whenever possible.

95 In the first AMEG scientific advice (EMA/AMEG, 2014), aminoglycosides and the subclass of penicillins,  
96 aminopenicillins, were temporarily placed in Category 2, pending more in-depth risk profiling. The  
97 Committee for Medicinal Products for Veterinary Use (CVMP)'s reflection papers on aminoglycosides  
98 (EMA/CVMP/AWP, 2018b) and aminopenicillins (EMA/CVMP/AWP, 2018a), in draft) recognise that in  
99 accordance with the categorisation criteria in the first AMEG report, all veterinary authorised  
100 aminoglycosides and amoxicillin-clavulanate combinations would be placed in Category 2. However, as  
101 the use of these antimicrobials in veterinary medicine was considered to present a lower risk to human  
102 health compared to quinolones and 3<sup>rd</sup>- and 4<sup>th</sup>-generation cephalosporins, the CVMP recommended  
103 that a further stratification of the original AMEG categorisation should be considered. Further, it was  
104 suggested that the addition of an intermediate category would improve the utility of the categorisation  
105 as a risk management tool by avoiding the counterproductive outcome of too many antimicrobials  
106 being placed in the higher risk category.

107 **Category C** ("Caution") has been added as an intermediate category, taking account of the  
108 considerations above. This category includes individual antimicrobial classes listed in different  
109 categories by WHO, including the HPCIA macrolides. For those substances proposed for inclusion in this  
110 category, there are in general alternatives in human medicine in the EU but there are few alternatives  
111 in veterinary medicine for certain indications.

112 Antimicrobial classes that may select for resistance to a substance in Category A through specific  
113 multiresistance genes have also been placed in this category.

114 These antimicrobials should only be used when there is no substance in Category D that would be  
115 effective.

116 **Category D** ("Prudence") is the lowest risk category. While the risk to public health associated with  
117 the use in veterinary medicine of substances included in this category is considered low, a number of  
118 the substances in this category are listed as WHO CIAs (aminopenicillins, natural penicillins and  
119 isoxazolylpenicillin). It is acknowledged that these antimicrobials are not devoid of negative impact on  
120 resistance development and spread, in particular through co-selection. Therefore, while there are no  
121 specific recommendations to avoid use of Category D substances, there is a general recommendation  
122 that prudent use principles should be adhered to in everyday practice to keep the risk from use of  
123 these classes as low as possible. Unnecessary use and unnecessarily long treatment periods should be  
124 avoided and group treatment should be restricted to situations where individual treatment is not  
125 feasible.

126 The risk management measures applied to the individual AMEG categories should be seen as  
127 complementary to the provisions in the new regulation on veterinary medicines (Official Journal of the  
128 European Union, 2019) in relation to use of antimicrobials for prophylaxis, metaphylaxis and under the  
129 "cascade".

130 This categorisation does not directly translate into a treatment guideline for use of antimicrobials in  
131 veterinary medicine, but can be used as a tool by those preparing guidelines. In veterinary medicine,

132 the variety of animal species, the different routes of administration (from intramammary treatment of  
 133 individual cows to treatment of many hundreds of fish by in-feed medication) and diversity of  
 134 indications are all factors that have to be taken into account for treatment guidelines. Further, types of  
 135 production systems, the presence of different diseases and occurrence of antimicrobial resistance may  
 136 differ between regions. Therefore, treatment guidelines need to be regionally or even locally developed  
 137 and implemented. Development and implementation of evidence-based national and regional  
 138 treatment guidelines are encouraged.

139 A summary table specifying the categorisation for each class or subclass of antimicrobials is provided  
 140 below.

141 **Table 1.** Summary of the AMEG categorisation

AMEG Categories	Antimicrobial class, subclasses, substances
<b>Category A</b> ("Avoid")	<ul style="list-style-type: none"> <li>• Amidinopenicillins</li> <li>• Carbapenems and other penems</li> <li>• Cephalosporins, Other cephalosporins and penems (ATC code J01DI)</li> <li>• Glycopeptides</li> <li>• Glycylcyclines</li> <li>• Lipopeptides</li> <li>• Monobactams</li> <li>• Oxazolidinones</li> <li>• Penicillins: carboxypenicillins and ureidopenicillins combinations with <math>\beta</math>-lactamase inhibitors</li> <li>• Phosphonic acid derivates (e.g. fosfomycin)</li> <li>• Pseudomonic acid</li> <li>• Riminofenazines</li> <li>• Streptogramins</li> <li>• Sulfones</li> <li>• Drugs used solely to treat tuberculosis or other mycobacterial diseases</li> </ul>
<b>Category B</b> ("Restrict")	<ul style="list-style-type: none"> <li>• Cephalosporins, 3rd- and 4th-generation</li> <li>• Polymyxins (e.g. colistin)</li> <li>• Quinolones (fluoroquinolones and other quinolones)</li> </ul>
<b>Category C</b> ("Caution")	<ul style="list-style-type: none"> <li>• Aminoglycosides and aminocyclitol</li> <li>• Aminopenicillins in combination with <math>\beta</math>-lactamase inhibitors (e.g. amoxicillin-clavulanic acid)</li> <li>• Amphenicols (florfenicol &amp; thiamphenicol)</li> <li>• Cephalosporins, 1st- and 2nd-generation and cephamycins</li> <li>• Macrolides</li> <li>• Lincosamides</li> <li>• Pleuromutilins</li> <li>• Rifamycins</li> </ul>
<b>Category D</b> ("Prudence")	<ul style="list-style-type: none"> <li>• Aminopenicillins, without <math>\beta</math>-lactamase inhibitors</li> <li>• Cyclic polypeptides (bacitracin)</li> <li>• Nitrofuran derivatives (e.g. nitrofurantoin)*</li> <li>• Nitroimidazoles*</li> <li>• Penicillins: Anti-staphylococcal penicillins (<math>\beta</math>-lactamase-resistant penicillins)</li> </ul>

AMEG Categories	Antimicrobial class, subclasses, substances
	<ul style="list-style-type: none"> <li>• Penicillins: Natural, narrow spectrum penicillins (<math>\beta</math>-lactamase-sensitive penicillins)</li> <li>• Steroid antibacterials (fusidic acid)*</li> <li>• Sulfonamides, dihydrofolate reductase inhibitors and combinations</li> <li>• Tetracyclines</li> </ul> <p>(* Authorised for companion animals only)</p>

142

143 After this AMEG scientific advice is finally adopted in 2019, an infographic and other communication  
 144 materials for the specific purpose of publicising the categorisation will be developed by the EMA.

## 145 2. Introduction

### 146 2.1. Background

147 The European Commission (EC) requested in April 2013 a scientific advice from the European  
 148 Medicines Agency (EMA) on the impact of the use of antibiotics in animals on public health and animal  
 149 health and measures to manage the possible risk to humans.

150 The scientific advice was prepared by the Antimicrobial Advice *ad hoc* Expert Group (AMEG) and a  
 151 response to the EC request was published by the EMA in December 2014 (EMA/AMEG, 2014).

152 One of the questions requested a ranking of classes or groups of antibiotics according to the relative  
 153 importance for their use in human medicine. When the categorisation of antimicrobials (answer to  
 154 question 2) was published, the necessity of further, more in-depth risk-profiling of aminoglycosides  
 155 and aminopenicillins was highlighted. The Committee for Medicinal Products for Veterinary Use (CVMP),  
 156 with the scientific input of its Antimicrobials Working Party (AWP), is in the process of finalising its  
 157 considerations on these classes of antimicrobials.

158 Following the discovery of *mcr-1*, a horizontally transferable resistance gene identified in bacteria of  
 159 food animal origin (Liu et al., 2015), the EC requested a re-assessment of the earlier advice on the  
 160 impact of the use of colistin products in veterinary medicine on public and animal health. The updated  
 161 advice on colistin, published by the EMA in 2016, resulted in a reclassification of this substance to the  
 162 higher risk category (category 2) of the AMEG classification (EMA/AMEG, 2016).

163 In July 2017, the EC asked the EMA to update its advice published in 2014. Regarding the  
 164 categorisation of antimicrobials, the EC requested that the AMEG review the original classification and  
 165 update as necessary taking account of the following specific points:

- 166 • Categorisation of aminoglycosides and penicillins;
- 167 • Further refinements of the criteria for the categorisation (e.g. including route of administration);
- 168 • Improved communication of the categorisation;
- 169 • Consideration of additional categorisation for antimicrobials categorised by the World Health  
 170 Organisation (WHO) as highly important and important (in addition to the critically important  
 171 antimicrobials);

- 172 • Consideration of other recent work of the WHO on classification of antimicrobials and pathogens  
173 (e.g. the 20th edition of the WHO Model List of Essential Medicines and the WHO Global priority list  
174 of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics);
- 175 • Consideration of any other relevant work in this area (e.g. OIE list of antimicrobial agents of  
176 veterinary importance).

## 177 **2.2. Scope of the response**

178 The scope of the present document is limited to addressing the European Commission's request to  
179 update the 2014 advice on the categorisation of antimicrobials.

180 It should be noted that in its most recent request for advice, the EC also requested that the AMEG  
181 further elaborate on the 'early hazard characterisation' proposed in its 2014 advice as a means of  
182 assessing the risk to public health from AMR for new antimicrobials prior to submission of a marketing  
183 authorisation application. The AMEG response to this specific request is published in a separate  
184 document (EMA/682199/2017).

## 185 **3. Considerations for the response**


### 186 **3.1. Risk to public health**

187 The risk to public health from the development, emergence and spread of resistance consequent to use  
188 of antimicrobials (AMs) in veterinary medicine is dependent on multiple risk factors (Graveland et al.,  
189 2010; Persoons et al., 2011). Figure 1 summarises the chain of events that may follow from use of  
190 antimicrobials in animals resulting in a compromised antimicrobial treatment in humans.

191

192

193 **Figure 1.** The chain of events that may follow from use of antimicrobials in animals resulting in  
194 compromised antimicrobial treatment in humans



195

196 Although lists can be useful tools during risk assessments, the categorisation of AMs according to AMR  
197 has certain limits. This is mainly because co-selection between similar and also highly different classes  
198 of antimicrobials, may be present. As an example, co-selection exists between similar compounds such  
199 as amoxicillin and 3<sup>rd</sup>-generation cephalosporins (Persoons et al., 2012). Another example is  
200 tetracyclines, which facilitate spread of MRSA in livestock (Price et al., 2012). In other words,  
201 restrictions on one class alone might not have the desired impact because of co-selection of AMR.

### 202 **3.2. Consideration of other recent work on classification of antimicrobials** 203 **and pathogens**

#### 204 **3.2.1. WHO**

##### 205 **3.2.1.1. WHO list of Critically important antimicrobials**

206 Following two tripartite WHO/FAO/OIE consultations on non-human antimicrobial usage and  
207 antimicrobial resistance (WHO, 2003; WHO, 2004), WHO has published a list of critically important  
208 antimicrobial agents for human medicine (WHO, 2005; WHO, 2007; WHO, 2011; WHO, 2012; WHO,  
209 2016; WHO, 2017a).

210 The ranking identifies three categories: Critically Important Antimicrobials (CIA), Highly Important  
211 Antimicrobials (HIA) and Important Antimicrobials (IA).

212 Furthermore, a prioritisation has been performed among CIAs to identify the Highest Priority Critically  
213 Important Antimicrobials (HPCIA).

214 The HPCIA category includes quinolones, 3<sup>rd</sup> and higher generation cephalosporins, macrolides and  
215 ketolides, glycopeptides and polymyxins.

216 As noted in the 5<sup>th</sup> Revision of Critically Important Antimicrobials for Human Medicine (WHO, 2017a),  
217 these lists are intended "to be used as a reference to help formulate and prioritize risk assessment and  
218 risk management strategies for containing antimicrobial resistance mainly due to non-human use".

219 "The use of this list, in conjunction with the OIE list of antimicrobials of veterinary importance and the  
220 WHO Model Lists of Essential Medicines, will allow for prioritization of risk management strategies in  
221 the human sector, the animal sector, and in agriculture, through a coordinated One Health approach."

### 222 **3.2.1.1.1. The WHO list is built on two criteria**

223 • **Criterion 1.** The antimicrobial class is the sole, or one of limited available therapies, to treat  
224 serious bacterial infections in people.

225 • **Criterion 2.** The antimicrobial class is used to treat infections in people caused by either: (1)  
226 bacteria that may be transmitted to humans from non-human sources, or (2) bacteria that may  
227 acquire resistance genes from non-human sources.

228 If both of these criteria are fulfilled the compound or class is regarded as CIA.

229 If one of these criteria are fulfilled the compound or class is regarded as HIA.

230 If none of these criteria are fulfilled the compound or class is regarded as IA.

231 The list of CIAs and HIAs, which meet WHO Criterion 1, is presented with comments specific to the EU  
232 in the Annex (Table A1).

### 233 **3.2.1.1.2. Criteria of prioritisation among the CIA**

234 Antimicrobials within the critically important category are further prioritised by WHO.

235 The following three criteria are used for prioritisation:

236 • **Prioritization criterion 1:** *High absolute number of people, or high proportion of use in patients*  
237 *with serious infections in health care settings affected by bacterial diseases for which the*  
238 *antimicrobial class is the sole or one of few alternatives to treat serious infections in humans.*

239 • **Prioritization criterion 2:** *High frequency of use of the antimicrobial class for any indication in*  
240 *human medicine, or else high proportion of use in patients with serious infections in health care*  
241 *settings, since use may favour selection of resistance in both settings.*

242 • **Prioritization criterion 3:** *The antimicrobial class is used to treat infections in people for which*  
243 *there is evidence of transmission of resistant bacteria (e.g. non-typhoidal Salmonella and*  
244 *Campylobacter spp.) or resistance genes (high for E. coli and Enterococcus spp.) from non-human*  
245 *sources.*

246 Antimicrobial classes that meet all three prioritization criteria (1, 2, and 3) are considered the *highest*  
247 *priority critically important antimicrobials.*

248 **3.2.1.2. WHO Guidelines on use of medically- important antimicrobials in food-producing**  
249 **animals**

250 In 2017, WHO published guidelines on use of medically-important antimicrobials in food-producing  
251 animals (WHO, 2017e). These guidelines were developed by the Guideline Development Group (GDG)  
252 using the WHO guideline development process and are based on two systematic reviews using  
253 standard methods and narrative literature reviews by topic experts. The GDG used the GRADE (grading  
254 of recommendations, assessment, development and evaluation) approach to appraise and use the  
255 evidence identified to develop recommendations. The main recommendations are summarised in  
256 Figure 2.

257 **Figure 2.** Recommendations in the WHO guidelines on use of medically important antimicrobials in  
258 food-producing animals<sup>2</sup>

---

Recommendations

---

- 1 The GDG recommends an overall reduction in use of all classes of medically important antimicrobials in food-producing animals.
- 2 The GDG recommends complete restriction of use of all classes of medically important antimicrobials in food-producing animals for growth promotion.
- 3 The GDG recommends complete restriction of use of all classes of medically important antimicrobials in food-producing animals for prevention of infectious diseases that have not yet been clinically diagnosed.

*Specific considerations: when a veterinary professional judges that there is a high risk of spread of a particular infectious disease, use of antimicrobials for disease prevention is justified, if such a judgement is made on the basis of recent culture and sensitivity testing results.*

- 4 a – The GDG suggests that antimicrobials classified as critically important for human medicine should not be used for control of the dissemination of a clinically diagnosed infectious disease identified within a group of food-producing animals.  
b – The GDG suggests that antimicrobials classified as highest priority critically important for human medicine should not be used for treatment of food-producing animals with a clinically diagnosed infectious disease.

*To prevent harm to animal health and welfare, exceptions to recommendations 4a and 4b can be made when, in the judgment of veterinary professionals, bacterial culture and sensitivity results demonstrate that the selected drug is the only treatment option.*

---

259

260 **3.2.2. WHO essential substances**

261 The WHO Model Lists of Essential Medicines include medicines needed to treat common infections in  
262 humans, taking account of their clinical efficacy and safety and cost-effectiveness. Since 1977, WHO  
263 updates the lists every two years.

264 Two lists are available: the current versions are the 20<sup>th</sup> WHO Essential Medicines List (EML) and the  
265 6<sup>th</sup> WHO Essential Medicines List for Children (EMLc). Both lists were last updated in March 2017 and  
266 can be found on the WHO website (WHO, 2017b).

267 As part of the 2017 review, a new categorisation of antibacterials into three groups was proposed:

---

<sup>2</sup> <https://aricjournal.biomedcentral.com/articles/10.1186/s13756-017-0294-9>

- 268 • ACCESS – first and second choice antibiotics for the empiric treatment of most common infectious  
269 syndromes;
- 270 • WATCH – antibiotics with higher resistance potential whose use as first and second choice  
271 treatment should be limited to a small number of syndromes or patient groups; and
- 272 • RESERVE – antibiotics to be used mainly as 'last resort' treatment options.

273 The WATCH group includes the majority of the highest priority antimicrobials on the list of CIAs for  
274 Human Medicine.

275 Of the HPCIAAs only polymyxin E (colistin) and 4<sup>th</sup>-generation cephalosporins (e.g. cefipime) are placed  
276 in the Reserve Group.

### 277 **3.2.3. Global priority list of antibiotic-resistant bacteria to guide research, 278 discovery, and development of new antibiotics**

279 In 2016, WHO Member States mandated WHO to develop a global priority list of antimicrobial-resistant  
280 bacteria to guide research and development (R&D) of new and effective antibiotics. The main goal of  
281 this list is to prioritise funding and facilitate global R&D strategies.


282 The global priority list was developed by applying a multi-criteria decision analysis (MCDA) technique,  
283 which allows the evaluation of different alternatives according to multiple criteria, incorporating both  
284 expert opinion and evidence-based data in a transparent, explicit, and deliberative fashion. The list  
285 was developed in five steps: (a) selection of the antibiotic-resistant bacteria to be prioritised, (b)  
286 selection of criteria for prioritisation (all-cause mortality, healthcare and community burden,  
287 prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in hospital and  
288 community settings, treatability and current pipeline), (c) data extraction and synthesis, (d) scoring of  
289 alternatives and weighting of criteria by experts (this was done blindly, i.e. based only on the  
290 characteristics of the antibiotic-resistant bacteria, but without knowing the names of these bacteria),  
291 and (e) finalisation of the ranking.

292 WHO published a global priority list in December 2017 (Tacconelli et al., 2018; WHO, 2017d). In the  
293 list, antibiotic-resistant bacteria are ranked in three groups according to the assessed priority for R&D  
294 of new and effective antibiotics: priority 1 – critical, priority 2 – high, and priority 3 – medium (Figure  
295 3) (WHO, 2017c).

296 Third-generation cephalosporin-resistant and/or carbapenem-resistant Enterobacteriaceae and  
297 carbapenem-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa* were listed among the  
298 antibiotic-resistant bacteria for which there is a critical need for new effective antibiotics. Vancomycin-  
299 resistant *Enterococcus faecium*, methicillin-resistant *Staphylococcus aureus* (MRSA), as well as  
300 fluoroquinolone-resistant *Campylobacter* spp. and *Salmonella* spp., were listed among antimicrobial-  
301 resistant bacteria for which R&D of new effective antibiotics is of high priority.

302

303 **Figure 3.** Prioritization of pathogens to guide research and development of new antibiotics (WHO,  
 304 2017d)  
 305



306

### 307 **3.2.4. OIE List of Antimicrobials of Veterinary Importance**

308 Following two tripartite WHO/FAO/OIE consultations on non-human antimicrobial usage and  
 309 antimicrobial resistance (WHO, 2003; WHO, 2004), the OIE published a list of antimicrobial agents of  
 310 veterinary importance in 2007. This list was updated in 2013, 2015 and 2018 (OIE, 2018).

311 *The OIE list is based on a questionnaire sent to all OIE member countries*

- 312 • **Criterion 1.** Importance of the antimicrobial based on answers by OIE member countries. This  
 313 criterion was met when a majority of the respondents (more than 50%) identified the importance  
 314 of the antimicrobial class in their response to the questionnaire.

- 315 • **Criterion 2.** Treatment of serious animal diseases and availability of alternative antimicrobial  
316 agents. This criterion was met when compounds within the class were identified as essential  
317 against specific infections and there was a lack of sufficient therapeutic alternatives.

318 If both these criteria are fulfilled the compound or class is regarded as a veterinary critically important  
319 antimicrobial agent (VCIA).

320 If one of these criteria are fulfilled the compound or class is regarded as a veterinary highly important  
321 antimicrobial agent (VHIA).

322 If none of these criteria are fulfilled the compound or class is regarded as a veterinary important  
323 antimicrobial agent (VIA).

324 OIE list includes recommendations for antimicrobials that are considered as critically important for both  
325 human and animal health (fluoroquinolones, 3<sup>rd</sup>-and 4<sup>th</sup>-generation cephalosporins and colistin) (OIE,  
326 2018). These recommendations include that these antimicrobials should not be used for prevention or  
327 as a first line treatment and that their use should ideally be based on the results of bacteriological  
328 tests.

329 Antimicrobial classes / sub classes used only in human medicine are not included in the OIE List.  
330 Recognising the need to preserve the effectiveness of the antimicrobial agents in human medicine, the  
331 OIE advises that careful consideration should be given regarding their potential use (including extra-  
332 label/off-label use) / authorisation in animals.

### 333 **3.3. Refinement of AMEG criteria**

334 The first AMEG report considered only antimicrobial classes that fulfilled the WHO's criterion 1 ('the  
335 antimicrobial class is the sole, or one of limited available therapies, to treat serious bacterial infections  
336 in people'), with the EU situation being taken into account. These classes are listed in Table A1 in  
337 Annex 1 to this report. The AMEG categorisation was based on three main criteria as follows: (i) the  
338 relative importance of the antimicrobial class for human medicine according to the WHO ranking, (ii)  
339 the likelihood of transfer of resistance, and (iii) if the class was authorised for use in a veterinary  
340 medicine in the EU. For the indicated antimicrobial classes, three categories were agreed by the AMEG:

- 341 • Category 1 - antimicrobials used in veterinary medicine where the risk for public health is  
342 estimated as low or limited,  
343 • Category 2 - antimicrobials used in veterinary medicine where the risk for public health is  
344 estimated higher and  
345 • Category 3 - antimicrobials not approved for use in veterinary medicine.

346 Criteria (i) and (ii) above are used to categorise classes or sub-classes as Category 1 or Category 2  
347 antimicrobials. For Category 1 classes or subclasses of antimicrobials, prudent use is recommended.  
348 For Category 2 classes or subclasses, restrictions on use are needed. Category 3 included classes that  
349 are currently not authorised in veterinary medicines.

350 An objective of the current exercise is to review and update, as appropriate, the original AMEG  
351 categorisation (to consider additional criteria and/or refine the existing criteria). There are several  
352 reasons for undertaking this review.

353 Firstly, with regard to the aminoglycosides (AGs), the CVMP's reflection paper recognises that in  
354 accordance with the categorisation criteria in the first AMEG report, all veterinary authorised AGs  
355 would be placed in Category 2. However, their use in veterinary medicine was considered to have a

356 lower risk to human health compared with quinolones and 3<sup>rd</sup>- and 4<sup>th</sup>-generation cephalosporins.  
357 Therefore, it was suggested that a further stratification of the AMEG's categorisation should be  
358 considered. Likewise, for the aminopenicillins, the CVMP's (draft) risk profiling suggests that a further  
359 stratification would be needed to enable a distinction in the ranking between the Category 2  
360 substances and amoxicillin-clavulanate combinations, and between the latter and the straight  
361 aminopenicillins. The addition of an intermediate category is expected to improve the utility of the  
362 categorisation as a risk management tool by avoiding the counterproductive outcome of too many  
363 antimicrobials being placed in a single 'higher risk' category with no possibility for prioritisation  
364 between them and where formal restrictions are necessary.

365 In addition, further thought was given to the criterion on the likelihood of transfer of resistance. It was  
366 questioned if the scoring of the factors taken into consideration for this criterion could be integrated to  
367 provide a reliable qualitative assessment. It was also proposed that further consideration should be  
368 given to specific mechanisms of resistance/genes that might have particularly important consequences  
369 for human health. These elements are discussed in section 3.4.

370 Also, with experience gained following application of the original AMEG categorisation, it was  
371 considered that additional criteria should be taken into account. When considering the chain of events  
372 leading from antimicrobial use in veterinary medicine to consequences on public health arising from  
373 AMR, possible criteria, in addition to those used in the first AMEG report (the importance of the  
374 antimicrobial class in human medicine and the probability of AMR transfer), that could be considered to  
375 improve the categorisation of antimicrobials include:

- 376 • **Criteria relating to antimicrobial class:** Chemical properties; Pharmacological properties;  
377 Spectrum of activity (e.g. narrow versus broad; associated hazards); Mechanisms of resistance  
378 (e.g. location) / co / cross resistance.
- 379 • **Criteria relating to conditions of use:** Animal species; indications (e.g. treatment versus  
380 prophylaxis or metaphylaxis); dose and duration; route of administration (e.g. different category  
381 for different route of administration); impact on gastrointestinal tract (lumen concentration,  
382 shedding of resistant bacteria/resistance genes etc.; importance of the antimicrobials in veterinary  
383 medicine (e.g. OIE list); availability of antimicrobial alternatives in veterinary medicine.
- 384 • **Criteria relating to prevalence of resistance:** Pathogens, commensals, zoonoses, frequency of  
385 resistance, transfer of resistance or mutations.
- 386 • **Criteria relating to environmental aspects:** Degradability of antimicrobials in animals and  
387 animal waste, persistence of antimicrobial resistance genes and antimicrobial resistant bacteria in  
388 manure or slurry, evidence of environmental transfer.

389 After considering the different potential criteria listed above, the following two were selected for more  
390 detailed consideration:

- 391 • **Route of administration:** According to the mandate the AMEG agreed to further consider the  
392 route of administration as a criterion to refine the categorisation. As the largest reservoir of AMR  
393 following the administration of an antimicrobial results from the exposure of the gut flora, the  
394 route of administration is discussed extensively in Chapter 3.3.1 of this report.
- 395 • **Indications for veterinary use and availability of alternative antimicrobials of lesser risk:**  
396 The impact on animal health may be considered as part of the approach to categorisation.

397 Consideration of the risk to public health has to be balanced with the importance of the substance  
398 for animal health. The importance of the substance for animal health is determined to a great  
399 extent by the availability of alternative treatment options for given indications in given species.

400 From the perspective of protecting human health, the greater the availability of alternative  
401 treatment options for veterinary indications, the more restrictions on veterinary use for a given AM  
402 can be tolerated without an adverse impact on animal health. Conversely, for those veterinary  
403 indications where the availability of alternative treatment options is limited, restriction on  
404 veterinary use for a given AM has the potential to impact negatively on animal health. This is  
405 notwithstanding the fact that proportionate restrictions should be placed on the use of such classes  
406 also for the management of the AMR risk to animal health. In addition it should be considered that  
407 that restriction of one antimicrobial class could lead to an increase in use of other restricted classes  
408 authorised for the same indications.

409 The objective, therefore, is to consider the importance and availability of antimicrobial alternatives  
410 in veterinary medicine, and to identify if antimicrobials of lower risk to both public and animal  
411 health are available for the same indication.

412 Applying this criterion to the categorisation of individual AM (sub)classes relied on expert  
413 judgement of AMEG members using information available in the form of the OIE list and the  
414 reflection papers on various antimicrobial classes published by the CVMP/SAGAM/AWP.

### 415 **3.3.1. Impact of the route of administration on antimicrobial resistance**

416 There are different factors directly related to the administration of an antimicrobial that affect the  
417 occurrence of AMR. These include: the type and formulation of the antimicrobial agent; the dose; the  
418 total animal biomass exposed to the antimicrobial (i.e. individual treatment versus mass medication);  
419 the treatment interval and the treatment duration. The formulation determines the route of  
420 administration but relatively little attention has been given to the association between the antimicrobial  
421 formulation and the rise of multidrug-resistant (MDR) organisms.

422 Across the EU as a whole, approximately 90% of all antimicrobials prescribed to livestock are given *via*  
423 the oral route (EMA/EFSA, 2017; EMA/ESVAC, 2017; Filippitzi et al., 2014; Timmerman et al., 2006).  
424 Administration of antimicrobial agents through either bulk animal feed or the drinking water supply,  
425 rather than by injection, has major economic and ergonomic advantages. In addition, potential  
426 unwanted effects of injection such as carcass damage or residues at an injection site are avoided. In  
427 some situations (e.g. commercial chicken production, aquaculture) oral administration to the whole  
428 group of animals is almost always the only feasible option. Furthermore, the withdrawal time (the  
429 minimum period between the last administration of a veterinary medicinal product to an animal and  
430 the production of foodstuffs from that animal which under normal conditions of use is necessary to  
431 ensure that such foodstuffs do not contain residues in quantities harmful to public health) is in general  
432 longer for VMPs administered by injection compared to VMPs administered orally.

433 However, for orally administered antimicrobials there are several opportunities for incorrect intake of  
434 dose and for the antimicrobial to present an AMR selection pressure before the agent reaches the  
435 target tissue at a concentration able to inhibit or kill the microorganism involved in an infection.

436 For in-feed medication, adequate mixing and homogenous distribution of the AM relies on the particle  
437 size and electrostatic properties of the premix, as well as the final composition of the feed and the  
438 mixing equipment used (Peeters, 2018). Further, the same equipment may also be used for the

439 production, storage and/or transport of both medicated and unmedicated feed, with the potential  
440 carry-over of antimicrobial residues (Filippitzi et al., 2016). Oral administration *via* drinking water can  
441 be more precisely dosed compared to medication administered in food (Filippitzi, 2018). Although for  
442 medication delivered via this route or in milk, the final concentration can still be highly variable and  
443 may be further influenced by factors such as water hardness, pH, temperature, light (Luthman and  
444 Jacobsson, 1983) and complex formation (with e.g. Ca<sup>++</sup> in the milk replacer diet). It may, therefore,  
445 be difficult to control dosing so that it is consistent with the Summary of Product Characteristics (SPC)  
446 of the VMP.

447 Other factors contributing to variable intake of oral group medications include a relatively poor control  
448 over intake due to hierarchy in the flock/group, a lower intake by diseased animals, uncertain duration  
449 of therapy and potential for cross contamination of feed.

450 Of utmost importance with respect to the selection and containment of resistance is that oral  
451 antimicrobials may induce changes in the digestive tract microbiota, starting from the oropharynx and  
452 ending in the faeces, and by consequence in the environment. This is well documented for different  
453 antimicrobial agents in animals and humans (Crémieux et al., 2003; Sørum and Sunde, 2001).

454 The difference between oral and injectable formulations concerning the selection and spread of AMR in  
455 the faecal flora alone is shown to be extremely high. e.g. in a randomised controlled study in rodents  
456 the increase in the number of resistant coliforms in the group treated orally with ampicillin was 10,000  
457 fold higher than in the group treated intravenously. The impact of oral versus intravenous  
458 administration of tetracycline on the carriage of resistant enterococci was over a 100 fold and it was  
459 suggested that this lower but significant difference may in part be due to biliary excretion of  
460 tetracycline. (Zhang et al., 2013). Similar findings demonstrating substantial benefits of injectables  
461 over oral administration in relation to development of antimicrobial resistance in the digestive tract  
462 have been published in controlled studies in other animal species (Bibbal et al., 2007; Chantziaras et  
463 al., 2017; Checkley et al., 2010; Wiuff et al., 2003). On a larger scale, microbiome studies have shown  
464 oral antimicrobials to have detrimental and persistent effects on the gut (Zaura et al., 2015). For this  
465 reason, and also due to high livestock densities that facilitate rapid exchange of multi-resistance within  
466 and between production cycles (Heuer et al., 2002), the routine use of oral (group) medication has  
467 been questioned (Catry, 2017).

468 Further considerations relevant for the selection pressure in the digestive tract, such as accompanying  
469 diet, absorption, reabsorption, passage rate, biodegradation and the luminal volume have recently  
470 been reviewed (Volkova et al., 2017).

471 Selection of AMR may also be pronounced after injection (Wiuff et al., 2003) given that certain  
472 antimicrobials administered parenterally can be actively excreted in the gut, *via* bile, where a similar  
473 selection pressure for AMR can be expected. Further research is needed into the impact on the  
474 selection of AMR in gastrointestinal microbiota by newer antimicrobial substances with long half-lives  
475 that are administered as a single injection (e.g. certain macrolides) (Zaheer et al., 2013). Rectal or  
476 sublingual administration to bypass the first pass effect (Steinman et al., 2000) and thereby also the  
477 selection pressure in the vast majority of the digestive tract without certain disadvantages of  
478 injectables, seems attractive from a research and development point of view.

479 The "Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal  
480 husbandry in the European Union, and the resulting impacts on food safety" (RONAFA report) stated  
481 that oral administration of antimicrobials in livestock is of particular concern in terms of promoting the  
482 development of AMR due to the high exposure of gastrointestinal commensal bacteria, and the

483 sometimes prolonged duration of treatment or exposure, especially for products administered in feed  
484 (EMA/EFSA, 2017). The purely preventative use of oral group treatments without clinical signs present  
485 (prophylaxis) should therefore be actively discouraged. Unjustified metaphylaxis is also of major  
486 concern. These issues are directly addressed in the new veterinary medicines regulation (Official  
487 Journal of the European Union, 2019).

488 The general consensus guidance to optimise antimicrobial drug use in both human and veterinary  
489 medicine is to give an appropriate dose for a minimum period of time (Thomas et al., 1998; Zhao and  
490 Drlica, 2001). In order to limit exposure of the microbiome, the antimicrobial selection pressure should  
491 be as local and short as possible, in line with current PK/PD strategies (Lees et al., 2018). The duration  
492 of therapy must be as short as possible but without jeopardising clinical recovery. It has been  
493 suggested that this may be achieved in practice by continuing therapy up until two days after  
494 symptoms have resolved (Chardin et al., 2009).

495 A suggested listing of routes of administration and formulations, ranked in order from those with in  
496 general lower effect on the selection of AMR to those that would be expected to have higher impact on  
497 resistance, is proposed as follows:

- 498 • Local individual treatment (e.g. udder injector, eye or ear drops);
- 499 • Parenteral individual treatment (intravenously, intramuscularly, subcutaneously);
- 500 • Oral individual treatment (tablets, oral bolus);
- 501 • Injectable group medication (metaphylaxis), only if appropriately justified;
- 502 • Oral group medication via drinking water/milk replacer (metaphylaxis), only if appropriately  
503 justified.
- 504 • Oral medication *via* feed/premixes or top dressing (EMA/EFSA, 2017) (metaphylaxis), only if  
505 appropriately justified.

506 This subchapter is based on a simple review of literature. The conclusions drawn and proposed order of  
507 ranking should be confirmed by a systematic review followed by a meta-analysis in which clinical  
508 efficacy and microbiological impacts should be studied as outcomes.

509 Given that antimicrobials in each (sub)class are available in a number of different formulations and for  
510 administration by different routes, the AMEG chose not to include the route of administration as an  
511 additional criterion for the categorisation. It was the view of the group that to consider the relative  
512 AMR risk for all the different formulation/antimicrobial class combinations within the categorisation  
513 would be highly complex and difficult to evidence. Nevertheless, when factoring AMR risk into  
514 prescribing decisions, the aim should be to use the list above together with the AMEG categorisation to  
515 select both the formulation/route of administration and class that will have the least impact on the  
516 selection of AMR.

### 517 **3.4. Transmission of antimicrobial-resistant bacteria or resistance** 518 **determinants between animals and man**

519 The likelihood of spread of AMR between animals and humans depends on a number of factors that  
520 influence either the spread of organisms exhibiting such resistance or the spread of resistance genes.  
521 Four different criteria defining the risk for spread are discussed below. The resistance to a particular  
522 substance/class has highest risk for spread if all four criteria are fulfilled.

523 The likelihood of spread varies over time and depends on the “bug-drug” combination. The level of  
524 detection also depends on the sampling frame, origin of samples and the methods used for sampling,  
525 for culture and for susceptibility testing. Whether the criteria are fulfilled for a certain substance or  
526 class may therefore need to be modified over time if new data become available from studies  
527 conducted under different conditions, or in the event that the relevant resistance mechanisms of the  
528 bacteria under investigation are proven to have evolved and reorganised.

529 Exposure to antimicrobials amplifies resistance (Levy, 2002; MacKenzie et al., 2007). In general, when  
530 there is a decrease in the exposure of animals to antimicrobials a decrease in resistance is observed  
531 (Hanon et al., 2015). The same considerations are applicable to antimicrobial usage in human  
532 medicine. Nevertheless resistance can persist in the absence of antimicrobial use (Enne et al., 2001).  
533 If this is the case (or in cases of co-resistance), reduction of consumption of a certain substance, in  
534 both veterinary and human medicine, will not necessarily lead to consequent reduction in AMR.

535 It should also be realised that although the transmission of AMR from animals to humans is  
536 undoubtedly highly important and is of particular relevance to this document, spread of AMR from  
537 humans to animals can also occur as a consequence of antimicrobial usage in human medicine  
538 (ECDC/EFSA/EMA, 2017). Examples of such transfer have been documented in relation to the  
539 appearance of decreased susceptibility to carbapenems in *Salmonella* spp., and *E. coli* in pigs and  
540 poultry in Germany (Fernández et al., 2018; Fischer et al., 2017). Similarly epidemiological evidence  
541 as well as whole genome sequencing of LA-MRSA from pigs and associated human cases in  
542 Norway clearly indicates that primary introduction to sow farms occurred through human-to-animal  
543 transmission (Grøntvedt et al., 2016). Studies have also documented transfer of MRSA from farmers to  
544 dairy cows in Sweden (Unnerstad et al., 2018).

545 Several highly successful clones of MDR bacteria that have spread EU-wide and in some cases  
546 worldwide in recent years include *E. coli* ST131 (Mathers et al., 2015), monophasic *Salmonella*  
547 Typhimurium (García et al., 2017; Hopkins et al., 2010a) and LA-MRSA (Kinross et al., 2017). Of these  
548 *E. coli* ST131 is an almost strictly human pathogen and its spread has been for the most part in the  
549 human population (Mathers et al., 2015), whereas monophasic *S. Typhimurium* and LA-MRSA are  
550 zoonotic pathogens and their spread may have been facilitated by the use of antimicrobials in food  
551 animals (EFSA, 2010; Grøntvedt et al., 2016).

552 Aspects of evolution and organisation of the resistance mechanisms are presented below according to  
553 four criteria to describe the likelihood of spread:

- 554 1) The presence of a chromosomal mutation contributing to the development of resistance to a  
555 clinically-relevant antimicrobial. Such mutations may occur randomly, and may give rise to  
556 both high level or low level resistance e.g. mutational resistance to fluoroquinolones in  
557 *Campylobacter* spp. (high level) or *Salmonella* spp. (low level). Alternatively, a series of  
558 stepwise mutations may be required before resistance reaches a level regarded as of  
559 therapeutic importance. Stability of the mutation(s) in the chromosome is also required for a  
560 critical level of spread of organisms exhibiting such resistance, whereby mutational resistance  
561 passes from the parent to the daughter bacterial colonies (clonal spread). A single mutational  
562 event giving rise to resistance to a particular antimicrobial might result in resistance to several  
563 substances within related classes of antimicrobial agents.
- 564 2) Organisation of non-chromosomal resistance genes into horizontally-transferable elements  
565 (Carattoli, 2009), enabling localisation on DNA outside the bacterial chromosome (e.g.  
566 conjugative or mobilisable plasmids, transposons, integron-gene cassettes). The likelihood of  
567 further spread is variable, dependent on the plasmid, the presence or absence of genes

568 mediating plasmid transfer, the presence of unrelated transferable plasmids which can mediate  
569 the transfer of plasmids without the necessary transfer-related genes by mobilisation, and  
570 whether horizontal plasmid/gene transfer is limited to one type of organism or if it crosses  
571 borders between related or distinct bacterial species.

- 572 3) Other factors such as: (a) the incorporation of plasmid- or transposon/integron-mediated  
573 resistance into the bacterial chromosome in discrete 'resistance islands', which may require  
574 mobilisation by other plasmids or by bacteriophages for horizontal transfer either within or  
575 between bacterial species; (b) presence of plasmid addiction systems. Such systems involve  
576 plasmid-mediated genes encoding toxin-antitoxin proteins where they serve to stabilise the  
577 plasmid within a bacterial population and, in the case of plasmids which code for resistance to  
578 a range of antimicrobials, lessen their chances of loss when antibiotic selection pressure is  
579 withdrawn. Such systems are becoming increasingly identified in plasmids belonging to a wide  
580 range of incompatibility groups, and have an important role in the maintenance of such  
581 plasmids in host bacteria.
- 582 4) The presence of a cluster of resistance genes will enable more efficient spread by co-selection.  
583 This process allows resistance spread for substance A when the unrelated substance B is used,  
584 because of linkage of resistance genes and subsequent co-transfer.

585 In the first AMEG report, for each antimicrobial class, influencing factors including those above were  
586 assigned a numerical score and crudely integrated to give a qualitative estimate of the overall  
587 probability of resistance transfer. For this updated report, the AMEG agreed that these values (see  
588 3.4.2 for explanation), although individually informative for each factor, are not 'mathematically  
589 scaled' and that there is no validation that they can be combined to predict the probability of  
590 resistance transfer. The qualitative assessment (high, medium, low) based on this information has  
591 therefore been removed from the tables in this updated advice. While the AMEG agreed that a  
592 qualitative estimate of the overall probability of resistance transfer should not be incorporated into the  
593 approach to categorisation of individual AM (sub)classes, the AMEG was of the view that account  
594 should be taken of specific resistance genes associated with certain classes where transmission of  
595 these specific resistance genes could have important consequences for human health (that is, where  
596 these are mobile and confer multi-resistance to antimicrobials that are 'last resort' or used solely in  
597 human medicine). Resistance mechanisms are documented in Table 2 and where particularly relevant  
598 for the final categorisation they are discussed in the 'rationale' column for each class in Table 4.

599 It was agreed that the criterion should be amended as follows: *The Knowledge of factors influencing*  
600 *the likelihood and possible consequences of AMR transfer from animals to humans. In the new*  
601 *categorisation individual mechanisms of resistance have been considered more specifically for e.g.*  
602 *those genes associated with mobile multiresistance.*

603 In addition to the factors listed above, that for the most part relate only to genetic mechanisms, there  
604 are many other factors that may affect the probability of transfer of resistant bacteria or its  
605 determinants from animals to humans which reflect the conditions of use of the antimicrobial  
606 substance, e.g. dosing route and regimen, volume of usage, animal husbandry conditions. These must  
607 be taken into consideration for a full public health risk assessment (Codex Alimentarius, 2009; Codex  
608 Alimentarius, 2011).

609 For bacteria that may be foodborne there are a number of additional factors to consider such as  
610 consumption habits, environmental factors and the processes between slaughter and intake of food  
611 (Codex Alimentarius, 2009; Codex Alimentarius, 2011).

612 Tables 2 and 3 below list the classes/substances under assessment, adding information on the  
613 bacterial hazards of zoonotic potential and the various resistance mechanisms.  
614

615 **3.4.1. Consideration of AM classes not taken into account in AMEG 1 advice<sup>†</sup> and those given further consideration<sup>§</sup>**

616 Several antimicrobial classes were not considered in the first advice from AMEG or have been given further consideration for this updated advice to provide a  
 617 complete categorisation of antimicrobials. For the additional antimicrobial classes, the hazard of potential zoonotic relevance as well as an overview of  
 618 indications in human medicine and resistance mechanisms are provided in Table 2.

619 **Table 2.** Overview of indications in human medicine and relevant mechanisms of resistance for antimicrobials not covered by AMEG 1 advice (for details and  
 620 references see Table 3)

Antimicrobial class**	Hazard of potential zoonotic relevance	Overview of indications in human medicine and resistance mechanisms
Amidinopenicillins	Enterobacteriaceae	<ul style="list-style-type: none"> <li>• Narrow spectrum of activity.</li> <li>• One of the first choices for uncomplicated urinary tract infections (UTI).</li> <li>• Important antimicrobials and should be preserved, since effectiveness of other oral antibiotics is declining.</li> <li>• Only mutational resistance described.</li> <li>• No description of successful clones of relevance to animals.</li> </ul>
Aminoglycosides	Enterobacteriaceae <i>Enterococcus</i> spp.	<ul style="list-style-type: none"> <li>• Important antimicrobials used alone, or in conjunction with other antimicrobials for the treatment of serious Gram-negative infections.</li> <li>• Can also be used in combination for Gram-positive infections (<i>S. aureus</i>, streptococci and enterococci), such as endocarditis.</li> <li>• Also used as part of first-line therapeutic regimens for infections with multidrug-resistant <i>Mycobacterium tuberculosis</i> and as part of treatment combinations for non-tuberculous mycobacteria.</li> <li>• Three main mechanisms of resistance are:               <ul style="list-style-type: none"> <li>• reduction of the intracellular concentration of the antimicrobial;</li> <li>• enzymatic modification of the drug;</li> </ul> </li> </ul>

<sup>†</sup> For substances considered in the first AMEG report, Table 2 of that report (reproduced here in Annex 1, Table A1) includes information on indications in human medicine and the hazards of potential zoonotic relevance.

<sup>§</sup> Aminoglycosides and Aminopenicillins have been included in the table as further consideration of their categorization was requested by the EC in its 2017 mandate. The information on Polymyxins has been updated in view of the AMEG's revised advice, 2016. Expanded information has been provided on Macrolides.

\*\* Examples of ATC and ATCvet codes for the antimicrobial groups, subgroups and substances are provided in Annex A2, Table A2.

Antimicrobial class**	Hazard of potential zoonotic relevance	Overview of indications in human medicine and resistance mechanisms
		<ul style="list-style-type: none"> <li>• modification of the molecular target.</li> <li>• Resistance genes often located on mobile elements thereby facilitating spread between different bacterial species and between animals and humans.</li> <li>• Same resistance genes found in isolates from humans and animals.</li> </ul>
Aminopenicillins	<i>Enterococcus</i> spp. Enterobacteriaceae	<ul style="list-style-type: none"> <li>• Aminopenicillins and their inhibitor combinations are one of the limited therapeutic options for infections caused by <i>Listeria monocytogenes</i> and <i>Enterococcus</i> spp.</li> <li>• Among the most commonly used antimicrobials in the EU for the treatment of various infections, e.g. respiratory tract, abdominal, soft tissue and urinary tract infections.</li> <li>• Main mechanisms of bacterial resistance to aminopenicillins are: <ul style="list-style-type: none"> <li>• alterations in penicillin-binding proteins (PBP) mediated by the <i>mec</i> genes ;</li> <li>• hydrolysis by <math>\beta</math>-lactamases.</li> <li>• presence of efflux pumps/ alterations in expression of outer membrane proteins.</li> </ul> </li> <li>• Use can create selection pressure leading to emergence of resistance and possible transmission of drug-resistant bacteria or resistance genes from non-human sources to humans.</li> </ul>
Amphenicols	Enterobacteriaceae Staphylococci <i>Salmonella</i> spp. <i>Campylobacter</i> spp.	<ul style="list-style-type: none"> <li>• Chloramphenicol second line antimicrobial.</li> <li>• Broad spectrum including both Gram-positive and Gram-negative bacteria.</li> <li>• Antimicrobial which is mainly used in low and middle income countries for treatment of typhoid.</li> <li>• Chromosomal mutations as well as horizontal gene transfer.</li> <li>• Predominant mechanism of resistance enzymatic inactivation (<i>cat</i>).</li> <li>• Resistance can also be due to exporter genes (<i>cmIA</i>, <i>fexA</i>, <i>fexB</i>, and <i>floR</i>), as well as the MDR ene <i>cf</i>r that confers resistance to phenicols as well as lincosamides, oxazolidinones, pleuromutilins, and streptogramin A.</li> <li>• ABC transporter gene, <i>optrA</i>, confers resistance to phenicols and oxazolidinones, in <i>Enterococcus</i> and <i>Staphylococcus</i> spp.</li> <li>• Both <i>cf</i>r and <i>optrA</i> confer transferable resistance to linezolid.</li> <li>• <i>optrA</i> also confers resistance to tedizolid.</li> </ul>
Cephalosporins, 1 <sup>st</sup> - and 2 <sup>nd</sup> -	Enterobacteriaceae	<ul style="list-style-type: none"> <li>• 1<sup>st</sup>-generation cephalosporins have good activity against Gram-positive bacteria, e.g.</li> </ul>

Antimicrobial class**	Hazard of potential zoonotic relevance	Overview of indications in human medicine and resistance mechanisms
generation, and cephamycins	MSSA (Methicillin-susceptible <i>Staphylococcus aureus</i> )	<p>for treatment of MSSA and streptococci.</p> <ul style="list-style-type: none"> <li>• Modest activity against Gram-negative bacteria.</li> <li>• Use in humans include skin and soft tissue infections, streptococcal pharyngitis, bacteraemia, endocarditis and others.</li> <li>• 2<sup>nd</sup> - generation cephalosporins have less activity against Gram-positive bacteria and more towards Gram-negative bacteria.</li> <li>• Cephamycins have also anaerobic activity.</li> <li>• 1<sup>st</sup>- and 2<sup>nd</sup>-generation cephalosporins recommended and most used antibiotics for surgical prophylaxis.</li> <li>• Resistance mainly due to <math>\beta</math>-lactamases (ESBLs and AmpC) and decreased ability to bind to penicillin-binding proteins (PBPs) (e.g <i>mecA</i>).</li> <li>• ESBL genes often located on plasmids.</li> <li>• <i>ampC</i> genes commonly located on the chromosome but may also be found on plasmids.</li> <li>• Some of these <i>ampC</i> genes are expressed inducibly; others constitutively.</li> <li>• Cephamycins (cefoxitin and cefotetan) not hydrolyzed by majority of ESBLs but by AmpC-type <math>\beta</math>-lactamases.</li> </ul>
Cyclic polypeptides (bacitracin)	N/A	<ul style="list-style-type: none"> <li>• Bacitracin mostly used topically for superficial skin infections caused by Gram-positive bacteria.</li> <li>• Four bacitracin resistance mechanisms: a) <i>bacA</i> gene, renamed to <i>uppP</i>, in <i>S. aureus</i>, <i>S. pneumoniae</i>, <i>E. faecalis</i>, b) <i>bcrABC</i> genes, c) overproduction of undecaprenol kinase, d) mutations inhibiting synthesis of exopolysaccharides.</li> <li>• <i>bcrABD</i> operon located on plasmids in <i>C. perfringens</i> and <i>E. faecalis</i> as part of a MDR encoding conjugative plasmid associated with high-level resistance to bacitracin in <i>E. faecalis</i> in chickens.</li> <li>• <i>E. faecalis</i> isolates in humans and chickens shown to have homology and thus point to zoonotic potential.</li> </ul>
Macrolides	<i>Campylobacter</i> spp., <i>Staphylococcus aureus</i>	<ul style="list-style-type: none"> <li>• In humans, macrolides are used to treat atypical community-acquired pneumonia, <i>H. pylori</i> infection (as part of triple combination therapy), <i>Chlamydia</i> infections, acute non-specific urethritis, shigellosis, salmonellosis, campylobacteriosis, and pertussis. Macrolides are also a useful alternative for treatment in patients allergic to penicillins and cephalosporins.</li> <li>• Mechanisms of resistance include modification of the target, drug inactivation and drug</li> </ul>

Antimicrobial class **	Hazard of potential zoonotic relevance	Overview of indications in human medicine and resistance mechanisms
		<p>efflux. Resistance conferred by chromosomal mutations as well as horizontal transfer of resistance genes (<i>erm</i>, <i>vga</i>, <i>Inu</i>, <i>lmr</i>, <i>cfr</i>).</p> <ul style="list-style-type: none"> <li>The most common resistance mechanism is a target site modification mediated by at least 32 different rRNA methylases (<i>erm</i> genes) described in 34 bacterial genera, which reduces the binding of the macrolides, lincosamides and streptogramin B to the ribosomal target site.</li> <li>Many of the <i>erm</i> genes have been identified in Gram-positive, Gram-negatives and anaerobic bacteria and can be horizontally transferred (associated with conjugative or non-conjugative transposons, which tend to reside on the chromosomes). Macrolide-resistant <i>Campylobacter</i> spp. can be transmitted from animals to humans via food of animal origin.</li> </ul>
Lincosamides	MRSA (Methicillin-resistant <i>Staphylococcus aureus</i> )	<ul style="list-style-type: none"> <li>In humans, lincosamides (clindamycin) used to treat infections caused by anaerobic and Gram-positive bacteria, e.g. staphylococci (including MSSA, MRSA and coagulase-negative staphylococci) and streptococci.</li> <li>Mechanisms of resistance include modification of the target, drug inactivation and drug efflux.</li> <li>Resistance conferred by chromosomal mutations as well as horizontal transfer of resistance genes (<i>erm</i>, <i>vga</i>, <i>Inu</i>, <i>lmr</i>, <i>cfr</i>).</li> <li>Most common resistance mechanism is target site modification mediated by <i>erm</i> genes described in numerous bacterial genera, which are frequently associated with mobile genetic elements, e.g. transposons and can be horizontally transferred.</li> <li>Homology between animal and human isolates demonstrated.</li> <li>MDR <i>cfr</i> confers resistance not only to lincosamides but also to phenicols, streptogramin A, pleuromutilins and oxazolidinones.</li> </ul>
Nitrofurantoin derivatives (e.g. nitrofurantoin)	N/A	<ul style="list-style-type: none"> <li>Nitrofurantoin is one of the first choices of antimicrobials for treating uncomplicated UTI in women, including treatment of UTIs with ESBL-producing Enterobacteriaceae.</li> <li>Resistance either via chromosomal mutations and also plasmid-mediated via efflux genes, e.g. <i>oqxA/B</i>, which confer MDR, including to nitrofurantoin.</li> </ul>
Nitroimidazoles	<i>C. difficile</i>	<ul style="list-style-type: none"> <li>Nitroimidazoles, mainly metronidazole and tinidazole, mostly used to treat infections caused by anaerobic bacteria.</li> <li>Metronidazole considered first line therapy in the paediatric population for <i>Clostridioides</i></li> </ul>

Antimicrobial class**	Hazard of potential zoonotic relevance	Overview of indications in human medicine and resistance mechanisms
		<p>(<i>Clostridium</i>) <i>difficile</i> (<i>C. difficile</i>).</p> <ul style="list-style-type: none"> <li>• In the adult population can be used for treatment of mild to moderate infections with <i>C. difficile</i> when first line therapy not available.</li> <li>• Nitroimidazoles also used for the treatment of certain intestinal parasites (e.g. <i>Giardia lamblia</i>, <i>Entamoeba histolytica</i>).</li> <li>• Metronidazole classified as an essential medicine by WHO and important to preserve, since widely used in humans, including surgical prophylaxis in penicillin-allergic patients.</li> <li>• Resistance reported worldwide but mechanisms have not been extensively studied.</li> <li>• <i>nim</i> genes encoding resistance in <i>Bacteroides</i> spp. found on plasmids which are highly transferable between <i>Bacteroides</i> spp. in the ecosystem, animals and humans.</li> <li>• <i>C. difficile</i> has mobile genetic elements that can horizontally transfer resistance; homology in genetic sequences between animals and humans.</li> <li>• Successful <i>C. difficile</i> clones, such as ribotype 078n found in animals and humans.</li> </ul>
Penicillins: Anti-staphylococcal penicillins ( $\beta$ -lactamase-resistant penicillins )	MSSA (Methicillin-susceptible <i>Staphylococcus aureus</i> )	<ul style="list-style-type: none"> <li>• Important antimicrobials for treatment of methicillin-susceptible staphylococci and syphilis.</li> <li>• Resistance due to importation of <i>mec</i> genes leading to changes in penicillin binding protein 2 (PBP2) and to lesser degree due to mutations in the other penicillin binding proteins.</li> <li>• Horizontal transfer of resistance. Predominant mechanism in staphylococci including LA-MRSA mediated by <i>mecA</i> gene. Changes in PBP2 can also be mediated by <i>mecC</i> as well as <i>mecB</i>.</li> <li>• <i>mec</i> gene situated in the SCC med cassette that can be transferred between <i>S. aureus</i> and coagulase-negative staphylococci.</li> <li>• Assessment for probability of resistance transfer and likelihood of zoonotic transfer based on <i>mecA</i>- positive staphylococci</li> <li>• Risk for zoonotic transfer predominantly an occupational hazard.</li> </ul>
Pleuromutilins	MRSA (Methicillin-resistant <i>Staphylococcus aureus</i> )	<ul style="list-style-type: none"> <li>• Pleuromutilins only used topically for treatment of bacterial skin infections, e.g. <i>S. aureus</i>.</li> <li>• Resistance derives from chromosomal mutations.</li> <li>• In addition, resistance genes (e.g. <i>vga</i>, <i>cfr</i>) are located on mobile genetic elements.</li> <li>• The <i>cfr</i> gene mediates resistance not only to pleuromutilins, phenicols, lincosamides and streptogramin A, but also to oxazolidinones.</li> </ul>

Antimicrobial class **	Hazard of potential zoonotic relevance	Overview of indications in human medicine and resistance mechanisms
		<ul style="list-style-type: none"> <li>Found in many bacterial species, including MRSA.</li> </ul>
Polymyxins (e.g. colistin)	Enterobacteriaceae	<ul style="list-style-type: none"> <li>Polymyxins, most notably colistin, are antibiotics that have re-emerged for treatment of multidrug-resistant Gram- negative infections, e.g. MDR <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i> and Enterobacteriaceae, usually when alternative effective therapeutic options are limited or non-existent.</li> <li>Chromosomal colistin resistance increasing in most EU/EEA countries.</li> <li>Resistance also due to plasmid-mediated <i>mcr</i> gene reported globally from animals, food products, the environment and as well in human clinical and non-clinical (screening) specimens.</li> <li>Presence of horizontally transferable colistin resistance in food animals, food products, the environment, paired with high rates of <i>in vitro</i> transfer between bacteria, worrisome for human medicine, as presence confers full resistance to colistin, rendering bacteria pandrug-resistant and likely resulting in poor patient outcomes.</li> <li>Further studies needed to evaluate direct transfer of <i>mcr</i> genes from food animals and food to humans.</li> </ul>
Pseudomonic acid	MRSA (Methicillin-resistant <i>Staphylococcus aureus</i> )	<ul style="list-style-type: none"> <li>Mupirocin first line antimicrobial available for decolonisation of <i>Staphylococcus aureus</i> (MSSA and MRSA) in humans and therefore, needs to be preserved.</li> <li><i>Staphylococcus aureus</i> decolonisation shown to significantly reduce morbidity and mortality in patient who undergo certain types of surgery.</li> <li>Clonal transfer, including Livestock Associated (LA)-MRSA and horizontal gene transfer (<i>mupA</i>, <i>mupB</i>) shown.</li> </ul>
Steroid antibacterials (fusidic acid)	MRSA (Methicillin-resistant <i>Staphylococcus aureus</i> )	<ul style="list-style-type: none"> <li>Fusidic acid mainly used for combination therapy in humans (systemic treatment) of staphylococcal infections or topically for treatment of skin or eye infections.</li> <li>Mutational resistance (<i>fusA</i>), genes on mobile elements (<i>fusB</i>, <i>fusC</i>), as well as spread of resistance through successful clones of staphylococci described.</li> </ul>
Streptogramins	Enterococcus spp. (glycopeptide-resistant <i>E. faecium</i> ) and MRSA (Methicillin-resistant	<ul style="list-style-type: none"> <li>Streptogramin family of antimicrobials consists of mixture of two groups of substances acting synergistically: streptogramin A and streptogramin B. Quinupristin-dalfopristin and pristinamycin could theoretically be alternatives in human medicine to treat glycopeptide-resistant enterococci and MRSA infections, but are presently considered</li> </ul>

Antimicrobial class **	Hazard of potential zoonotic relevance	Overview of indications in human medicine and resistance mechanisms
	<i>Staphylococcus aureus</i> )	obsolete. <ul style="list-style-type: none"> <li>Resistance genes (e.g. <i>erm</i>, <i>cfr</i>, <i>vga</i>, <i>lsa</i>, <i>sal(A)</i>) described and some of these in multiple bacterial species including staphylococci and enterococci.</li> <li>Clonal transfer (LA-MRSA) as well as horizontal transfer of genes described. MDR genes: <i>cfr</i>, <i>lsaA</i> and <i>lsaE</i> of particular concern.</li> <li><i>cfr</i> gene mediates resistance not only to streptogramin A, phenicols, lincosamides and pleuromutilins, but also to oxazolidinones,</li> <li>Found in many bacterial species, including MRSA.</li> </ul>
Sulfonamides, dihydrofolate reductase inhibitors and combinations	Enterobacteriaceae, <i>Staphylococcus aureus</i>	<ul style="list-style-type: none"> <li>These combinations used for the treatment of UTIs, bronchitis, otitis media, pneumonia, staphylococcal (MSSA and MRSA) skin infections and the prevention and treatment of <i>Pneumocystis (Carinii) Jiroveci</i> pneumonia and traveller's diarrhoea.</li> <li>Resistance to both has spread extensively and rapidly. Mainly due to the horizontal spread of resistance genes, expressing drug-insensitive variants of the target enzymes dihydropteroate synthase and dihydrofolate reductase, for sulfonamide and trimethoprim, respectively.</li> <li>Chromosomal resistance as well as transfer by mobile genetic elements (<i>sul1</i>, <i>sul2</i>, <i>sul3</i>, <i>dfrr</i>).</li> <li><i>sul1</i> gene is part of class 1 integrons and thus often associated with other resistance genes.</li> </ul>

621

### 622 3.4.2. Mechanisms for transfer of resistance genes and resistant bacteria

623 Based on the literature review summarised in table 2, and with reference to Table 3 of the first AMEG report, the information available on various ways of  
624 transfer of resistance were defined and scored (Table 3) based on the criteria below:

625 **Transmission of resistance through successful clone(s).** Defined as the vertical transfer of a resistance gene through the parent to the daughter bacterium in a successful,  
626 highly disseminated drug-resistant clone of bacteria through a bacterial population, e.g. *E. coli* ST131 clone, MRSP CC(71) clone, MRSA ST398 clone. Probability (1 to 3):

- 627 1. no vertical transmission of gene described as associated with a particular successful drug-resistant clone;
- 628 2. gene is exclusively on the core bacterial chromosome in a particular successful drug-resistant clone (e.g. ST131);
- 629 3. gene is not only on a mobile genetic element, e.g. plasmid, but is also part of a highly-transmissible, successful drug-resistant clone (e.g. ST131)

630 **Horizontal transmission** Defined as a transfer of resistance gene by means of mobile genetic elements. Probability (1 to 3):  
631

- 632 1. no mobile genetic element described;  
633 2. gene is exclusively on the core bacterial chromosome but can be mobilised;  
634 3. gene is on a mobile genetic element, e.g. plasmid, transposon.  
635

636 **Co-selection of resistance.** Defined as a type of resistance where use of one antimicrobial favours the occurrence of resistance to other antimicrobial classes or sub-classes  
637 with a different spectrum. In this table, co-selection is limited to situations when different resistance genes are co-located on one mobile genetic element or are located in a  
638 genetic environment together with other resistance genes in such a way that there is a potential for mobilisation (e.g. IS-elements or resistance islands). A special case when  
639 one gene mediates resistance to several unrelated antimicrobial classes is also included. Probability (1 to 3):

- 640 1. no linkage of the gene with other resistance genes has been described, nor is it located in a genetic environment favouring mobilisation of the former gene and other  
641 resistance genes;  
642 2. **either** linkage of the gene with other resistance genes on a mobile genetic element **or** location of the gene in a genetic environment favouring mobilisation of the gene  
643 together with other resistance genes have been described;  
644 3. **both** linkage of the gene with other resistance genes on a mobile genetic element **and** location of the gene in a genetic environment favouring mobilisation of the gene  
645 together with other resistance gene has been described.  
646

647 **Transmission of resistance through zoonotic or commensal food-borne bacteria.** Defined as transmission of resistance through zoonotic pathogens (e.g. *Salmonella*  
648 spp., *Campylobacter* spp., MRSA, *E. coli* (VTEC/STEC) or transmission of resistance through commensal food-borne bacteria (e.g. *E. coli*, *Enterococcus* spp.). Probability (1 to  
649 3):

- 650 1. no transmission of resistance through zoonotic pathogens or commensal food-borne bacteria;  
651 2. **either** transmission of resistance through zoonotic pathogens **or** through commensal food-borne bacteria;  
652 3. **both** transmission of resistance through zoonotic pathogens **and** through commensal food-borne bacteria.  
653

654 **Similarity of resistance:** Genes: defined as a similar resistance gene detected in bacterial isolates of animal and human origin; Mobile genetic elements: defined as a similar  
655 resistance-conferring mobile genetic element detected in bacterial isolates of animal and human origin; Drug-resistant bacteria: defined as a similar bacterium harbouring a  
656 resistance gene (either chromosomally or mobile genetic element-encoded) of animal and human origin. Probability (1 to 3):

- 657 1. unknown resistance similarity;  
658 2. resistance genes have been shown to be similar between animals and humans;  
659 3. **both** resistance genes **and** mobile genetic elements have been shown to be similar between animals and humans;  
660 4. resistance genes, mobile genetic elements and drug-resistant bacteria have **all** been shown to be similar between animals and humans.  
661

662

663 **Table 3.** Classification of antimicrobial classes according to their likelihood for transfer of resistance genes and resistant bacteria via different mechanisms.  
 664 For definitions of criteria for the different columns please see above.

Antimicrobial classes, subclasses, substances <sup>††</sup>	Transmission of resistance through successful clone(s)	Horizontal transmission of resistance	Co-selection of resistance	Transmission of resistance through zoonotic or commensal food-borne bacteria	Similarity of resistance	References
Amidinopenicillins	1	1	1	1	1	EMA/CVMP/AWP (2018a) Frimodt-Moller (2017) Kahlmeter and Poulsen (2012) Poulsen et al. (2013) Thulin et al. (2015) Thulin et al. (2017)
Aminoglycosides	3	3	3	3	3	Chen et al. (2007) Davis et al. (2010) Deng et al. (2011) Du et al. (2009) EMA/CVMP/AWP (2018b) Gonzalez-Zorn et al. (2005) Hopkins et al. (2010b) Liu et al. (2008)
Aminopenicillins including $\beta$ -lactamase inhibitors combinations	3	3	3	3	3	EMA/CVMP/AWP (2018a)
Amphenicols	3	3	3	3	4	Long et al. (2006) Schwarz et al. (2004) Shen et al. (2013) Wang et al. (2015) Zhao et al. (2016)
Carbapenems and other penems	3	3	3	2	2	Dortet et al. (2014) EFSA BIOHAZ Panel

<sup>††</sup> Examples of ATC and ATCvet codes for the antimicrobial groups, subgroups and substances are provided in Annex A2, Table A2.

Antimicrobial classes, subclasses, substances <sup>++</sup>	Transmission of resistance through successful clone(s)	Horizontal transmission of resistance	Co-selection of resistance	Transmission of resistance through zoonotic or commensal food-borne bacteria	Similarity of resistance	References
						(2013) Le Hello et al. (2013)
Cephalosporins: 1 <sup>st</sup> - and 2 <sup>nd</sup> -generation and cephamycins	3	3	3	3	3	Gazouli et al. (1996) Knothe et al. (1983) Mulvey et al. (2005)
Cephalosporins: 3 <sup>rd</sup> -and 4 <sup>th</sup> -generation	3	3	3	3	4	Catry et al. (2010) EFSA BIOHAZ Panel (2011) EMA/CVMP (2012) EMA/CVMP/SAGAM (2009) Kluytmans et al. (2012) Liebana et al. (2013)
Cephalosporins: Other cephalosporins and penems (ATC code J01DI)	1	1	1	1	1	Casapao et al. (2012) Curcio (2014) Pillar et al. (2008) Steed and Rybak (2010)
Cyclic polypeptides (bacitracin)	3	3	3	3	4	Chancey et al. (2012) Charlebois et al. (2012) Chen et al. (2016) Han et al. (2015) Manson et al. (2004) Olsen et al. (2012) Poulsen et al. (2012) Wang et al. (2014)
Glycopeptides	2	2	2	2	2	Braga et al. (2013) Rice (2012) Silveira et al. (2013)
Glycylcyclines	2	1	2	1	1	EMA/AMEG (2013)

Antimicrobial classes, subclasses, substances <sup>++</sup>	Transmission of resistance through successful clone(s)	Horizontal transmission of resistance	Co-selection of resistance	Transmission of resistance through zoonotic or commensal food-borne bacteria	Similarity of resistance	References
Lincosamides	3	3	3	3	3	EMA/CVMP/SAGAM (2011)
Lipopeptides	1	1	1	1	1	Bayer et al. (2013) Kelesidis and Chow (2014) Kelesidis (2015)
Macrolides (including ketolides)	3	3	3	3	2	EMA/CVMP/SAGAM (2011) Pyorala et al. (2014) Roberts (2008) Roberts (2011)
Monobactams	3	3	3	3	2	Catry et al. (2010) EFSA BIOHAZ Panel (2011) EMA/CVMP (2012) EMA/CVMP/SAGAM (2009) Kluytmans et al. (2012) Liebana et al. (2013)
Nitrofurantoin	3	3	3	3	3	Chen et al. (2012) García et al. (2017) Giske (2015) Ho et al. (2016) Li et al. (2013) Liu et al. (2013) Liu et al. (2018) Osei Sekyere (2018) Perez et al. (2013) Sandegren et al. (2008)
Nitroimidazoles	3	3	3	3	4	Álvarez-Pérez et al. (2014)

Antimicrobial classes, subclasses, substances <sup>++</sup>	Transmission of resistance through successful clone(s)	Horizontal transmission of resistance	Co-selection of resistance	Transmission of resistance through zoonotic or commensal food-borne bacteria	Similarity of resistance	References
						Álvarez-Pérez et al. (2017) Andrés-Lasheras et al. (2018) Baines et al. (2008) Brazier et al. (1999) Dingsdag and Hunter (2017) Freeman et al. (2015) Knetsch et al. (2014) Kuijper and Wilcox (2008) Löfmark et al. (2005) Miyamoto et al. (2013) Nguyen and Vedantam (2011) Nikolich et al. (1994) Shoemaker et al. (2001) Snyderman et al. (2016) Peng et al. (2017) Pirš et al. (2013) Snyderman et al. (2015)
Oxazolidinones	3	3	2	1	2	Bonilla et al. (2010) Diaz et al. (2012) Endimiani et al. (2011) Gu et al. (2012) Liu et al. (2012) Mendes et al. (2014) Sanchez Garcia et al. (2010)

Antimicrobial classes, subclasses, substances <sup>++</sup>	Transmission of resistance through successful clone(s)	Horizontal transmission of resistance	Co-selection of resistance	Transmission of resistance through zoonotic or commensal food-borne bacteria	Similarity of resistance	References
Penicillins: Anti-staphylococcal penicillins ( $\beta$ -lactamase-resistant penicillins) <sup>**</sup>	3	2	2	2 <sup>§§</sup>	4	Becker et al. (2018) Peeters et al. (2015) Price et al. (2012) Ward et al. (2014)
Penicillins: Natural, narrow-spectrum penicillins ( $\beta$ -lactamase-sensitive penicillins), carboxypenicillins and ureidopenicillins	3	1	2	2	2	Bush and Jacoby (2010) Jacoby (2012) U.S. National Library of Medicine (last accessed: 2018)
Phosphonic acid derivates (e.g. fosfomicin)	3	3	2	1	1	Karageorgopoulos et al. (2012) Oteo et al. (2009) Pérez et al. (2014) Wachino et al. (2010)
Pleuromutilins	2	3	2	3	4	Hauschild et al. (2012) Kadlec and Schwarz (2009) Kadlec et al. (2010) Kehrenberg and Schwarz (2006) Kehrenberg et al. (2009) Mendes et al. (2011) Shen et al. (2013) Wendlandt et al. (2013b)
Polymyxins (e.g. colistin)	3	1	2	3	3	EMA/AMEG (2016) Halaby et al. (2013) Monaco et al. (2014)
Pseudomonic acid	3	3	3	3	4	Desroches et al. (2013)

<sup>\*\*</sup> The assessment is based on the most frequent gene coding for resistance against antistaphylococcal penicillins (*mecA*)

<sup>§§</sup> Foodborne transmission has been implicated but is at the present time considered to be very rare (EFSA risk assessment)

Antimicrobial classes, subclasses, substances <sup>++</sup>	Transmission of resistance through successful clone(s)	Horizontal transmission of resistance	Co-selection of resistance	Transmission of resistance through zoonotic or commensal food-borne bacteria	Similarity of resistance	References
						Hurdle et al. (2005) Kadlec et al. (2012) Malik et al. (2005) Patel et al. (2009) Rahman et al. (1989) Rossi et al. (2016) van Duijkeren et al. (2011) Wendlandt et al. (2013a) Werckenthin et al. (2001)
Quinolones (Fluoroquinolones and other quinolones)	3	3	2	3	2	Aldred et al. (2014) EMA/CVMP (2010) EMA/CVMP/SAGAM (2007) Poirel et al. (2008)
Rifamycins	2	3	2	2	2	Arlet et al. (2001) Floss and Yu (2005) Tupin et al. (2010)
Riminofenazines	1	1	1	1	1	Grosset et al. (2012) Hartkoorn et al. (2014)
Steroid antibacterials (fusidic acid)	3	3	3	1	4	Bulajic et al. (2017) Chen et al. (2010) Chen et al. (2014) Clark et al. (2015) Loeffler et al. (2008) Nemeghaire et al. (2014) Norström et al. (2009) Obaidat et al. (2018) Sala et al. (2016) Sousa et al. (2017)

Antimicrobial classes, subclasses, substances <sup>++</sup>	Transmission of resistance through successful clone(s)	Horizontal transmission of resistance	Co-selection of resistance	Transmission of resistance through zoonotic or commensal food-borne bacteria	Similarity of resistance	References
						Ugwu et al. (2015)
Streptogramins	3	3	3	2	3	EMA/CVMP/SAGAM (2011) Hershberger et al. (2004) Pyorala et al. (2014) Simjee et al. (2006) Wendlandt et al. (2012)  <i>See also pleuromutilins</i>
Sulfonamides, dihydrofolate reductase inhibitors and combinations	3	3	3	3	3	Estrada et al. (2016) Hennequin et al. (2018) Hsu et al. (2014) Sköld (2000) Sköld (2001) Vila-Costa et al. (2017)
Sulfones	1	1	1	1	1	Veziris et al. (2013)
Tetracyclines	3	3	3	3	4	Butaye et al. (2003) Butaye et al. (2006) Chopra and Roberts (2001)
Drugs used solely to treat tuberculosis or other mycobacterial diseases (e.g. isoniazid)	2	2	2	2	2	Ando et al. (2014) Bernardes-Genisson et al. (2013) Gagneux (2012)

665  
666  
667  
668

## 669 **4. Categorisation**

670 The new AMEG categorisation builds on the conclusions of the first AMEG report and takes into account  
671 recent information and assessments. The criteria for the categorisation have been refined as discussed  
672 in Chapter 3, taking as an additional criterion the availability of alternative antimicrobials in veterinary  
673 medicine with lower AMR risk to animal and public health. Considering use of the new criterion and  
674 taking account of the recommendations included in the reflection papers recently published by the EMA  
675 on the use of aminopenicillins and aminoglycosides, an additional category has been included, so that  
676 there are now four categories, A to D. For consistency with other existing classifications at the  
677 international level, the order of the categories, in terms of level of risk, has now been reversed with  
678 the lowest risk category last.

679 The updated criteria are as follows:

- 680 *1. If the (sub)class or group is authorised for use as a veterinary medicine*
- 681 *2. The importance of the (sub)class or group to human medicine according to the WHO ranking*  
682 *and taking into account the EU situation (Tables 2 and 4).*
- 683 *3. The <knowledge of factors influencing the> likelihood and possible consequences of AMR*  
684 *transfer from animals to humans. In the new categorisation individual mechanisms of*  
685 *resistance have been considered more specifically for e.g. those genes associated with mobile*  
686 *multiresistance e.g. 'cfr' (Tables 2 and 3).*
- 687 *4. The availability of alternative antimicrobial (sub)classes in veterinary medicine with lower AMR*  
688 *risk to animal and public health (Table 4).*

689 A discussion of the updated criteria is given in sections 3.3 and 3.4 of the report. With regard to the  
690 route of administration, this has not been included as a criterion for the categorisation for reasons  
691 discussed in 3.3.1. The exception is for steroid antibacterials (fusidic acid) where it was taken into  
692 account that this class is only administered locally in animals.

693 In this updated advice, all antimicrobial classes were considered for categorisation and a summary of  
694 the evidence supporting the application of the criteria and the overall rationale for the categorisation  
695 have been added in Table 4. Supporting evidence is derived from published literature, reflection papers  
696 on individual antimicrobial classes published by CVMP, and expert opinion, as documented in tables 2,  
697 3 and 4 of this report. The categorisations of WHO and OIE, and further WHO documents were also  
698 taken into account. For classes in Category A, the only consideration was the absence of authorisation  
699 of a substance from the class in a veterinary medicine. The final categorisation for other (sub)classes  
700 was based on the judgement of the AMEG in weighting the remaining three criteria, although the key  
701 considerations for each category are stated in sections 4.1 to 4.4, below.

702 The categorisation should be understood to operate at the level of (sub)classes. Examples of ATC and  
703 ATCvet codes for the antimicrobial groups, subgroups and substances included in each AMEG category  
704 are provided in Annex A2, Table A2.

705 Individual substances not authorised as veterinary medicine themselves, but which belong to a class  
706 containing molecules that are authorised as veterinary medicines, should be considered as having the  
707 same categorisation as the parent (sub)class. Although the categorisation may be used to help with

708 prescribing decisions made under the “cascade”<sup>9</sup>, it cannot take account of all the principles to be  
709 considered and importantly the welfare of the individual animal(s). Therefore the categorisation does  
710 not override the complete rules of the prescribing “cascade” in which AMR risk is a factor to consider  
711 alongside other criteria as laid out in legislation.

## 712 ***Risk management measures to be applied to each category***

713 It should be noted that under the new regulation on veterinary medicines (Official Journal of the  
714 European Union, 2019) certain important provisions are included regarding the use of antimicrobials in  
715 animals in order to address the risks to public and animal health from AMR:

- 716 • A list is to be established of antimicrobials (or groups of antimicrobials) to be reserved for  
717 treatment of certain infections in humans only (Article 32). These substances shall not be used  
718 under the “cascade” to treat animals (Article 111).
- 719 • A list is to be established of antimicrobials that shall not be used under the “cascade”, or shall  
720 only be used under the “cascade” subject to conditions (Article 111)
- 721 • The use of antibiotic medicinal products for prophylaxis is limited to administration to individual  
722 animals only, in exceptional cases, when the risk of infection is very high and the  
723 consequences are likely to be severe (Article 111)
- 724 • Antimicrobial medicinal products shall only be used for metaphylaxis when the risk of spread of  
725 infection in the group of animals is high and where no appropriate alternatives are available  
726 (Article 111).

727 The risk management measures applied to the individual AMEG categories should be seen as being  
728 complementary to these provisions. As the categorisation is made at the level of (sub)classes of  
729 antimicrobials, risk management measures can be indicated at high level, only. These measures are  
730 stated *in italics* for each category below. Further examples of risk management measures that have  
731 been applied to certain classes of products (e.g. under CVMP referrals) are available in the Annex to  
732 the Commission’s Guidelines for the prudent use of antimicrobials in veterinary medicine (European  
733 Commission, 2015). Restrictions on the use of certain antimicrobials may also be applied by individual  
734 member states on their territory.

### 735 ***4.1. Category A: “Avoid”***

736 A number of the antimicrobial (sub)classes listed are not authorised in veterinary medicine and these  
737 are presented separately as Category A.

738 *Risk management measures: In the absence of established maximum residue limits for foodstuff of*  
739 *animal origin, use of these classes of AM in food-producing animals is prohibited and they may only be*  
740 *administered to individual companion animals exceptionally, in compliance with the prescribing*  
741 *“cascade”.*

742 *The extent of use of these classes, and hence overall selection pressure for AMR, would be low*  
743 *provided the restrictions detailed in the prescribing “cascade” are complied with.*

---

<sup>9</sup> Articles 10 and 11 of Directive 2001/82/EC. The prescribing “cascade” is a provision in legislation which, when no suitable authorised product is available and under exceptional circumstances, allows a veterinarian to use a veterinary medicinal product outside of its authorised conditions of use, or to use an unauthorised medicine, according to given criteria.

744 In the event of a future Marketing Authorisation application for a veterinary medicinal product  
745 containing a substance in this category, the benefits of use of the proposed veterinary medicine in  
746 animals are considered alongside a risk assessment that takes account of the importance of the  
747 substance to human health and the risk of transfer of resistance of relevance for public health from  
748 treated animals to humans.

#### 749 **4.2. Category B: "Restrict"**

750 Classes in HPCIA (see chapter 3.2.1.1. for WHO criteria) are included in Category B with the exception  
751 of macrolides and those (sub)classes which are not authorized in veterinary medicine in the EU.

752 Category B includes quinolones (fluoroquinolones and other quinolones), 3<sup>rd</sup>- and 4<sup>th</sup>-generation  
753 cephalosporins and polymyxins.

754 Risk to public health resulting from veterinary use needs to be mitigated by specific restrictions.

755 *Risk management measures: These antimicrobials should be considered only for the treatment of*  
756 *clinical conditions when there are no alternative antimicrobials in categories C or D that could be*  
757 *effective. Especially for this category, use should be based on the results of antimicrobial susceptibility*  
758 *testing, whenever possible<sup>10</sup>.*

#### 759 **4.3. Category C: "Caution"**

760 Antimicrobials for which there are alternatives in human medicine for their indications but which  
761 comply with one or both of the following criteria:

- 762
- 763 • For the veterinary indication under treatment, there are few or no alternatives belonging to  
764 Category D. Some examples of these indications are given in Table 4, alongside the relevant  
(sub)class.
  - 765 • The antimicrobial selects for resistance to a substance in Category A through specific  
766 multiresistance genes

767 Antimicrobials placed in this category present a higher AMR risk for human and/or animal health than  
768 antimicrobials placed in Category D, as assessed by AMEG.

769 *Risk management measures: These antimicrobials should only be used when there is no substance in*  
770 *Category D that would be effective.*

#### 771 **4.4. Category D: "Prudence"**

772 Category D includes antimicrobials where there are alternative treatments in human and veterinary  
773 medicine for their indications and that do not select for resistance to Category A through specific  
774 multiresistance genes.

---

<sup>10</sup> In accordance with the draft "Guideline on the summary of product characteristics for veterinary medicinal products containing antimicrobial substances" (EMA/CVMP/383441/2005-Rev. 1), the following recommendation is made for all antimicrobial products: 'Use of the product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target bacteria at farm level, or at local/regional level.'

775 Antimicrobials placed in this category present a lower AMR risk than antimicrobials placed in Category  
776 C as assessed by AMEG and should be used where possible as first line treatments.

777 *Risk management measures: These antimicrobials are not devoid of negative impact on resistance*  
778 *development and spread. To keep the risk from use of these antimicrobial classes as low as possible it*  
779 *is important that responsible use principles are complied with in everyday practice (EMA/EFSA, 2017;*  
780 *Official Journal of the European Union, 2015). Unnecessary use and unnecessarily long treatment*  
781 *periods should be avoided and group treatment restricted to situations where individual treatment is*  
782 *not feasible.*

783  
784  
785

**Table 4.** AMEG Categorisation table

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
<b>Amidinopenicillins</b>	Multidrug-resistant (MDR) Enterobacteriaceae	HIA	N/D	Not approved <sup>15</sup>	Not applicable	N/A	A	See chapter 4.1.  For these antimicrobials, if at any time in the future an approval is granted for use in veterinary medicine, the antimicrobial class should then be categorised according to the defined criteria
<b>Carbapenems and other penems</b>	MDR Gram-negative bacteria (e.g. extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae)	CIA	N/D			3	A	
<b>Cephalosporins: Other cephalosporins and penems (ATC code J01DI)</b>	Staphylococci (e.g. MRSA); MDR <i>Streptococcus pneumoniae</i>	HPCIA	N/D			3	A	
<b>Glycopeptides</b>	Staphylococci (e.g. MRSA), MDR <i>Streptococcus pneumoniae</i> , MDR <i>streptococci</i>	HPCIA	N/D			3	A	
<b>Glycylcyclines</b>	MDR Gram-negative bacteria, Staphylococci (e.g. MRSA)	CIA	N/D			3	A	
<b>Lipopeptides</b>	Staphylococci (e.g. MRSA), MDR <i>Enterococcus spp.</i> , <i>Streptococcus pneumoniae</i>	CIA	N/D			3	A	
<b>Monobactams</b>	MDR Gram-negative	CIA	N/D			3	A	

<sup>11</sup> Examples of ATC and ATCvet codes for the antimicrobial groups, subgroups and substances included in each AMEG category are provided in Annex A2, Table A2.

<sup>12</sup> WHO categorisation: HPCIA>CIA>HIA>IA

<sup>13</sup> OIE categorisation: VCIA>VHIA>VIA

<sup>14</sup> For polymyxins, the revision of 2016 has been taken into account

<sup>15</sup> Approved means approved in at least one Member State

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
	bacteria, especially those producing metallo-beta-lactamases (MBL)							
<b>Oxazolidinones</b>	Staphylococci (e.g. MRSA), MDR <i>Enterococcus</i> spp. (e.g. VRE), MDR <i>Mycobacterium tuberculosis</i> , MDR <i>Streptococcus pneumoniae</i>	CIA	N/D			3	A	
<b>Penicillins: carboxypenicillins and ureidopenicillins combinations with <math>\beta</math>-lactamase inhibitors</b>	MDR <i>Pseudomonas</i> spp., MDR Enterobacteriaceae	CIA	N/D			3	A	
<b>Phosphonic acid derivates (e.g. fosfomycin)</b>	MRSA, penicillin-non-susceptible <i>S. pneumoniae</i> , MDR <i>E. coli</i> (and other susceptible Enterobacteriaceae), MDR enterococci (e.g. VRE)	CIA	N/D			3	A	
<b>Pseudomonic acid</b>	MDR staphylococci (e.g. MRSA)	HIA	N/D			N/A	A	
<b>Riminoferazines</b>	Leprosy, MDR <i>Mycobacterium tuberculosis</i>	HIA	N/D			3	A	
<b>Streptogramins</b>	Staphylococci (e.g. MRSA), MDR <i>Enterococcus</i> spp. (e.g. VRE)	HIA	VIA			N/A	A	
<b>Sulfones</b>	Leprosy	HIA	N/D			3	A	
<b>Drugs used solely to treat tuberculosis or other mycobacterial</b>	Tuberculosis and other <i>Mycobacterium</i> spp. diseases	CIA	N/D			3	A	

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
<b>diseases</b>								
<b>Cephalosporins, 3<sup>rd</sup>- and 4<sup>th</sup>-generation</b>	Acute bacterial meningitis and disease due to <i>Salmonella</i> spp. in children, gonococcal infections	HPCIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in individual animals only, for systemic and local treatment (recommendations of restrictions apply)	Among few alternatives for treatment of severe (life threatening) sepsis in various animals (Enterobacteriaceae with confirmed or suspected resistance to antimicrobials in Category C and D) Among few alternatives for treatment of respiratory tract infections where AMR to antimicrobials in Category C and D has been confirmed	2	B	See chapter 4.2.
<b>Polymyxins (e.g. colistin)</b>	MDR <i>Pseudomonas aeruginosa</i> , MDR <i>Acinetobacter baumannii</i> and MDR Enterobacteriaceae ( <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> )	HPCIA	VHIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments (recommendations of restrictions apply).	Among few alternatives for treatment of colibacillosis (e.g. weaning diarrhoea in pigs) ( <i>E. coli</i> with resistance to Category C and D).	2	B	
<b>Quinolones (fluoroquinolones and other quinolones)</b>	<i>Campylobacter</i> spp., <i>Salmonella</i> spp. invasive infection, MDR <i>Shigella</i> spp., <i>Pseudomonas aeruginosa</i> , <i>Streptococcus pneumoniae</i> and MDR tuberculosis	HPCIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatment (recommendations of restrictions apply).	Among few alternatives for treatment of diarrhoeas in piglets ( <i>E. coli</i> with resistance to Category C and D). Among few alternatives for treatment of severe (life threatening) sepsis in various animals (Enterobacteriaceae with confirmed or suspected resistance to antimicrobials in Category C and D) Few alternatives for treatment of e.g. <i>Aeromonas salmonicida</i> and <i>Flavobacterium</i> spp. in farmed fish (older quinolones)	2	B	
<b>Aminoglycosides and aminocyclitol</b>	Enterococcal endocarditis, MDR Gram-negative bacteria	CIA/IA	VCIA	Approved for use in food-producing and companion animals. Formulations for use	Among few alternatives for treatment of weaning diarrhoea, some alternatives	2	C	

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
	(particularly Enterobacteriaceae and <i>Pseudomonas</i> spp.), MDR tuberculosis			in group and individual animals, for systemic and local treatments.	are Category B. Few alternatives for treatment of infections with <i>Pseudomonas</i> spp. Few alternatives for MDR Enterobacteriaceae, some alternatives are Category B.			medicine. There is a high potential for transmission of AG-resistance determinants between animals and humans. But the risk to human health is lower compared to antimicrobials in Category B. Spectinomycin presents a lower risk than other AGs. See also CVMP reflection paper on Aminoglycosides (EMA/CVMP/AWP, 2018b).
<b>Aminopenicillins in combination with <math>\beta</math>-lactamase inhibitors (e.g. amoxicillin-clavulanic acid, co-amoxiclav)</b>	Enterobacteriaceae	CIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments.	Few alternatives for urinary tract infections in dogs, caused by bacteria that are resistant to alternatives in Category D and some in C. Few alternatives for treatment of skin infections with staphylococci in dogs.	<b>2</b>	<b>C</b>	Aminopenicillins combined with beta-lactamase inhibitors are critically important in human medicine.  Amoxicillin-clavulanate has a wider spectrum and thus it is likely that it has higher chance to select multidrug resistant organisms, ESBLs and AmpC compared to aminopenicillins alone.  There are few or no antimicrobial alternative treatments presenting a lesser risk available for certain indications in veterinary medicine.  See also CVMP reflection paper on Aminopenicillins (EMA/CVMP/AWP, 2018a).
<b>Amphenicols (florfenicol &amp; thiamphenicol)</b>	MDR Enterobacteriaceae	HIA	VCIA	Approved for use in food-producing animals as formulations for use in group and individual animals, for	Few alternatives for treatment of e.g. <i>Aeromonas salmonicida</i> and <i>Flavobacterium</i> spp in	<b>N/A</b>	<b>C</b>	Antimicrobial class with high probability of resistance transfer. May lead to resistance to last resort

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
				systemic and local treatments. For use in companion animals as formulations for local treatments.	farmed fish, one alternative in Category B. Among few alternatives for treatment of respiratory tract infections caused by bacteria resistant to alternatives in Category D.			antimicrobials class. Several genes can code individually for resistance to amphenicols. Of special concern is the acquisition of either the <i>cf</i> r or <i>op</i> trA genes, since these also encode for resistance to antimicrobial classes of critical importance to human medicine (e.g. oxazolidinones, streptogramin A). However, currently the <i>cf</i> r or <i>op</i> trA genes are considered at a low prevalence in European animal bacterial isolates. Should this situation change to an increased prevalence then the classification of this antimicrobial class may need to be re-assessed.  Few or no antimicrobial alternative treatments presenting a lesser risk are available for certain indications in veterinary medicine
<b>Cephalosporins, 1<sup>st</sup>- and 2<sup>nd</sup>-generation and cephamycins</b>	Enterobacteriaceae, MSSA, surgical prophylaxis	HIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in individual animals, for systemic and local treatments.	Few alternatives for treatment of skin infections with staphylococci in dogs	<b>N/A</b>	<b>C</b>	May lead to resistance to last resort antimicrobial class. However, few or no antimicrobial alternatives treatment presenting a lesser risk are available for certain indications in veterinary medicine.
<b>Macrolides</b>	<i>Legionella</i> spp., <i>Campylobacter</i> spp., invasive MDR <i>Salmonella</i> spp. and <i>Shigella</i> spp. infections	HPCIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments.	Among few alternative antimicrobials for treatment of haemorrhagic digestive disease in pigs ( <i>Lawsonia intracellularis</i> ). Important for treatment of mycoplasma	<b>1</b>	<b>C</b>	Antimicrobial class with high probability of resistance transfer. For the treatment of zoonotic pathogens (mainly <i>Campylobacter</i> spp.) in

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
					infections in pigs and poultry. Newer macrolides are among few alternatives for treatment of respiratory tract infections caused by bacteria that are resistant to alternatives in Category D. Some alternatives are Category B. Among few alternatives for treatment of foot-rot in sheep and goats.			humans, there are alternative antimicrobials such as fluoroquinolones, although fluoroquinolone resistance in <i>Campylobacter spp.</i> is high in most EU/EEA countries. The <i>erm</i> genes are considered to be of low prevalence in animal isolates of these pathogens in the EU. Should the occurrence of resistance increase the categorisation of this antimicrobial class may need to be re-assessed.  Few or no antimicrobial alternative treatments presenting a lesser risk are available for certain indications in veterinary medicine.
<b>Lincosamides</b>	Staphylococci (e.g. MRSA)	HIA	VHIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments.		<b>N/A</b>	<b>C</b>	Cross resistance between macrolides, lincosamides and streptogramins.
<b>Pleuromutilins</b>	<i>Staphylococcus spp.</i> (e.g. MRSA)	IA	VHIA	Approved for use in food-producing species for group and individual animal treatments.	Few or no alternatives for treatment of infections with <i>Brachyspira spp.</i> in pigs	<b>N/A</b>	<b>C</b>	Antimicrobial class with high probability of resistance transfer. May lead to resistance to last resort antimicrobials class especially to linezolid (oxazolidinone). However, few or no antimicrobial alternative treatments presenting a lesser risk is available in veterinary medicine.
<b>Rifamycins</b>	Mycobacterial diseases including tuberculosis	CIA	VHIA	Approved for use in food-producing species for local	Few treatment options for <i>Rhodococcus equi</i> pneumonia	<b>1</b>	<b>C</b>	Rifampin (rifampicin) continues to be part of the

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
	Adjunct treatment for prosthetic staphylococcal infections, prophylaxis for exposure to <i>N. meningitidis</i>			treatment (intramammary formulations).	in horses (in combination with a macrolide)			essential combination antimicrobial treatment for <i>Mycobacterium tuberculosis</i> infections in human medicine. No hazard of zoonotic importance is identified, and extent of use in vet medicine is low. The concerns of its use in veterinary medicine are for the routine off-label use for oral treatment (and sometimes prophylaxis) of <i>Rhodococcus equi</i> infections in foals <sup>16</sup> . Resistance to rifampin develops rapidly and responsible use is essential.
<b>Aminopenicillins, without <math>\beta</math>-lactamase inhibitors</b>	<i>Streptococcus</i> spp., <i>Enterococcus</i> spp., <i>E. coli</i> , <i>Proteus mirabilis</i>	CIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments.	Very important for treatment of many diseases in a broad range of animal species.	<b>2</b>	<b>D</b>	See chapter 4.4.  CIA in human medicine due to high extent of use, although alternatives of last resort are available.  AMR at high level in some organisms due to extensive use for many decades in both humans and animals.  In case of further evidence indicates that veterinary use of aminopenicillins poses an added threat to public health due to animal-to-human resistance transfer, it could then be considered if a distinction in the categorisation should be

<sup>16</sup> List of substances essential for the treatment of *equidae*, Official Journal of the European Union. 2013. Commission Regulation (EU) No 122/2013 of 12 February 2013 amending Regulation (EC) No 1950/2006 establishing, in accordance with Directive 2001/82/EC of the European Parliament and of the Council on the Community code relating to veterinary medicinal products, a list of substances essential for the treatment of equidae. In <http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1416502774573&uri=CELEX:32013R0122>.

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
								made between straight aminopenicillins and narrow-spectrum penicillin  See also CVMP reflection paper on Aminopenicillins (EMA/CVMP/AWP, 2018a).  Narrow spectrum penicillins with a lower risk of AMR selection should be used for first line treatment where susceptibility testing suggests the likely efficacy of this approach.
<b>Cyclic polypeptides (bacitracin)</b>	Gram-positive bacteria (topical use)	IA	VHIA	Approved for use in food-producing animals. Formulations for use in group and individual animals, for local treatments.		<b>N/A</b>	<b>D</b>	See chapter 4.4.
<b>Nitrofurans derivatives (e.g. nitrofurantoin)</b>	Enterobacteriaceae (uncomplicated urinary tract infections)	IA	N/D	Approved for use in companion animals only.		<b>N/A</b>	<b>D</b>	
<b>Nitroimidazoles</b>	Anaerobic bacteria, intestinal parasites, <i>C. difficile</i>	IA	N/D	Approved use in companion animals. Formulations for use in individual animals for systemic treatment.	Among the few alternatives available for treatment of anaerobic infections in non-food producing animals.	<b>N/A</b>	<b>D</b>	
<b>Penicillins: Anti-staphylococcal penicillins (β-lactamase-resistant penicillins)</b>	<i>Staphylococcus aureus</i> (e.g. MSSA)	HIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in individual animals, for local treatments.		<b>1</b>	<b>D</b>	
<b>Penicillins: Natural, narrow spectrum penicillins (β-lactamase-sensitive penicillins)</b>	<i>Streptococcus</i> spp., <i>Enterococcus</i> spp.	CIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments.		<b>1</b>	<b>D</b>	

Antimicrobial classes, subclasses, substances <sup>11</sup>	Examples of important indications in human medicine	WHO <sup>12</sup>	OIE <sup>13</sup>	Use in veterinary medicine	Examples of indications where there are few alternatives in veterinary medicine	AMEG categorisation		Main rationale for categorisation
						previous	new <sup>14</sup>	
<b>Steroid antibacterials (fusidic acid)</b>	Staphylococci (e.g. MSSA)	HIA	VIA	Approved for use in companion animals, for use in individual animals for local treatment.		N/A	D	
<b>Sulfonamides, dihydrofolate reductase inhibitors and combinations</b>	Enterobacteriaceae, Staphylococci (e.g. MRSA)	HIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments.	No alternatives for treatment of certain protozoal infections.	N/A	D	
<b>Tetracyclines</b>	<i>Brucella</i> spp.	HIA	VCIA	Approved for use in food-producing and companion animals. Formulations for use in group and individual animals, for systemic and local treatments.	No alternatives for treatment of heartwater ( <i>Ehrlichia ruminantium</i> ) and anaplasmosis, although disease with low incidence. Fewer alternatives for vector-borne diseases in dogs and cats.	1	D	

786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798

**Abbreviations in Table 4:**

WHO categorisation:

- HPCIA: Highest Priority Critically Important Antimicrobials
- CIA: Critically important Antimicrobials
- HIA: Highly Important Antimicrobials
- IA: Important Antimicrobials

OIE categorisation:

- VCIA: Veterinary Critically Important Antimicrobials
- VHIA: Veterinary Highly Important Antimicrobials
- VIA: Veterinary Important Antimicrobials

N/A: not applicable

N/D: not defined

## 799 **5. Use of AMEG Categorisation**

800 The AMEG has refined the ranking of the antimicrobials by adding an additional category. To harmonise  
801 with other lists, the order of the categories has been reversed compared to the first AMEG report.  
802 Additionally, in the current scientific advice, those antimicrobial classes which were not included in the  
803 previous ranking are also categorised. According to the revised criteria applied for the new  
804 antimicrobial categorisations described in chapter 3.3, not only the importance of the antimicrobial  
805 class in human medicine and knowledge of factors influencing the likelihood of resistance transfer are  
806 considered, but emphasis is now also placed on the importance and the availability of alternatives  
807 antimicrobials in veterinary medicine. These additional considerations make the methodology different  
808 from other categorisations made by international institutions (e.g. WHO, OIE) and thus the final  
809 ranking may differ. It should be noted that the proposed categorisation takes into account both the  
810 WHO and OIE lists of CIAs, thereby allowing an appropriate balance between animal health needs,  
811 human health needs and public health considerations.

812 The AMEG proposes to classify antimicrobials in four different categories, from A to D. For  
813 communication purposes, key action words have been attributed for each category.

- 814 • Category A (“Avoid”) corresponds to Category 3 in the first AMEG report, and includes  
815 antimicrobial classes not currently authorised in veterinary medicine.
- 816 • Category B (“Restrict”) corresponds to Category 2 in the first AMEG report, including  
817 substances listed as HPCIA by the WHO with the exception of macrolides and those which are  
818 not authorised as veterinary medicines in the EU. For these antimicrobials, risk to public health  
819 resulting from veterinary use needs to be mitigated by specific restrictions.
- 820 • Category C (“Caution”) was added in this report as an intermediate category. This category  
821 includes antimicrobial classes listed in different categories by WHO, including macrolides, which  
822 are listed by WHO as a HPCIA. For substances proposed for inclusion in this category, there are  
823 in general alternatives in human medicine in the EU but there are few alternatives in veterinary  
824 medicine for certain indications.
- 825 • Category D (“Prudence”) is the lowest risk category. While the risk to public health associated  
826 with the use in veterinary medicine of substances included in this category is considered low, a  
827 number of the substances in this category are listed as WHO CIAs (aminopenicillins, natural  
828 penicillins and isoxazolympenicillin).

829 This categorisation does not directly translate into a treatment guideline for use of antimicrobials in  
830 veterinary medicine, but can be used as a tool by those preparing guidelines. In veterinary medicine,  
831 the variety of animal species, the different routes of administration (from intramammary treatment of  
832 individual cows to treatment of many hundreds of fish by in-feed medication) and diversity of  
833 indications are all factors that have to be taken into account in treatment guidelines. Further, types of  
834 production systems, the presence of different diseases and occurrence of antimicrobial resistance may  
835 differ between regions. Therefore, treatment guidelines need to be regionally or even locally developed  
836 and implemented. Development and implementation of evidence-based national and regional  
837 treatment guidelines are encouraged.

- 838 • The categorisation itself is not a risk assessment but could be used as an independent guidance  
839 tool “e.g. for priority setting” as part of the risk analysis.

- 840 • This classification may serve as a starting point for discussions on any new further risk  
841 assessments on request from the EC regarding the implementation of the new veterinary  
842 regulation (Official Journal of the European Union, 2019).
- 843 • The categories could be used to provide background for the consequence assessment of a risk  
844 assessment for antimicrobial medicines.
- 845 • The categorisation should also be considered as a guidance tool for assessing the importance of  
846 antimicrobials when implementing prudent use measures.

847 Ideally, the criticality of use in veterinary medicine should be directly considered when creating  
848 treatment guidelines. For instance, there are situations where a substance could be approved and  
849 recommended as the first line treatment for a certain condition in a certain species where there are no  
850 effective alternatives even if the substance as such belongs to a category where the risk to public  
851 health is considered high. When risk to public health is considered in a benefit/risk perspective it could  
852 be that a higher risk level is found acceptable in case of a certain disease/species to be treated.  
853 Nevertheless, this reasoning has not been fully applied in this scientific advice due to lack of data on  
854 resistance in target animal pathogens.

855 This categorisation should be considered as one element when deciding on when/whether to use a  
856 certain class/substance in veterinary medicine but it may not be used as the sole base when creating  
857 treatment guidelines, for making decisions about prescribing under the “cascade” or when deciding on  
858 risk mitigation activities. It should not be interpreted as a recommendation for treatment guidelines.

859 Antimicrobial categorisation is a complex issue influenced by different factors such as the medical  
860 practices, availability and guidelines for antimicrobial therapy, which vary from country to country.  
861 Thus, for transparency of the categorisation process, defined criteria, based on evidence and experts’  
862 considerations, have been applied to provide a rationale for the ranking of antimicrobial drugs. As the  
863 categorisation is part of a dynamic process the relative importance of an antimicrobial and its usage  
864 could evolve over time due to changes in factors that determine the drug efficacy, e.g. emergence of  
865 resistance, the availability of new drugs in the market, or due to identification of a new indication. This  
866 categorisation should therefore be periodically (e.g. in 5 years) reviewed and, if necessary, revised on  
867 the basis of new scientific evidence or emerging information on changing patterns of antimicrobial use  
868 and/or resistance trends.

## 869 **Annex 1 - The WHO list in an EU perspective**

870 The list of substances and definitions for the WHO Criteria 1 and 2 are applicable for the EU. As  
871 indicated in the WHO list of critically important antimicrobials, “the implementation of the concept at  
872 the national level required that national considerations would be taken into account, and consequently  
873 lists may vary from country to country”.

874 Some comments are added in Table 2, addressing specifically the EU situation.

875 Table A1 presents an amended version of the WHO list of CIAs and HIAs modified to consider EU  
876 particulars. To reduce the number of items in the list, the antimicrobials are mainly presented as  
877 classes although some unique characteristics for individual subclasses or substances are presented as  
878 appropriate. The list is not exhaustive as some classes/substances on the WHO list but of less  
879 importance for human medicine in EU are omitted. For each class/compound, examples among the  
880 most important infective agents are listed. These agents are bacteria causing infections against which  
881 there are few treatment alternatives. Depending on resistance pattern/s, a listed compound may be

882 the sole available treatment. Some of these bacteria (or their resistance genes) do have an animal  
 883 reservoir and thus, in a sense, be zoonotic. In some cases resistance has been shown to spread  
 884 between animals and humans, in other cases such transfer remains a theoretical possibility. Hazards  
 885 ("bug/drug combinations", i.e. the bacteria when resistant against the antimicrobial in question) that  
 886 might in theory have such a zoonotic potential are listed in a separate column.

887 **Table A1.** Hazard of zoonotic relevance as identified by AMEG for antimicrobials that fulfil WHO  
 888 criterion 1

<b>Antimicrobial class</b>	<b>Bacterial targets in human medicine (for which availability of class/substance is critically important due to few alternatives)</b>	<b>Hazard of potential zoonotic relevance</b>
<b>Aminoglycosides</b>	<ul style="list-style-type: none"> <li>• Enterococcal endocarditis</li> <li>• Multidrug-resistant (MDR) Gram-negative bacteria (particularly Enterobacteriaceae and <i>Pseudomonas</i> spp.)</li> <li>• (MDR) tuberculosis</li> </ul>	Enterobacteriaceae <i>Enterococcus</i> spp.
<b>Carbapenems and other penems</b>	<ul style="list-style-type: none"> <li>• Multidrug-resistant (MDR) Gram-negative bacteria (e.g. Enterobacteriaceae)</li> </ul>	Enterobacteriaceae
<b>Cephalosporins, 3<sup>rd</sup>- and 4<sup>th</sup>-generation</b>	<ul style="list-style-type: none"> <li>• Acute bacterial meningitis and disease due to <i>Salmonella</i> spp. in children</li> <li>• Gonococcal infections</li> </ul>	Enterobacteriaceae
<b>Ceftaroline and ceftobiprole<sup>17</sup></b>	<ul style="list-style-type: none"> <li>• MDR staphylococci (e.g. MRSA)</li> <li>• Penicillin non-susceptible <i>Streptococcus pneumoniae</i> (PNSP)</li> </ul>	MRSA
<b>Cyclic esters (e.g. fosfomycin)<sup>18</sup></b>	<ul style="list-style-type: none"> <li>• ESBL ( extended-spectrum beta-lactamases)-producing <i>E. coli</i> causing UTI</li> <li>• MDR Gram-negative bacteria (IV formulation)</li> </ul>	Enterobacteriaceae
<b>Fluoroquinolones and other quinolones</b>	<ul style="list-style-type: none"> <li>• <i>Campylobacter</i> spp.</li> <li>• Invasive <i>Salmonella</i> spp. infection</li> <li>• MDR <i>Shigella</i> spp.</li> <li>• <i>Pseudomonas aeruginosa</i>, PNSP and MDR TB (tuberculosis) (intravenous/oral)</li> </ul>	<i>Campylobacter</i> spp. Enterobacteriaceae
<b>Glycopeptides</b>	<ul style="list-style-type: none"> <li>• MDR staphylococci (e.g. MRSA),</li> <li>• PNSP</li> </ul>	<i>Enterococcus</i> spp. MRSA
<b>Glycylcyclines</b>	<ul style="list-style-type: none"> <li>• MDR Gram-negative bacteria</li> <li>• MDR staphylococci (e.g. MRSA)</li> </ul>	MRSA Enterobacteriaceae
<b>Lipopeptides</b>	<ul style="list-style-type: none"> <li>• MDR staphylococci (e.g. MRSA)</li> </ul>	<i>Enterococcus</i> spp.

<sup>17</sup> Included in "Other cephalosporins and penems, ATC code J01DI" in other tables of the document.

<sup>18</sup> Included in "Phosphonic acid derivatives" in other tables of the document.

Antimicrobial class	Bacterial targets in human medicine (for which availability of class/substance is critically important due to few alternatives)	Hazard of potential zoonotic relevance
	<ul style="list-style-type: none"> <li>MDR <i>Enterococcus</i> spp.</li> <li>PNSP</li> </ul>	MRSA
<b>Macrolides (including ketolides)</b>	<ul style="list-style-type: none"> <li><i>Legionella</i> spp.</li> <li><i>Campylobacter</i> spp.</li> <li>Invasive MDR <i>Salmonella</i> spp. and <i>Shigella</i> spp. infections</li> </ul>	<i>Campylobacter</i> spp. Invasive <i>Salmonella</i> spp.
<b>Monobactams</b>	<ul style="list-style-type: none"> <li>MDR Gram-negative bacteria, especially those producing metallo-beta-lactamases (MBL)</li> </ul>	Enterobacteriaceae
<b>Oxazolidinones</b>	<ul style="list-style-type: none"> <li>MDR staphylococci (e.g. MRSA)</li> <li>MDR <i>Enterococcus</i> spp. (e.g. VRE)</li> <li>MDR TB</li> <li>PNSP</li> </ul>	<i>Enterococcus</i> spp. MRSA
<b>Penicillins, Natural</b>	<ul style="list-style-type: none"> <li>Syphilis</li> </ul>	None identified
<b>Penicillins: Aminopenicillins including combinations with <math>\beta</math>-lactamase inhibitors (e.g. amoxicillin + clavulanic acid)</b>	<ul style="list-style-type: none"> <li><i>Listeria</i> spp.</li> <li><i>Enterococcus</i> spp.</li> </ul>	<i>Enterococcus</i> spp. Enterobacteriaceae
<b>Penicillins: Carboxypenicillins and ureidopenicillins</b>	<ul style="list-style-type: none"> <li>MDR <i>Pseudomonas</i> spp.</li> <li>MDR Enterobacteriaceae (temocillin)</li> </ul>	Enterobacteriaceae
<b>Polymyxins</b>	<ul style="list-style-type: none"> <li>MDR Enterobacteriaceae</li> </ul>	Enterobacteriaceae
<b>Rifamycins</b>	<ul style="list-style-type: none"> <li>Mycobacterial diseases including tuberculosis</li> </ul>	None identified
<b>Riminofenazines</b>	<ul style="list-style-type: none"> <li>Leprosy</li> <li>MDR TB</li> </ul>	None identified
<b>Sulfones</b>	<ul style="list-style-type: none"> <li>Leprosy</li> </ul>	None identified
<b>Tetracyclines</b>	<ul style="list-style-type: none"> <li><i>Brucella</i> spp.</li> </ul>	<i>Brucella</i> spp.
<b>Drugs used solely to treat tuberculosis or other mycobacterial diseases</b> (in particular, isoniazid, pyrazinamide, ethambutol and capreomycin)	<ul style="list-style-type: none"> <li>Tuberculosis and other <i>Mycobacterium</i> spp. diseases</li> </ul>	None identified

889

890

891 **Annex 2 - ATC and ATCvet codes**

892 **Table A2.** Examples of ATC and ATCvet codes

AMEG categories	Antimicrobial groups, subgroups and substances	Examples of ATC code(s)	Examples of ATCvet code(s)
A	Amidinopenicillins	J01CA08 (pivmecillinam), J01CA11 (mecillinam)	QJ01CA08 (pivmecillinam), QJ01CA11 (mecillinam)
A	Carbapenems	J01DH	QJ01DH
A	Other cephalosporins* and penems	J01DI	QJ01DI
A	Glycopeptides	J01XA	QJ01XA
A	Glycylcyclines	J01AA12 (tigecycline)	QJ01AA12 (tigecycline)
A	Lipopeptides	J01XX09 (daptomycin)	QJ01XX09 (daptomycin)
A	Monobactams	J01DF	QJ01DF
A	Oxazolidinones	J01XX08 (linezolid), J01XX11 (tedizolid)	QJ01XX08 (linezolid), QJ01XX11 (tedizolid)
A	Penicillins: Carboxypenicillins and ureidopenicillins, including combinations with $\beta$ -lactamase inhibitors	J01CA03 (carbenicillin), J01CA09 (azlocillin), J01CA10 (mezlocillin), J01CA12 (piperacillin), J01CA13 (ticarcillin), J01CR03 (ticarcillin and $\beta$ -lactamase inhibitor), J01CR05 (piperacillin and $\beta$ -lactamase inhibitor)	QJ01CA03 (carbenicillin), QJ01CA09 (azlocillin), QJ01CA10 (mezlocillin), QJ01CA12 (piperacillin), QJ01CA13 (ticarcillin), QJ01CR03 (ticarcillin and $\beta$ -lactamase inhibitor), QJ01CR05 (piperacillin and $\beta$ -lactamase inhibitor)
A	Phosphonic acid derivatives	J01XX01 (fosfomycin)	QJ01XX01 (fosfomycin)
A	Pseudomonic acid (mupirocin)	D06AX09, R01AX06	QD06AX09, QR01AX06
A	Riminofenazines	J04BA01 (clofazimine)	QJ04BA01 (clofazimine)
A	Streptogramins	J01FG	Q01FG, QJ01FG90 (virginiamycin)
A	Sulfones	J04BA02 (dapson)	QJ04BA02 (dapson)
A	Drugs used solely to treat tuberculosis or other mycobacterial diseases	J04AA, J04AC, J04AD, J04AK, J04AM	QJ04AA, QJ04AC, QJ04AD, QJ04AK, QJ04AM
B	Cephalosporins, 3 <sup>rd</sup> - and 4 <sup>th</sup> -generation	J01DD, J01DE	QJ01DD, QJ01DE
B	Polymyxins (e.g. colistin)	J01XB, A07AA10 (colistin), A07AA05 (polymyxin B)	QJ01XB, QJ51XB, QA07AA10 (colistin), QA07AA05 (polymyxin B), QA07AA98 (colistin, combinations with other antibiotics), QJ01RA95 (polymyxins, combinations with other antibacterials) QG51AG07 (ampicillin and colistin)
B	Quinolones: fluoroquinolones and other quinolones	J01MA, J01MB	QJ01MA, QJ01MB
C	Aminoglycosides and aminocyclitol	J01GA, J01GB, A07AA (includes locally acting aminoglycosides), J04AB30 (capreomycin)	QJ01GA, QJ01GB, QJ51GA, QJ51GB, QJ51RG, QJ01RA97, QA07AA (includes locally acting aminoglycosides, QA07AA01

AMEG categories	Antimicrobial groups, subgroups and substances	Examples of ATC code(s)	Examples of ATCvet code(s)
			(neomycin))
<b>C</b>	Aminopenicillins, in combination with $\beta$ -lactamase inhibitors (e.g. amoxicillin-clavulanic acid, co-amoxiclav)	J01CR	QJ01CR
<b>C</b>	Amphenicols	J01BA	QJ01BA
<b>C</b>	Cephalosporins, 1 <sup>st</sup> - and 2 <sup>nd</sup> -generation, and cephamycins	J01DB, J01DC	QJ01DB, QJ01DC
<b>C</b>	Macrolides	J01FA	QJ01FA
<b>C</b>	Lincosamides	J01FF	QJ01FF
<b>C</b>	Pleuromutilins		QJ01XQ
<b>C</b>	Rifamycins	J04AB02 (rifampicin), J04AB03 (rifamycin), J04AB04 (rifabutin) and J04AB05 (rifapentine), J04AM02/J04AM05/J04AM06 (rifamycin combinations), A07AA11 (rifaximin), A07AA13 (new code rifamycin)	QJ04AB02/QJ54AB02 (rifampicin), QJ04AB03/QJ54AB03 (rifamycin), QJ04AB04 (rifabutin) and QJ04AB05 (rifapentine), QJ04AM02/QJ04AM05/QJ04AM06 (rifamycin combinations), QA07AA11 (rifaximin), QA07AA13 (new code rifamycin)
<b>D</b>	Aminopenicillins, without $\beta$ -lactamase inhibitors	QJ01CA01 (ampicillin), QJ01CA03 (amoxicillin), QJ01CA51 (ampicillin, combinations)	QJ51CA01 (ampicillin), QJ51CA03 (amoxicillin), QJ51CA51 (ampicillin, combinations), QG51AG04/05/07 (different ampicillin combinations)
<b>D</b>	Cyclic polypeptides (bacitracin)	J01XX10 (bacitracin)	QJ01XX10 (bacitracin), QA07AA93
<b>D</b>	Nitrofurantoin derivatives (e.g. nitrofurantoin)	J01XE, P01CC, A07AX03 (nifuroxazide), A07AX04 (nifurzide)	QJ01XE, QP51AC, QA07AX03 (nifuroxazide), QA07AX04 (nifurzide)
<b>D</b>	Nitroimidazoles	J01XD, P01AB	QJ01XD, QP51AA
<b>D</b>	Penicillins: Anti-staphylococcal penicillins ( $\beta$ -lactamase-resistant penicillins)	J01CF	QJ01CF, QJ51CF
<b>D</b>	Penicillins: Natural, narrow-spectrum penicillins ( $\beta$ -lactamase-sensitive penicillins)	J01CE	QJ01CE, QJ51CE
<b>D</b>	Steroid antibacterials (fusidic acid)	J01XC	QJ01XC
<b>D</b>	Sulfonamides, dihydrofolate reductase inhibitors and	J01EA, J01EB, J01EC, J01ED, J01EE, A07AB	QJ01EA, QJ01EQ, QJ01EW, QP51AG, QJ51E, QJ51RE, QA07AB

AMEG categories	Antimicrobial groups, subgroups and substances	Examples of ATC code(s)	Examples of ATCvet code(s)
	combinations		
<b>D</b>	Tetracyclines	J01AA, J01RA08	QJ01AA, QJ51A, QJ51RA, QJ01RA90 (tetracyclines, combinations with other antibacterials), QJ01RA08

893 \*Other than 1<sup>st</sup>-, 2<sup>nd</sup>-, 3<sup>rd</sup>- and 4<sup>th</sup>-generation

894 Disclaimer: This table is only indicative and should not replace the ATC/DDD Index ([link](#)) and ATCvet  
895 Index ([link](#)).

896

### 897 **Annex 3 – References**

- 898 Aldred, K.J., R.J. Kerns, and N. Osheroff, 2014. 'Mechanism of quinolone action and resistance',  
899 Biochemistry, Vol. 53 (10), pp.1565-1574.
- 900 Álvarez-Pérez, S., J.L. Blanco, C. Harmanus, E. Kuijper, and M.E. García, 2017. 'Subtyping and  
901 antimicrobial susceptibility of Clostridium difficile PCR ribotype 078/126 isolates of human and  
902 animal origin', Veterinary microbiology, Vol. 199 pp.15-22.
- 903 Álvarez-Pérez, S., J.L. Blanco, E. Martínez-Navado, T. Peláez, C. Harmanus, E. Kuijper, and M.E.  
904 García, 2014. 'Shedding of Clostridium difficile PCR ribotype 078 by zoo animals, and report of  
905 an unstable metronidazole-resistant isolate from a zebra foal (Equus quagga burchellii)',  
906 Veterinary microbiology, Vol. 169 (3-4), pp.218-222.
- 907 Ando, H., T. Miyoshi-Akiyama, S. Watanabe, and T. Kirikae, 2014. 'A silent mutation in mabA confers  
908 isoniazid resistance on Mycobacterium tuberculosis', Molecular microbiology, Vol. 91 (3),  
909 pp.538-547.
- 910 Andrés-Lasheras, S., I. Martín-Burriel, R.C. Mainar-Jaime, M. Morales, E. Kuijper, J.L. Blanco, M.  
911 Chirino-Trejo, and R. Bolea, 2018. 'Preliminary studies on isolates of Clostridium difficile from  
912 dogs and exotic pets', BMC veterinary research, Vol. 14 (1), p.77.
- 913 Arlet, G., D. Nadjar, J.-L. Herrmann, J.-L. Donay, M. Rouveau, P.H. Lagrange, and A. Philippon, 2001.  
914 'Plasmid-mediated rifampin resistance encoded by an arr-2-like gene cassette in Klebsiella  
915 pneumoniae producing an ACC-1 class C  $\beta$ -lactamase', Antimicrobial agents and  
916 chemotherapy, Vol. 45 (10), pp.2971-2972.
- 917 Baines, S.D., R. O'connor, J. Freeman, W.N. Fawley, C. Harmanus, P. Mastrantonio, E.J. Kuijper, and  
918 M.H. Wilcox, 2008. 'Emergence of reduced susceptibility to metronidazole in Clostridium  
919 difficile', Journal of antimicrobial chemotherapy, Vol. 62 (5), pp.1046-1052.
- 920 Bayer, A.S., T. Schneider, and H.G. Sahl, 2013. 'Mechanisms of daptomycin resistance in  
921 Staphylococcus aureus: role of the cell membrane and cell wall', Annals of the New York  
922 Academy of Sciences, Vol. 1277 (1), pp.139-158.
- 923 Becker, K., S. van Alen, E.A. Idelevich, N. Schleimer, J. Seggewiß, A. Mellmann, U. Kaspar, and G.  
924 Peters, 2018. 'Plasmid-encoded transferable mecB-mediated methicillin resistance in  
925 Staphylococcus aureus', Emerging infectious diseases, Vol. 24 (2), p.242.
- 926 Bernardes-Genisson, V., C. Deraeve, A. Chollet, J. Bernadou, and G. Pratviel, 2013. 'Isoniazid: an  
927 update on the multiple mechanisms for a singular action', Current medicinal chemistry, Vol. 20  
928 (35), pp.4370-4385.
- 929 Bibbal, D., V. Dupouy, J.-P. Ferré, P.-L. Toutain, O. Fayet, M.-F. Prère, and A. Bousquet-Mélou, 2007.  
930 'Impact of three ampicillin dosage regimens on selection of ampicillin resistance in  
931 Enterobacteriaceae and excretion of blaTEM genes in swine feces', Applied and Environmental  
932 Microbiology, Vol. 73 (15), pp.4785-4790.
- 933 Bonilla, H., M.D. Huband, J. Seidel, H. Schmidt, M. Lescoe, S.P. McCurdy, M.M. Lemmon, L.A. Brennan,  
934 A. Tait-Kamradt, and L. Puzniak, 2010. 'Multicity outbreak of linezolid-resistant Staphylococcus  
935 epidermidis associated with clonal spread of a cfr-containing strain', Clinical infectious  
936 diseases, Vol. 51 (7), pp.796-800.

- 937 Braga, T.M., C. Pomba, and M.F.S. Lopes, 2013. 'High-level vancomycin resistant *Enterococcus*  
938 *faecium* related to humans and pigs found in dust from pig breeding facilities', *Veterinary*  
939 *microbiology*, Vol. 161 (3-4), pp.344-349.
- 940 Brazier, J.S., S.L. Stubbs, and B.I. Duerden, 1999. 'Metronidazole resistance among clinical isolates  
941 belonging to the *Bacteroides fragilis* group: time to be concerned?', *Journal of Antimicrobial*  
942 *Chemotherapy*, Vol. 44 (4), pp.580-581.
- 943 Bulajic, S., S. Colovic, D. Misic, J. Djordjevic, R. Savic-Radovanovic, J. Asanin, and T. Ledina, 2017.  
944 'Enterotoxin production and antimicrobial susceptibility in *S taphylococci* isolated from  
945 traditional raw milk cheeses in Serbia', *Journal of Environmental Science and Health, Part B*,  
946 Vol. 52 (12), pp.864-870.
- 947 Bush, K., and G.A. Jacoby, 2010. 'Updated functional classification of  $\beta$ -lactamases', *Antimicrobial*  
948 *agents and chemotherapy*, Vol. 54 (3), pp.969-976.
- 949 Butaye, P., A. Cloeckert, and S. Schwarz, 2003. 'Mobile genes coding for efflux-mediated  
950 antimicrobial resistance in Gram-positive and Gram-negative bacteria', *International journal of*  
951 *antimicrobial agents*, Vol. 22 (3), pp.205-210.
- 952 Butaye, P., G.B. Michael, S. Schwarz, T.J. Barrett, A. Brisabois, and D.G. White, 2006. 'The clonal  
953 spread of multidrug-resistant non-typhi *Salmonella* serotypes', *Microbes and Infection*, Vol. 8  
954 (7), pp.1891-1897.
- 955 Carattoli, A., 2009. 'Resistance plasmid families in *Enterobacteriaceae*', *Antimicrobial agents and*  
956 *chemotherapy*, Vol. 53 (6), pp.2227-2238.
- 957 Casapao, A.M., M.E. Steed, D.P. Levine, and M.J. Rybak, 2012. 'Ceftaroline fosamil for community-  
958 acquired bacterial pneumonia and acute bacterial skin and skin structure infection', *Expert*  
959 *opinion on pharmacotherapy*, Vol. 13 (8), pp.1177-1186.
- 960 Catry, B., 2017. 'Antimicrobial policies in animals and human health', *Archives of Public Health*, Vol. 75  
961 (1), p.62.
- 962 Catry, B., E. Van Duijkeren, M.C. Pomba, C. Greko, M.A. Moreno, S. Pyorala, M. Ruzauskas, P.  
963 Sanders, E.J. Threlfall, F. Ungemach, K. Torneke, C. Munoz-Madero, and J. Torren-Edo, 2010.  
964 'Reflection paper on MRSA in food-producing and companion animals: epidemiology and control  
965 options for human and animal health', *Epidemiol Infect*, Vol. 138 (5), pp.626-644.
- 966 Chancey, S.T., D. Zähler, and D.S. Stephens, 2012. 'Acquired inducible antimicrobial resistance in  
967 Gram-positive bacteria', *Future microbiology*, Vol. 7 (8), pp.959-978.
- 968 Chantziaras, I., A. Smet, F. Haesebrouck, F. Boyen, and J. Dewulf, 2017. 'Studying the effect of  
969 administration route and treatment dose on the selection of enrofloxacin resistance in  
970 commensal *Escherichia coli* in broilers', *Journal of Antimicrobial Chemotherapy*, Vol. 72 (7),  
971 pp.1991-2001.
- 972 Chardin, H., K. Yasukawa, N. Nouacer, C. Plainvert, P. Aucouturier, A. Ergani, V. Descroix, R. Toledo-  
973 Arenas, J. Azerad, and A. Bouvet, 2009. 'Reduced susceptibility to amoxicillin of oral  
974 streptococci following amoxicillin exposure', *Journal of medical microbiology*, Vol. 58 (8),  
975 pp.1092-1097.
- 976 Charlebois, A., L.-A. Jalbert, J. Harel, L. Masson, and M. Archambault, 2012. 'Characterization of genes  
977 encoding for acquired bacitracin resistance in *Clostridium perfringens*', *PLoS One*, Vol. 7 (9),  
978 p.e44449.
- 979 Checkley, S.L., J.R. Campbell, M. Chirino-Trejo, E.D. Janzen, and C.L. Waldner, 2010. 'Associations  
980 between antimicrobial use and the prevalence of antimicrobial resistance in fecal *Escherichia*  
981 *coli* from feedlot cattle in western Canada', *The Canadian Veterinary Journal*, Vol. 51 (8),  
982 p.853.
- 983 Chen, H.-J., W.-C. Hung, Y.-T. Lin, J.-C. Tsai, H.-C. Chiu, P.-R. Hsueh, and L.-J. Teng, 2014. 'A novel  
984 fusidic acid resistance determinant, *fusF*, in *Staphylococcus cohnii*', *Journal of Antimicrobial*  
985 *Chemotherapy*, Vol. 70 (2), pp.416-419.
- 986 Chen, H.-J., W.-C. Hung, S.-P. Tseng, J.-C. Tsai, P.-R. Hsueh, and L.-J. Teng, 2010. 'Fusidic acid  
987 resistance determinants in *Staphylococcus aureus* clinical isolates', *Antimicrobial agents and*  
988 *chemotherapy*, Vol. 54 (12), pp.4985-4991.
- 989 Chen, L., Z.L. Chen, J.H. Liu, Z.L. Zeng, J.Y. Ma, and H.X. Jiang, 2007. 'Emergence of *RmtB*  
990 methylase-producing *Escherichia coli* and *Enterobacter cloacae* isolates from pigs in China', *J*  
991 *Antimicrob Chemother*, Vol. 59 (5), pp.880-885.
- 992 Chen, M.-Y., F. Lira, H.-Q. Liang, R.-T. Wu, J.-H. Duan, X.-P. Liao, J.L. Martínez, Y.-H. Liu, and J. Sun,  
993 2016. 'Multilevel selection of *bcrABDR*-mediated bacitracin resistance in *Enterococcus faecalis*  
994 from chicken farms', *Scientific reports*, Vol. 6 p.34895.

- 995 Chen, X., W. Zhang, W. Pan, J. Yin, Z. Pan, S. Gao, and X. Jiao, 2012. 'Prevalence of qnr, aac (6')-Ib-  
996 cr, qepA, and oqxAB in Escherichia coli Isolates from Humans, Animals, and Environment',  
997 Antimicrobial agents and chemotherapy, Vol. pp.AAC. 06191-06111.
- 998 Chopra, I., and M. Roberts, 2001. 'Tetracycline antibiotics: mode of action, applications, molecular  
999 biology, and epidemiology of bacterial resistance', Microbiol Mol Biol Rev, Vol. 65 (2), pp.232-  
1000 260 ; second page, table of contents.
- 1001 Clark, S., A. Loeffler, and R. Bond, 2015. 'Susceptibility in vitro of canine methicillin-resistant and-  
1002 susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities  
1003 for topical therapy of canine superficial pyoderma', Journal of Antimicrobial Chemotherapy, Vol.  
1004 70 (7), pp.2048-2052.
- 1005 Codex Alimentarius, 2009. 'Code of practice to minimize and contain antimicrobial resistance (CAC/RCP  
1006 61-2005). Animal food production. Second edition',  
1007 <http://www.fao.org/docrep/012/i1111e/i1111e.pdf>
- 1008 Codex Alimentarius, 2011. 'Guidelines for risk analysis of foodborne antimicrobial resistance (CAC/GL  
1009 77- 2011)', [http://www.codexalimentarius.org/download/standards/11776/CXG\\_077e.pdf](http://www.codexalimentarius.org/download/standards/11776/CXG_077e.pdf)
- 1010 Crémieux, A.-C., C. Muller-Serieys, X. Panhard, F. Delatour, M. Tchimichkian, F. Mentre, and A.  
1011 Andremont, 2003. 'Emergence of resistance in normal human aerobic commensal flora during  
1012 telithromycin and amoxicillin-clavulanic acid treatments', Antimicrobial agents and  
1013 chemotherapy, Vol. 47 (6), pp.2030-2035.
- 1014 Curcio, D., 2014. 'Multidrug-resistant Gram-negative bacterial infections: are you ready for the  
1015 challenge?', Current clinical pharmacology, Vol. 9 (1), pp.27-38.
- 1016 Davis, M.A., K.N. Baker, L.H. Orfe, D.H. Shah, T.E. Besser, and D.R. Call, 2010. 'Discovery of a gene  
1017 conferring multiple-aminoglycoside resistance in Escherichia coli', Antimicrobial agents and  
1018 chemotherapy, Vol. 54 (6), pp.2666-2669.
- 1019 Deng, Y., L. He, S. Chen, H. Zheng, Z. Zeng, Y. Liu, Y. Sun, J. Ma, Z. Chen, and J.H. Liu, 2011. 'F33:A-  
1020 :B- and F2:A-:B- plasmids mediate dissemination of rmtB-blaCTX-M-9 group genes and rmtB-  
1021 qepA in Enterobacteriaceae isolates from pets in China', Antimicrob Agents Chemother, Vol. 55  
1022 (10), pp.4926-4929.
- 1023 Desroches, M., J. Potier, F. Laurent, A.-S. Bourrel, F. Doucet-Populaire, J.-W. Decusser, M.  
1024 Archambaud, G. Aubert, M. Biendo, and G. Blanchard-Marche, 2013. 'Prevalence of mupirocin  
1025 resistance among invasive coagulase-negative staphylococci and methicillin-resistant  
1026 Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone  
1027 harbouring mupA', Journal of Antimicrobial Chemotherapy, Vol. 68 (8), pp.1714-1717.
- 1028 Diaz, L., P. Kiratisin, R.E. Mendes, D. Panesso, K.V. Singh, and C.A. Arias, 2012. 'Transferable plasmid-  
1029 mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis',  
1030 Antimicrob Agents Chemother, Vol. 56 (7), pp.3917-3922.
- 1031 Dingsdag, S.A., and N. Hunter, 2017. 'Metronidazole: an update on metabolism, structure-cytotoxicity  
1032 and resistance mechanisms', Journal of Antimicrobial Chemotherapy, Vol.
- 1033 Dortet, L., L. Poirel, and P. Nordmann, 2014. 'Worldwide dissemination of the NDM-type  
1034 carbapenemases in Gram-negative bacteria', BioMed research international, Vol. 2014
- 1035 Du, X.D., C.M. Wu, H.B. Liu, X.S. Li, R.C. Beier, F. Xiao, S.S. Qin, S.Y. Huang, and J.Z. Shen, 2009.  
1036 'Plasmid-mediated ArmA and RmtB 16S rRNA methylases in Escherichia coli isolated from  
1037 chickens', J Antimicrob Chemother, Vol. 64 (6), pp.1328-1330.
- 1038 ECDC/EFSA/EMA, 2017. 'Second joint report on the integrated analysis of the consumption of  
1039 antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and  
1040 food-producing animals (JIACRA II)',  
1041 [https://www.ema.europa.eu/documents/report/ecdc/efsa/ema-second-joint-report-integrated-  
1042 analysis-consumption-antimicrobial-agents-occurrence\\_en.pdf](https://www.ema.europa.eu/documents/report/ecdc/efsa/ema-second-joint-report-integrated-analysis-consumption-antimicrobial-agents-occurrence_en.pdf)
- 1043 EFSA, 2010. 'Scientific Opinion on monitoring and assessment of the public health risk of "Salmonella  
1044 Typhimurium-like" strains', 8. <http://www.efsa.europa.eu/en/efsajournal/doc/1826.pdf>
- 1045 EFSA BIOHAZ Panel, 2011. 'Scientific Opinion on the public health risks of bacterial strains producing  
1046 extended-spectrum  $\beta$ -lactamases and/or AmpC  $\beta$ -lactamases in food and food-producing  
1047 animals', EFSA Journal, Vol. 9(8):2322
- 1048 EFSA BIOHAZ Panel, 2013. 'Scientific Opinion on Carbapenem resistance in food animal ecosystems',  
1049 EFSA Journal, Vol. 11(12) (3501), p.70.
- 1050 EMA/AMEG, 2013. 'Use of glycolcyclines in animals in the European Union: development of resistance  
1051 and possible impact on human and animal health',  
1052 [https://www.ema.europa.eu/documents/report/use-glycolcyclines-animals-european-union-  
1053 development-resistance-possible-impact-human-animal-health\\_en.pdf](https://www.ema.europa.eu/documents/report/use-glycolcyclines-animals-european-union-development-resistance-possible-impact-human-animal-health_en.pdf)

- 1054 EMA/AMEG, 2014. 'Answers to the requests for scientific advice on the impact on public health and  
1055 animal health of the use of antibiotics in animals - Answer to the second request from the EC  
1056 (ranking of antibiotics); Answer to the third request from the EC (new antibiotics); Answer to  
1057 the fourth request from the EC (risk mitigation options) (EMA/381884/2014)',  
1058 [https://www.ema.europa.eu/documents/other/answers-requests-scientific-advice-impact-](https://www.ema.europa.eu/documents/other/answers-requests-scientific-advice-impact-public-health-animal-health-use-antibiotics-animals_en.pdf)  
1059 [public-health-animal-health-use-antibiotics-animals\\_en.pdf](https://www.ema.europa.eu/documents/other/answers-requests-scientific-advice-impact-public-health-animal-health-use-antibiotics-animals_en.pdf)
- 1060 EMA/AMEG, 2016. 'Updated advice on the use of colistin products in animals within the European  
1061 Union: development of resistance and possible impact on human and animal health  
1062 (EMA/CVMP/CHMP/231573/2016)', [https://www.ema.europa.eu/documents/scientific-](https://www.ema.europa.eu/documents/scientific-guideline/updated-advice-use-colistin-products-animals-within-european-union-development-resistance-possible_en-0.pdf)  
1063 [guideline/updated-advice-use-colistin-products-animals-within-european-union-development-](https://www.ema.europa.eu/documents/scientific-guideline/updated-advice-use-colistin-products-animals-within-european-union-development-resistance-possible_en-0.pdf)  
1064 [resistance-possible\\_en-0.pdf](https://www.ema.europa.eu/documents/scientific-guideline/updated-advice-use-colistin-products-animals-within-european-union-development-resistance-possible_en-0.pdf)
- 1065 EMA/CVMP, 2010. 'Opinion following an Article 35 referral for all veterinary medicinal products  
1066 containing quinolones including fluoroquinolones intended for use in food-producing species',  
1067 [https://www.ema.europa.eu/documents/referral/opinion-following-article-35-referral-all-](https://www.ema.europa.eu/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones_en.pdf)  
1068 [veterinary-medicinal-products-containing-quinolones\\_en.pdf](https://www.ema.europa.eu/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones_en.pdf)
- 1069 EMA/CVMP. 2012. Opinion following an Article 35 referral for all veterinary medicinal products  
1070 containing systemically administered (parenteral and oral) 3rd and 4th generation  
1071 cephalosporins intended for use in food producing species. In  
1072 <https://www.ema.europa.eu/medicines/veterinary/referrals/cephalosporins>.
- 1073 EMA/CVMP/AWP, 2018a. 'Reflection paper on the use of aminopenicillins and their beta-lactamase  
1074 inhibitor combinations in animals in the European Union: development of resistance and impact  
1075 on human and animal health (EMA/CVMP/AWP/842786/2015)',  
1076 [https://www.ema.europa.eu/aminopenicillins-their-beta-lactamase-inhibitor-combinations-](https://www.ema.europa.eu/aminopenicillins-their-beta-lactamase-inhibitor-combinations-animals-european-union-development)  
1077 [animals-european-union-development](https://www.ema.europa.eu/aminopenicillins-their-beta-lactamase-inhibitor-combinations-animals-european-union-development)
- 1078 EMA/CVMP/AWP, 2018b. 'Reflection paper on use of aminoglycosides in animals in the European  
1079 Union: development of resistance and impact on human and animal health  
1080 (EMA/CVMP/AWP/721118/2014)', [https://www.ema.europa.eu/en/use-aminoglycosides-](https://www.ema.europa.eu/en/use-aminoglycosides-animals-european-union-development-resistance-impact-human-animal-health)  
1081 [animals-european-union-development-resistance-impact-human-animal-health](https://www.ema.europa.eu/en/use-aminoglycosides-animals-european-union-development-resistance-impact-human-animal-health)
- 1082 EMA/CVMP/SAGAM, 2011. 'Reflection paper on the use of macrolides, lincosamides and streptogramins  
1083 (MLS) in food-producing animals in the European Union: development of resistance and impact  
1084 on human and animal health', [https://www.ema.europa.eu/en/use-macrolides-lincosamides-](https://www.ema.europa.eu/en/use-macrolides-lincosamides-streptogramins-food-producing-animals-european-union-development)  
1085 [streptogramins-food-producing-animals-european-union-development](https://www.ema.europa.eu/en/use-macrolides-lincosamides-streptogramins-food-producing-animals-european-union-development)
- 1086 EMA/EFSA, 2017. 'Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents  
1087 in animal husbandry in the European Union, and the resulting impacts on food safety  
1088 (RONAFA)', 15:1. [https://www.ema.europa.eu/en/veterinary-](https://www.ema.europa.eu/en/veterinary-regulatory/overview/antimicrobial-resistance/advice-impacts-using-antimicrobials-animals/reducing-use-antimicrobial-agents-animal-husbandry)  
1089 [regulatory/overview/antimicrobial-resistance/advice-impacts-using-antimicrobials-](https://www.ema.europa.eu/en/veterinary-regulatory/overview/antimicrobial-resistance/advice-impacts-using-antimicrobials-animals/reducing-use-antimicrobial-agents-animal-husbandry)  
1090 [animals/reducing-use-antimicrobial-agents-animal-husbandry](https://www.ema.europa.eu/en/veterinary-regulatory/overview/antimicrobial-resistance/advice-impacts-using-antimicrobials-animals/reducing-use-antimicrobial-agents-animal-husbandry)
- 1091 EMA/ESVAC, 2017. 'European Medicines Agency, European Surveillance of Veterinary Antimicrobial  
1092 Consumption. Sales of veterinary antimicrobial agents in 30 European countries in 2015  
1093 (EMA/184855/2017). Trends from 2010 to 2015. Seventh ESVAC report.',  
1094 [https://www.ema.europa.eu/documents/report/seventh-esvac-report-sales-veterinary-](https://www.ema.europa.eu/documents/report/seventh-esvac-report-sales-veterinary-antimicrobial-agents-30-european-countries-2015_en.pdf)  
1095 [antimicrobial-agents-30-european-countries-2015\\_en.pdf](https://www.ema.europa.eu/documents/report/seventh-esvac-report-sales-veterinary-antimicrobial-agents-30-european-countries-2015_en.pdf)
- 1096 EMEA/CVMP/SAGAM, 2007. 'Public statement on the use of (fluoro)quinolones in food-producing  
1097 animals in the European Union: development of resistance and impact on human and animal  
1098 health (EMEA/CVMP/SAGAM/184651/2005)',  
1099 [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Public\\_statement/2009/10/WC5000](http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/10/WC500005152.pdf)  
1100 [05152.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/10/WC500005152.pdf)
- 1101 EMEA/CVMP/SAGAM, 2009. 'Revised reflection paper on the use of 3rd and 4th generation  
1102 cephalosporins in food producing animals in the European Union: development of resistance  
1103 and impact on human and animal health (EMEA/CVMP/SAGAM/81730/2006-Rev.1)',  
1104 [https://www.ema.europa.eu/documents/scientific-guideline/revised-reflection-paper-use-third-](https://www.ema.europa.eu/documents/scientific-guideline/revised-reflection-paper-use-third-fourth-generation-cephalosporins-food-producing-animals-european_en.pdf)  
1105 [fourth-generation-cephalosporins-food-producing-animals-european\\_en.pdf](https://www.ema.europa.eu/documents/scientific-guideline/revised-reflection-paper-use-third-fourth-generation-cephalosporins-food-producing-animals-european_en.pdf)
- 1106 Endimiani, A., M. Blackford, E.C. Dasenbrook, M.D. Reed, S. Bajaksouszian, A.M. Hujer, S.D. Rudin,  
1107 K.M. Hujer, V. Perreten, and L.B. Rice, 2011. 'Emergence of linezolid-resistant *Staphylococcus*  
1108 *aureus* after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio', *Antimicrobial*  
1109 *agents and chemotherapy*, Vol. 55 (4), pp.1684-1692.
- 1110 Enne, V.I., D.M. Livermore, P. Stephens, and L. Hall, 2001. 'Persistence of sulphonamide resistance in  
1111 *Escherichia coli* in the UK despite national prescribing restriction', *The Lancet*, Vol. 357 (9265),  
1112 pp.1325-1328.

- 1113 Estrada, A., D.L. Wright, and A.C. Anderson, 2016. 'Antibacterial antifolates: from development  
1114 through resistance to the next generation', *Cold Spring Harbor perspectives in medicine*, Vol. 6  
1115 (8),  
1116 European Commission, 2015. 'Commission staff working document - Guidelines for the prudent use of  
1117 antimicrobials in veterinary medicine. Practical examples (SWD(2015) 171 final)',  
1118 [http://ec.europa.eu/health/sites/health/files/antimicrobial\\_resistance/docs/2015\\_prudent\\_use](http://ec.europa.eu/health/sites/health/files/antimicrobial_resistance/docs/2015_prudent_use_guidelines_annex_en.pdf)  
1119 [\\_guidelines\\_annex\\_en.pdf](http://ec.europa.eu/health/sites/health/files/antimicrobial_resistance/docs/2015_prudent_use_guidelines_annex_en.pdf)  
1120 Fernández, J., B. Guerra, and M. Rodicio, 2018. 'Resistance to Carbapenems in Non-Typhoidal  
1121 Salmonella enterica Serovars from Humans, Animals and Food', *Veterinary sciences*, Vol. 5 (2),  
1122 p.40.  
1123 Filippitzi, M., B. Callens, B. Pardon, D. Persoons, and J. Dewulf, 2014. 'Antimicrobial use in pigs,  
1124 broilers and veal calves in Belgium', *VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT*, Vol. 83 (5),  
1125 pp.215-224.  
1126 Filippitzi, M.E. 2018. Modelling the risks and consequences of antimicrobial treatment in pigs through  
1127 feed and water mass medication (PhD dissertation). In Ghent University Belgium.  
1128 Filippitzi, M.E., S. Sarrazin, H. Imberechts, A. Smet, and J. Dewulf, 2016. 'Risk of cross-contamination  
1129 due to the use of antimicrobial medicated feed throughout the trail of feed from the feed mill to  
1130 the farm', *Food Additives & Contaminants: Part A*, Vol. 33 (4), pp.644-655.  
1131 Fischer, J., M. San José, N. Roschanski, S. Schmogger, B. Baumann, A. Irrgang, A. Friese, U. Roesler, R.  
1132 Helmuth, and B. Guerra, 2017. 'Spread and persistence of VIM-1 Carbapenemase-producing  
1133 Enterobacteriaceae in three German swine farms in 2011 and 2012', *Veterinary microbiology*,  
1134 Vol. 200 pp.118-123.  
1135 Floss, H.G., and T.-W. Yu, 2005. 'Rifamycin mode of action, resistance, and biosynthesis', *Chemical*  
1136 *reviews*, Vol. 105 (2), pp.621-632.  
1137 Freeman, J., J. Vernon, K. Morris, S. Nicholson, S. Todhunter, C. Longshaw, and M.H. Wilcox, 2015.  
1138 'Pan-European longitudinal surveillance of antibiotic resistance among prevalent *Clostridium*  
1139 *difficile* ribotypes', *Clinical Microbiology and Infection*, Vol. 21 (3), pp.248. e249-248. e216.  
1140 Fridomdt-Moller, N., 2017. 'Mecillinam-Reversion of Resistance and How to Test It', *EBioMedicine*, Vol.  
1141 23 pp.4-5.  
1142 Gagneux, S., 2012. 'Host-pathogen coevolution in human tuberculosis', *Phil. Trans. R. Soc. B*, Vol. 367  
1143 (1590), pp.850-859.  
1144 García, V., I. Montero, M. Bances, R. Rodicio, and M.R. Rodicio, 2017. 'Incidence and Genetic Bases of  
1145 Nitrofurantoin Resistance in Clinical Isolates of Two Successful Multidrug-Resistant Clones of  
1146 *Salmonella enterica* Serovar Typhimurium: Pandemic "DT 104" and pUO-StVR2', *Microbial Drug*  
1147 *Resistance*, Vol. 23 (4), pp.405-412.  
1148 Gazouli, M., L.S. Tzouveleki, E. Prinarakis, V. Miriagou, and E. Tzelepi, 1996. 'Transferable cefoxitin  
1149 resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated  
1150 group 1 beta-lactamase (LAT-2)', *Antimicrobial agents and chemotherapy*, Vol. 40 (7),  
1151 pp.1736-1740.  
1152 Giske, C.G., 2015. 'Contemporary resistance trends and mechanisms for the old antibiotics colistin,  
1153 temocillin, fosfomicin, mecillinam and nitrofurantoin', *Clinical Microbiology and Infection*, Vol.  
1154 21 (10), pp.899-905.  
1155 Gonzalez-Zorn, B., T. Teshager, M. Casas, M.C. Porrero, M.A. Moreno, P. Courvalin, and L. Dominguez,  
1156 2005. 'armA and aminoglycoside resistance in *Escherichia coli*', *Emerg Infect Dis*, Vol. 11 (6),  
1157 pp.954-956.  
1158 Graveland, H., J.A. Wagenaar, H. Heesterbeek, D. Mevius, E. van Duijkeren, and D. Heederik, 2010.  
1159 'Methicillin resistant *Staphylococcus aureus* ST398 in veal calf farming: human MRSA carriage  
1160 related with animal antimicrobial usage and farm hygiene', *PLoS One*, Vol. 5 (6), p.e10990.  
1161 Grøntvedt, C.A., P. Elstrøm, M. Stegger, R.L. Skov, P. Skytt Andersen, K.W. Larssen, A.M. Urdahl, Ø.  
1162 Angen, J. Larsen, and S. Åmdal, 2016. 'Methicillin-resistant *Staphylococcus aureus* CC398 in  
1163 humans and pigs in Norway: a "One Health" perspective on introduction and transmission',  
1164 *Clinical Infectious Diseases*, Vol. 63 (11), pp.1431-1438.  
1165 Grosset, J.H., T. Singer, and W.R. Bishai, 2012. 'New drugs for the treatment of tuberculosis: hope and  
1166 reality [State of the Art Series. New tools. Number 2 in the series]', *The International Journal*  
1167 *of Tuberculosis and Lung Disease*, Vol. 16 (8), pp.1005-1014.  
1168 Gu, B., T. Kelesidis, S. Tsiodras, J. Hindler, and R.M. Humphries, 2012. 'The emerging problem of  
1169 linezolid-resistant *Staphylococcus*', *Journal of Antimicrobial Chemotherapy*, Vol. 68 (1), pp.4-  
1170 11.  
1171 Halaby, T., N. Al Naiemi, J. Kluytmans, J. van der Palen, and C.M. Vandenbroucke-Grauls, 2013.  
1172 'Emergence of colistin resistance in enterobacteriaceae after the introduction of selective

- 1173 digestive tract decontamination in an intensive care unit', *Antimicrob Agents Chemother*, Vol.  
 1174 57 (7), pp.3224-3229.
- 1175 Han, X., X.-D. Du, L. Southey, D.M. Bulach, T. Seemann, X.-X. Yan, T.L. Bannam, and J.I. Rood, 2015.  
 1176 'Functional analysis of a bacitracin resistance determinant located on ICECp1, a novel Tn916-  
 1177 like element from a conjugative plasmid in *Clostridium perfringens*', *Antimicrobial agents and*  
 1178 *chemotherapy*, Vol. 59 (11), pp.6855-6865.
- 1179 Hanon, J.-B., S. Jaspers, P. Butaye, P. Wattiau, E. Méroc, M. Aerts, H. Imberechts, K. Vermeersch, and  
 1180 Y. Van der Stede, 2015. 'A trend analysis of antimicrobial resistance in commensal *Escherichia*  
 1181 *coli* from several livestock species in Belgium (2011–2014)', *Preventive veterinary medicine*,  
 1182 Vol. 122 (4), pp.443-452.
- 1183 Hartkoorn, R.C., S. Uplekar, and S.T. Cole, 2014. 'Cross-resistance between clofazimine and  
 1184 bedaquiline through upregulation of MmpL5 in *Mycobacterium tuberculosis*', *Antimicrobial*  
 1185 *agents and chemotherapy*, Vol. 58 (5), pp.2979-2981.
- 1186 Hauschild, T., A.T. Fessler, K. Kadlec, C. Billerbeck, and S. Schwarz, 2012. 'Detection of the novel  
 1187 vga(E) gene in methicillin-resistant *Staphylococcus aureus* CC398 isolates from cattle and  
 1188 poultry', *The Journal of Antimicrobial Chemotherapy*, Vol. 67 (2), pp.503-504.
- 1189 Hennequin, C., V. Ravet, and F. Robin, 2018. 'Plasmids carrying DHA-1  $\beta$ -lactamases', *European*  
 1190 *Journal of Clinical Microbiology & Infectious Diseases*, Vol. pp.1-13.
- 1191 Hershberger, E., S. Donabedian, K. Konstantinou, M.J. Zervos, and G.M. Eliopoulos, 2004.  
 1192 'Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and  
 1193 epidemiology', *Clinical infectious diseases*, Vol. 38 (1), pp.92-98.
- 1194 Heuer, O.E., K. Pedersen, L.B. Jensen, M. Madsen, and J. Olsen, 2002. 'Persistence of vancomycin-  
 1195 resistant enterococci (VRE) in broiler houses after the avoparcin ban', *Microbial Drug*  
 1196 *Resistance*, Vol. 8 (4), pp.355-361.
- 1197 Ho, P.-L., K.-Y. Ng, W.-U. Lo, P.Y. Law, E.L.-Y. Lai, Y. Wang, and K.-H. Chow, 2016. 'Plasmid-mediated  
 1198 OqxAB is an important mechanism for nitrofurantoin resistance in *Escherichia coli*',  
 1199 *Antimicrobial agents and chemotherapy*, Vol. 60 (1), pp.537-543.
- 1200 Hopkins, K.L., J.A. Escudero, L. Hidalgo, and B. Gonzalez-Zorn, 2010a. '16S rRNA methyltransferase  
 1201 RmtC in *Salmonella enterica* serovar Virchow', *Emerging infectious diseases*, Vol. 16 (4),  
 1202 p.712.
- 1203 Hopkins, K.L., J.A. Escudero, L. Hidalgo, and B. Gonzalez-Zorn, 2010b. '16S rRNA methyltransferase  
 1204 RmtC in *Salmonella enterica* serovar Virchow', *Emerg Infect Dis*, Vol. 16 (4), pp.712-715.
- 1205 Hsu, J.-T., C.-Y. Chen, C.-W. Young, W.-L. Chao, M.-H. Li, Y.-H. Liu, C.-M. Lin, and C. Ying, 2014.  
 1206 'Prevalence of sulfonamide-resistant bacteria, resistance genes and integron-associated  
 1207 horizontal gene transfer in natural water bodies and soils adjacent to a swine feedlot in  
 1208 northern Taiwan', *Journal of hazardous materials*, Vol. 277 pp.34-43.
- 1209 Hurdle, J.G., A.J. O'Neill, L. Mody, I. Chopra, and S.F. Bradley, 2005. 'In vivo transfer of high-level  
 1210 mupirocin resistance from *Staphylococcus epidermidis* to methicillin-resistant *Staphylococcus*  
 1211 *aureus* associated with failure of mupirocin prophylaxis', *Journal of Antimicrobial*  
 1212 *Chemotherapy*, Vol. 56 (6), pp.1166-1168.
- 1213 Jacoby, G., 2012. ' $\beta$ -Lactamase classification and amino acid sequences for TEM, SHV and OXA  
 1214 extended-spectrum and inhibitor resistant enzymes', <http://www.lahey.org/Studies/>
- 1215 Kadlec, K., A.T. Fessler, T. Hauschild, and S. Schwarz, 2012. 'Novel and uncommon antimicrobial  
 1216 resistance genes in livestock-associated methicillin-resistant *Staphylococcus aureus*', *Clin*  
 1217 *Microbiol Infect*, Vol. 18 (8), pp.745-755.
- 1218 Kadlec, K., C.F. Pomba, N. Couto, and S. Schwarz, 2010. 'Small plasmids carrying vga(A) or vga(C)  
 1219 genes mediate resistance to lincosamides, pleuromutilins and streptogramin A antibiotics in  
 1220 methicillin-resistant *Staphylococcus aureus* ST398 from swine', *J Antimicrob Chemother*, Vol.  
 1221 65 (12), pp.2692-2693.
- 1222 Kadlec, K., and S. Schwarz, 2009. 'Novel ABC transporter gene, vga(C), located on a multiresistance  
 1223 plasmid from a porcine methicillin-resistant *Staphylococcus aureus* ST398 strain', *Antimicrobial*  
 1224 *Agents and Chemotherapy*, Vol. 53 (8), pp.3589-3591.
- 1225 Kahlmeter, G., and H.O. Poulsen, 2012. 'Antimicrobial susceptibility of *Escherichia coli* from  
 1226 community-acquired urinary tract infections in Europe: the ECO·SENS study revisited',  
 1227 *International journal of antimicrobial agents*, Vol. 39 (1), pp.45-51.
- 1228 Karageorgopoulos, D.E., V. Miriagou, L.S. Tzouveleakis, K. Spyridopoulou, and G.L. Daikos, 2012.  
 1229 'Emergence of resistance to fosfomycin used as adjunct therapy in KPC *Klebsiella pneumoniae*  
 1230 bacteraemia: report of three cases', *J Antimicrob Chemother*, Vol. 67 (11), pp.2777-2779.

- 1231 Kehrenberg, C., C. Cuny, B. Strommenger, S. Schwarz, and W. Witte, 2009. 'Methicillin-resistant and -  
 1232 susceptible *Staphylococcus aureus* strains of clonal lineages ST398 and ST9 from swine carry  
 1233 the multidrug resistance gene *cfr*', *Antimicrob Agents Chemother*, Vol. 53 (2), pp.779-781.
- 1234 Kehrenberg, C., and S. Schwarz, 2006. 'Distribution of florfenicol resistance genes *fexA* and *cfr* among  
 1235 chloramphenicol-resistant *Staphylococcus* isolates', *Antimicrob Agents Chemother*, Vol. 50 (4),  
 1236 pp.1156-1163.
- 1237 Kelesidis, T., 2015. 'The zoonotic potential of daptomycin non-susceptible enterococci', *Zoonoses and  
 1238 public health*, Vol. 62 (1), pp.1-6.
- 1239 Kelesidis, T., and A. Chow, 2014. 'Proximity to animal or crop operations may be associated with de  
 1240 novo daptomycin-non-susceptible *Enterococcus* infection', *Epidemiology & Infection*, Vol. 142  
 1241 (1), pp.221-224.
- 1242 Kinross, P., A. Petersen, R. Skov, E. Van Hauwermeiren, A. Pantosti, F. Laurent, A. Voss, J. Kluytmans,  
 1243 M.J. Struelens, and O. Heuer, 2017. 'Livestock-associated methicillin-resistant *Staphylococcus  
 1244 aureus* (MRSA) among human MRSA isolates, European Union/European Economic Area  
 1245 countries, 2013', *Eurosurveillance*, Vol. 22 (44),
- 1246 Kluytmans, J.A., I.T. Overvest, I. Willemsen, M.F. Kluytmans-Van Den Bergh, K. Van Der Zwaluw, M.  
 1247 Heck, M. Rijnsburger, C.M. Vandenbroucke-Grauls, P.H. Savelkoul, and B.D. Johnston, 2012.  
 1248 'Extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* from retail chicken meat and  
 1249 humans: comparison of strains, plasmids, resistance genes, and virulence factors', *Clinical  
 1250 Infectious Diseases*, Vol. 56 (4), pp.478-487.
- 1251 Knetsch, C., T. Connor, A. Mutreja, S. Van Dorp, I. Sanders, H. Browne, D. Harris, L. Lipman, E.  
 1252 Keessen, and J. Corver, 2014. 'Whole genome sequencing reveals potential spread of  
 1253 *Clostridium difficile* between humans and farm animals in the Netherlands, 2002 to 2011', *Euro  
 1254 surveillance: bulletin Europeen sur les maladies transmissibles= European communicable  
 1255 disease bulletin*, Vol. 19 (45), p.20954.
- 1256 Knothe, H., P. Shah, V. Krcmery, M. Antal, and S. Mitsuhashi, 1983. 'Transferable resistance to  
 1257 cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae*  
 1258 and *Serratia marcescens*', *Infection*, Vol. 11 (6), pp.315-317.
- 1259 Kuijper, E.J., and M.H. Wilcox. 2008. Decreased effectiveness of metronidazole for the treatment of  
 1260 *Clostridium difficile* infection? In *The University of Chicago Press*.
- 1261 Le Hello, S., D. Harrois, B. Bouchrif, L. Sontag, D. Elhani, V. Guibert, K. Zerouali, and F.-X. Weill,  
 1262 2013. 'Highly drug-resistant *Salmonella enterica* serotype Kentucky ST198-X1: a  
 1263 microbiological study', *The Lancet infectious diseases*, Vol. 13 (8), pp.672-679.
- 1264 Lees, P., T. Potter, L. Pelligand, and P.L. Toutain, 2018. 'Pharmacokinetic-pharmacodynamic  
 1265 integration and modelling of oxytetracycline for the calf pathogens *Mannheimia haemolytica*  
 1266 and *Pasteurella multocida*', *Journal of veterinary pharmacology and therapeutics*, Vol. 41 (1),  
 1267 pp.28-38.
- 1268 Levy, S.B., 2002. 'Factors impacting on the problem of antibiotic resistance', *Journal of Antimicrobial  
 1269 Chemotherapy*, Vol. 49 (1), pp.25-30.
- 1270 Li, L., X. Liao, Y. Yang, J. Sun, L. Li, B. Liu, S. Yang, J. Ma, X. Li, and Q. Zhang, 2013. 'Spread of  
 1271 *oqxAB* in *Salmonella enterica* serotype Typhimurium predominantly by IncHI2 plasmids',  
 1272 *Journal of Antimicrobial Chemotherapy*, Vol. 68 (10), pp.2263-2268.
- 1273 Liebana, E., A. Carattoli, T.M. Coque, H. Hasman, A.P. Magiorakos, D. Mevius, L. Peixe, L. Poirel, G.  
 1274 Schuepbach-Regula, K. Torneke, J. Torren-Edo, C. Torres, and J. Threlfall, 2013. 'Public health  
 1275 risks of enterobacterial isolates producing extended-spectrum beta-lactamases or AmpC beta-  
 1276 lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical  
 1277 methods, risk factors, and control options', *Clin Infect Dis*, Vol. 56 (7), pp.1030-1037.
- 1278 Liu, B.-T., Q.-E. Yang, L. Li, J. Sun, X.-P. Liao, L.-X. Fang, S.-S. Yang, H. Deng, and Y.-H. Liu, 2013.  
 1279 'Dissemination and characterization of plasmids carrying *oqxAB*-*bla*CTX-M genes in *Escherichia  
 1280 coli* isolates from food-producing animals', *PLoS one*, Vol. 8 (9), p.e73947.
- 1281 Liu, B., H. Wu, Y. Zhai, Z. He, H. Sun, T. Cai, D. He, J. Liu, S. Wang, and Y. Pan, 2018. 'Prevalence  
 1282 and molecular characterization of *oqxAB* in clinical *Escherichia coli* isolates from companion  
 1283 animals and humans in Henan Province, China', *Antimicrobial Resistance & Infection Control*,  
 1284 Vol. 7 (1), p.18.
- 1285 Liu, J.H., Y.T. Deng, Z.L. Zeng, J.H. Gao, L. Chen, Y. Arakawa, and Z.L. Chen, 2008. 'Coprovalence of  
 1286 plasmid-mediated quinolone resistance determinants *QepA*, *Qnr*, and *AAC(6')-Ib-cr* among 16S  
 1287 rRNA methylase *RmtB*-producing *Escherichia coli* isolates from pigs', *Antimicrob Agents  
 1288 Chemother*, Vol. 52 (8), pp.2992-2993.
- 1289 Liu, Y.-Y., Y. Wang, T.R. Walsh, L.-X. Yi, R. Zhang, J. Spencer, Y. Doi, G. Tian, B. Dong, and X. Huang,  
 1290 2015. 'Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and

- 1291 human beings in China: a microbiological and molecular biological study', *The Lancet Infectious*  
1292 *Diseases*, Vol. 16 (2), pp.161-168.
- 1293 Liu, Y., Y. Wang, S. Schwarz, Y. Li, Z. Shen, Q. Zhang, C. Wu, and J. Shen, 2012. 'Transferable  
1294 Multiresistance Plasmids Carrying cfr in *Enterococcus* spp. from Swine and Farm Environment',  
1295 *Antimicrobial Agents and Chemotherapy*, Vol.
- 1296 Loeffler, A., S. Baines, M. Toleman, D. Felmingham, S. Milsom, E. Edwards, and D. Lloyd, 2008. 'In  
1297 vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets',  
1298 *Journal of antimicrobial chemotherapy*, Vol. 62 (6), pp.1301-1304.
- 1299 Löfmark, S., H. Fang, M. Hedberg, and C. Edlund, 2005. 'Inducible metronidazole resistance and nim  
1300 genes in clinical *Bacteroides fragilis* group isolates', *Antimicrobial agents and chemotherapy*,  
1301 Vol. 49 (3), pp.1253-1256.
- 1302 Long, K.S., J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester, 2006. 'The Cfr rRNA  
1303 methyltransferase confers resistance to Phenicol, Lincosamides, Oxazolidinones,  
1304 Pleuromutilins, and Streptogramin A antibiotics', *Antimicrob Agents Chemother*, Vol. 50 (7),  
1305 pp.2500-2505.
- 1306 Luthman, J., and S. Jacobsson, 1983. 'The availability of tetracyclines in calves', *Nordisk*  
1307 *veterinaermedicin*, Vol. 35 (7-9), pp.292-299.
- 1308 MacKenzie, F., J. Bruce, M. Struelens, H. Goossens, J. Mollison, and I. Gould, 2007. 'Antimicrobial drug  
1309 use and infection control practices associated with the prevalence of methicillin-resistant  
1310 *Staphylococcus aureus* in European hospitals', *Clinical Microbiology and Infection*, Vol. 13 (3),  
1311 pp.269-276.
- 1312 Malik, S., H. Peng, and M.D. Barton, 2005. 'Antibiotic resistance in staphylococci associated with cats  
1313 and dogs', *Journal of applied microbiology*, Vol. 99 (6), pp.1283-1293.
- 1314 Manson, J.M., S. Keis, J.M. Smith, and G.M. Cook, 2004. 'Acquired bacitracin resistance in  
1315 *Enterococcus faecalis* is mediated by an ABC transporter and a novel regulatory protein, BcrR',  
1316 *Antimicrobial agents and chemotherapy*, Vol. 48 (10), pp.3743-3748.
- 1317 Mathers, A.J., G. Peirano, and J.D. Pitout. 2015. *Escherichia coli* ST131: the quintessential example of  
1318 an international multiresistant high-risk clone. In *Advances in applied microbiology*. Elsevier,  
1319 109-154.
- 1320 Mendes, R.E., L.M. Deshpande, and R.N. Jones, 2014. 'Linezolid update: stable in vitro activity  
1321 following more than a decade of clinical use and summary of associated resistance  
1322 mechanisms', *Drug Resistance Updates*, Vol. 17 (1-2), pp.1-12.
- 1323 Mendes, R.E., T.C. Smith, L. Deshpande, D.J. Diekema, H.S. Sader, and R.N. Jones, 2011. 'Plasmid-  
1324 borne vga(A)-encoding gene in methicillin-resistant *Staphylococcus aureus* ST398 recovered  
1325 from swine and a swine farmer in the United States', *Diagn Microbiol Infect Dis*, Vol. 71 (2),  
1326 pp.177-180.
- 1327 Miyamoto, Y., J. Kalisiak, K. Korthals, T. Lauwaet, D.Y. Cheung, R. Lozano, E.R. Cobo, P. Upcroft, J.A.  
1328 Upcroft, and D.E. Berg, 2013. 'Expanded therapeutic potential in activity space of next-  
1329 generation 5-nitroimidazole antimicrobials with broad structural diversity', *Proceedings of the*  
1330 *National Academy of Sciences*, Vol. 110 (43), pp.17564-17569.
- 1331 Monaco, M., T. Giani, M. Raffone, F. Arena, A. Garcia-Fernandez, S. Pollini, S.-I.C. Network Eu, H.  
1332 Grundmann, A. Pantosti, and G. Rossolini, 2014. 'Colistin resistance superimposed to endemic  
1333 carbapenem-resistant *Klebsiella pneumoniae*: a rapidly evolving problem in Italy, November  
1334 2013 to April 2014', *Euro surveillance: bulletin europeen sur les maladies transmissibles =*  
1335 *European communicable disease bulletin*, Vol. 19 (42), p.20939.
- 1336 Mulvey, M.R., E. Bryce, D.A. Boyd, M. Ofner-Agostini, A.M. Land, A.E. Simor, S. Paton, C.H.E.  
1337 Committee, and C.N.I.S. Program, 2005. 'Molecular characterization of cefoxitin-resistant  
1338 *Escherichia coli* from Canadian hospitals', *Antimicrobial agents and chemotherapy*, Vol. 49 (1),  
1339 pp.358-365.
- 1340 Nemeghaire, S., W. Vanderhaeghen, M.A. Argudín, F. Haesebrouck, and P. Butaye, 2014.  
1341 'Characterization of methicillin-resistant *Staphylococcus sciuri* isolates from industrially raised  
1342 pigs, cattle and broiler chickens', *Journal of Antimicrobial Chemotherapy*, Vol. 69 (11),  
1343 pp.2928-2934.
- 1344 Nguyen, M., and G. Vedantam, 2011. 'Mobile genetic elements in the genus *Bacteroides*, and their  
1345 mechanism (s) of dissemination', *Mobile genetic elements*, Vol. 1 (3), pp.187-196.
- 1346 Nikolich, M.P., G. Hong, N.B. Shoemaker, and A.A. Salyers, 1994. 'Evidence for natural horizontal  
1347 transfer of tetQ between bacteria that normally colonize humans and bacteria that normally  
1348 colonize livestock', *Applied and Environmental Microbiology*, Vol. 60 (9), pp.3255-3260.

- 1349 Norström, M., M. Sunde, H. Tharaldsen, T. Mørk, B. Bergsjø, and H. Kruse, 2009. 'Antimicrobial  
1350 resistance in Staphylococcus pseudintermedius in the Norwegian dog population', *Microbial*  
1351 *Drug Resistance*, Vol. 15 (1), pp.55-59.
- 1352 Obaidat, M.M., A.E.B. Salman, and A.A. Roess, 2018. 'High prevalence and antimicrobial resistance of  
1353 *mecA* Staphylococcus aureus in dairy cattle, sheep, and goat bulk tank milk in Jordan', *Tropical*  
1354 *animal health and production*, Vol. 50 (2), pp.405-412.
- 1355 Official Journal of the European Union. 2013. Commission Regulation (EU) No 122/2013 of 12 February  
1356 2013 amending Regulation (EC) No 1950/2006 establishing, in accordance with Directive  
1357 2001/82/EC of the European Parliament and of the Council on the Community code relating to  
1358 veterinary medicinal products, a list of substances essential for the treatment of equidae. In  
1359 [http://eur-lex.europa.eu/legal-](http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1416502774573&uri=CELEX:32013R0122)  
1360 [content/EN/TXT/?qid=1416502774573&uri=CELEX:32013R0122](http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1416502774573&uri=CELEX:32013R0122).
- 1361 Official Journal of the European Union, 2015. 'Commission notice - Guidelines for the prudent use of  
1362 antimicrobials in veterinary medicine (2015/C 299/04)',  
1363 [http://ec.europa.eu/health/antimicrobial\\_resistance/docs/2015\\_prudent\\_use\\_guidelines\\_en.pdf](http://ec.europa.eu/health/antimicrobial_resistance/docs/2015_prudent_use_guidelines_en.pdf)  
1364 [f](http://ec.europa.eu/health/antimicrobial_resistance/docs/2015_prudent_use_guidelines_en.pdf)
- 1365 Official Journal of the European Union, 2019. 'Regulation (EU) 2019/6 of the European Parliament and  
1366 of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive  
1367 2001/82/EC', [https://eur-lex.europa.eu/legal-](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32019R0006&from=EN)  
1368 [content/EN/TXT/PDF/?uri=CELEX:32019R0006&from=EN](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32019R0006&from=EN)
- 1369 OIE, 2018. 'OIE List Of Antimicrobial Agents Of Veterinary Importance',  
1370 [http://www.oie.int/fileadmin/Home/eng/Our\\_scientific\\_expertise/docs/pdf/AMR/A\\_OIE\\_List\\_an](http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/AMR/A_OIE_List_antimicrobials_May2018.pdf)  
1371 [timicrobials\\_May2018.pdf](http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/AMR/A_OIE_List_antimicrobials_May2018.pdf)
- 1372 Olsen, R.H., H.C. Schønheyder, H. Christensen, and M. Bisgaard, 2012. 'Enterococcus faecalis of  
1373 human and poultry origin share virulence genes supporting the zoonotic potential of E.  
1374 faecalis', *Zoonoses and public health*, Vol. 59 (4), pp.256-263.
- 1375 Osei Sekyere, J., 2018. 'Genomic insights into nitrofurantoin resistance mechanisms and epidemiology  
1376 in clinical Enterobacteriaceae', *Future Science OA*, Vol. (0),
- 1377 Oteo, J., B. Orden, V. Bautista, O. Cuevas, M. Arroyo, R. Martínez-Ruiz, M. Pérez-Vázquez, M. Alcaraz,  
1378 S. García-Cobos, and J. Campos, 2009. 'CTX-M-15-producing urinary Escherichia coli O25b-  
1379 ST131-phylogroup B2 has acquired resistance to fosfomycin', *Journal of antimicrobial*  
1380 *chemotherapy*, Vol. 64 (4), pp.712-717.
- 1381 Patel, J.B., R.J. Gorwitz, and J.A. Jernigan, 2009. 'Mupirocin resistance', *Clinical infectious diseases*,  
1382 Vol. 49 (6), pp.935-941.
- 1383 Peeters, L. 2018. Carry-over of tetracyclines and sulphonamides-trimethoprim in pig feed : resistance  
1384 selection in the pig microbiota caused by doxycycline (PhD dissertation). In Ghent University.
- 1385 Peeters, L.E., M.A. Argudín, S. Azadikhah, and P. Butaye, 2015. 'Antimicrobial resistance and  
1386 population structure of Staphylococcus aureus recovered from pigs farms', *Veterinary*  
1387 *microbiology*, Vol. 180 (1-2), pp.151-156.
- 1388 Peng, Z., D. Jin, H.B. Kim, C.W. Stratton, B. Wu, Y.-W. Tang, and X. Sun, 2017. 'Update on  
1389 antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial  
1390 susceptibility testing', *Journal of clinical microbiology*, Vol. 55 (7), pp.1998-2008.
- 1391 Pérez, D.S., M.O. Tapia, and A.L. Soraci, 2014. 'Fosfomycin: Uses and potentialities in veterinary  
1392 medicine', *Open veterinary journal*, Vol. 4 (1), pp.26-43.
- 1393 Perez, F., S.D. Rudin, S.H. Marshall, P. Coakley, L. Chen, B.N. Kreiswirth, P.N. Rather, A.M. Hujer, P.  
1394 Toltzis, and D. Van Duin, 2013. 'OqxAB, a quinolone and olaquinox efflux pump, is widely  
1395 distributed among multidrug-resistant Klebsiella pneumoniae isolates of human origin',  
1396 *Antimicrobial agents and chemotherapy*, Vol. 57 (9), pp.4602-4603.
- 1397 Persoons, D., J. Dewulf, A. Smet, L. Herman, M. Heyndrickx, A. Martel, B. Catry, P. Butaye, and F.  
1398 Haesebrouck, 2012. 'Antimicrobial use in Belgian broiler production', *Prev Vet Med*, Vol. 105  
1399 (4), pp.320-325.
- 1400 Persoons, D., F. Haesebrouck, A. Smet, L. Herman, M. Heyndrickx, A. Martel, B. Catry, A. Berge, P.  
1401 Butaye, and J. Dewulf, 2011. 'Risk factors for ceftiofur resistance in Escherichia coli from  
1402 Belgian broilers', *Epidemiology and infection*, Vol. 139 (05), pp.765-771.
- 1403 Pillar, C.M., M.K. Aranza, D. Shah, and D.F. Sahm, 2008. 'In vitro activity profile of ceftobiprole, an  
1404 anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of  
1405 European origin', *Journal of antimicrobial chemotherapy*, Vol. 61 (3), pp.595-602.
- 1406 Pirš, T., J. Avberšek, I. Zdovc, B. Krt, A. Andlovic, T. Lejko-Zupanc, M. Rupnik, and M. Ocepek, 2013.  
1407 'Antimicrobial susceptibility of animal and human isolates of Clostridium difficile by broth  
1408 microdilution', *Journal of medical microbiology*, Vol. 62 (9), pp.1478-1485.

- 1409 Poirel, L., V. Cattoir, and P. Nordmann, 2008. 'Is plasmid-mediated quinolone resistance a clinically  
1410 significant problem?', *Clinical Microbiology and Infection*, Vol. 14 (4), pp.295-297.
- 1411 Poulsen, H.O., A. Johansson, S. Granholm, G. Kahlmeter, and M. Sundqvist, 2013. 'High genetic  
1412 diversity of nitrofurantoin-or mecillinam-resistant *Escherichia coli* indicates low propensity for  
1413 clonal spread', *Journal of Antimicrobial Chemotherapy*, Vol. 68 (9), pp.1974-1977.
- 1414 Poulsen, L.L., M. Bisgaard, N.T. Son, N.V. Trung, H.M. An, and A. Dalsgaard, 2012. 'Enterococcus  
1415 faecalis clones in poultry and in humans with urinary tract infections, Vietnam', *Emerging  
1416 infectious diseases*, Vol. 18 (7), p.1096.
- 1417 Price, L.B., M. Stegger, H. Hasman, M. Aziz, J. Larsen, P.S. Andersen, T. Pearson, A.E. Waters, J.T.  
1418 Foster, and J. Schupp, 2012. 'Staphylococcus aureus CC398: host adaptation and emergence  
1419 of methicillin resistance in livestock', *MBio*, Vol. 3 (1),
- 1420 Pyorala, S., K.E. Baptiste, B. Catry, E. van Duijkeren, C. Greko, M.A. Moreno, M.C. Pomba, M. Rantala,  
1421 M. Ruzauskas, P. Sanders, E.J. Threlfall, J. Torren-Edo, and K. Torneke, 2014. 'Macrolides and  
1422 lincosamides in cattle and pigs: use and development of antimicrobial resistance', *Vet J*, Vol.  
1423 200 (2), pp.230-239.
- 1424 Rahman, M., W. Noble, and B. Cookson, 1989. 'Transmissible mupirocin resistance in *Staphylococcus  
1425 aureus*', *Epidemiology & Infection*, Vol. 102 (2), pp.261-270.
- 1426 Rice, L.B. 2012. Mechanisms of resistance and clinical relevance of resistance to  $\beta$ -lactams,  
1427 glycopeptides, and fluoroquinolones. In *Mayo Clinic Proceedings*. Elsevier, 198-208.
- 1428 Roberts, M.C., 2008. 'Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone  
1429 resistance genes', *FEMS Microbiology Letters*, Vol. 282 (2), pp.147-159.
- 1430 Roberts, M.C., 2011. 'Environmental macrolide-lincosamide-streptogramin and tetracycline resistant  
1431 bacteria', *Frontiers in Microbiology*, Vol. 2 p.40.
- 1432 Rossi, C.C., N.C. Ferreira, M.L. Coelho, R.P. Schuenck, M.d.C.d.F. Bastos, and M. Giambiagi-deMarval,  
1433 2016. 'Transfer of mupirocin resistance from *Staphylococcus haemolyticus* clinical strains to  
1434 *Staphylococcus aureus* through conjugative and mobilizable plasmids', *FEMS microbiology  
1435 letters*, Vol. 363 (14),
- 1436 Sala, C., A. Morar, E. Tirziu, I. Nichita, M. Imre, and K. Imre, 2016. 'Environmental occurrence and  
1437 antibiotic susceptibility profile of *Listeria monocytogenes* at a slaughterhouse raw processing  
1438 plant in Romania', *Journal of food protection*, Vol. 79 (10), pp.1794-1797.
- 1439 Sanchez Garcia, M., M.A. De la Torre, G. Morales, B. Pelaez, M.J. Tolon, S. Domingo, F.J. Candel, R.  
1440 Andrade, A. Arribi, N. Garcia, F. Martinez Sagasti, J. Fereres, and J. Picazo, 2010. 'Clinical  
1441 outbreak of linezolid-resistant *Staphylococcus aureus* in an intensive care unit', *JAMA*, Vol. 303  
1442 (22), pp.2260-2264.
- 1443 Sandegren, L., A. Lindqvist, G. Kahlmeter, and D.I. Andersson, 2008. 'Nitrofurantoin resistance  
1444 mechanism and fitness cost in *Escherichia coli*', *Journal of Antimicrobial Chemotherapy*, Vol. 62  
1445 (3), pp.495-503.
- 1446 Schwarz, S., C. Kehrenberg, B. Doublet, and A. Cloeckaert, 2004. 'Molecular basis of bacterial  
1447 resistance to chloramphenicol and florfenicol', *FEMS microbiology reviews*, Vol. 28 (5), pp.519-  
1448 542.
- 1449 Shen, J., Y. Wang, and S. Schwarz, 2013. 'Presence and dissemination of the multiresistance gene *cfr*  
1450 in Gram-positive and Gram-negative bacteria', *The Journal of Antimicrobial Chemotherapy*, Vol.  
1451 68 (8), pp.1697-1706.
- 1452 Shoemaker, N., H. Vlamakis, K. Hayes, and A. Salyers, 2001. 'Evidence for Extensive Resistance Gene  
1453 Transfer among *Bacteroides* spp. and among *Bacteroides* and Other Genera in the Human  
1454 Colon', *Applied and environmental microbiology*, Vol. 67 (2), pp.561-568.
- 1455 Silveira, E., A.R. Freitas, P. Antunes, M. Barros, J. Campos, T.M. Coque, L. Peixe, and C. Novais, 2013.  
1456 'Co-transfer of resistance to high concentrations of copper and first-line antibiotics among  
1457 *Enterococcus* from different origins (humans, animals, the environment and foods) and clonal  
1458 lineages', *Journal of Antimicrobial Chemotherapy*, Vol. 69 (4), pp.899-906.
- 1459 Simjee, S., Y. Zhang, P.F. McDermott, S.M. Donabedian, M.J. Zervos, and J. Meng, 2006.  
1460 'Heterogeneity of *vat* (E)-carrying plasmids in *Enterococcus faecium* recovered from human  
1461 and animal sources', *International journal of antimicrobial agents*, Vol. 28 (3), pp.200-205.
- 1462 Sköld, O., 2000. 'Sulfonamide resistance: mechanisms and trends', *Drug Resistance Updates*, Vol. 3  
1463 (3), pp.155-160.
- 1464 Sköld, O., 2001. 'Resistance to trimethoprim and sulfonamides', *Veterinary research*, Vol. 32 (3-4),  
1465 pp.261-273.
- 1466 Snyderman, D., L. McDermott, N. Jacobus, C. Thorpe, S. Stone, S. Jenkins, E. Goldstein, R. Patel, B.  
1467 Forbes, and S. Mirrett, 2015. 'US-based national sentinel surveillance study for the

- 1468 epidemiology of Clostridium difficile-associated diarrheal isolates and their susceptibility to  
1469 fidaxomicin', *Antimicrobial agents and chemotherapy*, Vol. 59 (10), pp.6437-6443.
- 1470 Snyderman, D.R., N.V. Jacobus, and L.A. McDermott, 2016. 'In vitro evaluation of the activity of  
1471 imipenem-relebactam against 451 recent clinical isolates of Bacteroides group and related  
1472 species', *Antimicrobial agents and chemotherapy*, Vol. 60 (10), pp.6393-6397.
- 1473 Sørum, H., and M. Sunde, 2001. 'Resistance to antibiotics in the normal flora of animals', *Veterinary  
1474 research*, Vol. 32 (3-4), pp.227-241.
- 1475 Sousa, M., N. Silva, V. Manageiro, S. Ramos, A. Coelho, D. Gonçalves, M. Caniça, C. Torres, G. Igrejas,  
1476 and P. Poeta, 2017. 'First report on MRSA CC398 recovered from wild boars in the north of  
1477 Portugal. Are we facing a problem?', *Science of the Total Environment*, Vol. 596 pp.26-31.
- 1478 Steed, M.E., and M.J. Rybak, 2010. 'Ceftaroline: a new cephalosporin with activity against resistant  
1479 Gram-positive pathogens', *Pharmacotherapy: The Journal of Human Pharmacology and Drug  
1480 Therapy*, Vol. 30 (4), pp.375-389.
- 1481 Steinman, A., M. Gips, E. Lavy, I. Sinay, and S. Soback, 2000. 'Pharmacokinetics of metronidazole in  
1482 horses after intravenous, rectal and oral administration', *Journal of veterinary pharmacology  
1483 and therapeutics*, Vol. 23 (6), pp.353-357.
- 1484 Tacconelli, E., E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D.L. Monnet, C. Pulcini, G.  
1485 Kahlmeter, J. Kluytmans, and Y. Carmeli, 2018. 'Discovery, research, and development of new  
1486 antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis', *The Lancet  
1487 Infectious Diseases*, Vol. 18 (3), pp.318-327.
- 1488 Thomas, J.K., A. Forrest, S.M. Bhavnani, J.M. Hyatt, A. Cheng, C.H. Ballou, and J.J. Schentag, 1998.  
1489 'Pharmacodynamic evaluation of factors associated with the development of bacterial  
1490 resistance in acutely ill patients during therapy', *Antimicrobial agents and chemotherapy*, Vol.  
1491 42 (3), pp.521-527.
- 1492 Thulin, E., M. Sundqvist, and D.I. Andersson, 2015. 'Amdinocillin (mecillinam) resistance mutations in  
1493 clinical isolates and laboratory-selected mutants of Escherichia coli', *Antimicrobial agents and  
1494 chemotherapy*, Vol. 59 (3), pp.1718-1727.
- 1495 Thulin, E., M. Thulin, and D.I. Andersson, 2017. 'Reversion of high-level mecillinam resistance to  
1496 susceptibility in Escherichia coli during growth in urine', *EBioMedicine*, Vol. 23 pp.111-118.
- 1497 Timmerman, T., J. Dewulf, B. Catry, B. Feyen, G. Opsomer, A. de Kruif, and D. Maes, 2006.  
1498 'Quantification and evaluation of antimicrobial drug use in group treatments for fattening pigs  
1499 in Belgium', *Prev Vet Med*, Vol. 74 (4), pp.251-263.
- 1500 Tupin, A., M. Gualtieri, F. Roquet-Banères, Z. Morichaud, K. Brodolin, and J.-P. Leonetti, 2010.  
1501 'Resistance to rifampicin: at the crossroads between ecological, genomic and medical  
1502 concerns', *International journal of antimicrobial agents*, Vol. 35 (6), pp.519-523.
- 1503 U.S. National Library of Medicine. last accessed: 2018. How to Request New Alleles for Beta-  
1504 Lactamase, MCR, and Qnr Genes. In [https://www.ncbi.nlm.nih.gov/pathogens/submit-beta-  
1505 lactamase/](https://www.ncbi.nlm.nih.gov/pathogens/submit-beta-lactamase/).
- 1506 Ugwu, C.C., E. Gomez-Sanz, I.C. Agbo, C. Torres, and K.F. Chah, 2015. 'Characterization of mannitol-  
1507 fermenting methicillin-resistant staphylococci isolated from pigs in Nigeria', *Brazilian Journal of  
1508 Microbiology*, Vol. 46 (3), pp.885-892.
- 1509 Unnerstad, H.E., K. Mieziowska, S. Börjesson, H. Hedbäck, K. Strand, T. Hallgren, H. Landin, J. Skarin,  
1510 and B. Bengtsson, 2018. 'Suspected transmission and subsequent spread of MRSA from farmer  
1511 to dairy cows', *Veterinary Microbiology*, Vol.
- 1512 van Duijkeren, E., B. Catry, C. Greko, M.A. Moreno, M.C. Pomba, S. Pyorala, M. Ruzauskas, P.  
1513 Sanders, E.J. Threlfall, J. Torren-Edo, and K. Torneke, 2011. 'Review on methicillin-resistant  
1514 Staphylococcus pseudintermedius', *J Antimicrob Chemother*, Vol. 66 (12), pp.2705-2714.
- 1515 Veziris, N., A. Chauffour, S. Escolano, S. Henquet, M. Matsuoka, V. Jarlier, and A. Aubry, 2013.  
1516 'Resistance of M. leprae to Quinolones: A Question of Relativity?', *PLoS neglected tropical  
1517 diseases*, Vol. 7 (11), p.e2559.
- 1518 Vila-Costa, M., R. Gioia, J. Aceña, S. Pérez, E.O. Casamayor, and J. Dachs, 2017. 'Degradation of  
1519 sulfonamides as a microbial resistance mechanism', *Water research*, Vol. 115 pp.309-317.
- 1520 Volkova, V., C. Cazer, and Y. Gröhn, 2017. 'Models of antimicrobial pressure on intestinal bacteria of  
1521 the treated host populations', *Epidemiology & Infection*, Vol. 145 (10), pp.2081-2094.
- 1522 Wachino, J.-i., K. Yamane, S. Suzuki, K. Kimura, and Y. Arakawa, 2010. 'Prevalence of fosfomycin  
1523 resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification  
1524 of novel plasmid-mediated fosfomycin-modifying enzymes', *Antimicrobial agents and  
1525 chemotherapy*, Vol. 54 (7), pp.3061-3064.

- 1526 Wang, X.-M., X.-S. Li, Y.-B. Wang, F.-S. Wei, S.-M. Zhang, Y.-H. Shang, and X.-D. Du, 2014.  
1527 'Characterization of a multidrug resistance plasmid from *Enterococcus faecium* that harbours a  
1528 mobilized *bcrABDR* locus', *Journal of Antimicrobial Chemotherapy*, Vol. 70 (2), pp.609-611.
- 1529 Wang, Y., Y. Lv, J. Cai, S. Schwarz, L. Cui, Z. Hu, R. Zhang, J. Li, Q. Zhao, and T. He, 2015. 'A novel  
1530 gene, *optrA*, that confers transferable resistance to oxazolidinones and phenicols and its  
1531 presence in *Enterococcus faecalis* and *Enterococcus faecium* of human and animal origin',  
1532 *Journal of Antimicrobial Chemotherapy*, Vol. 70 (8), pp.2182-2190.
- 1533 Ward, M., C. Gibbons, P. McAdam, B. Van Bunnik, E. Girvan, G. Edwards, J.R. Fitzgerald, and M.  
1534 Woolhouse, 2014. 'Time-scaled evolutionary analysis of the transmission and antibiotic  
1535 resistance dynamics of *Staphylococcus aureus* CC398', *Applied and environmental  
1536 microbiology*, Vol. pp.AEM. 01777-01714.
- 1537 Wendlandt, S., A.T. Fessler, S. Monecke, R. Ehricht, S. Schwarz, and K. Kadlec, 2013a. 'The diversity  
1538 of antimicrobial resistance genes among staphylococci of animal origin', *Int J Med Microbiol*,  
1539 Vol. 303 (6-7), pp.338-349.
- 1540 Wendlandt, S., K. Kadlec, A.T. Feßler, S. Monecke, R. Ehricht, A.W. van de Giessen, P.D. Hengeveld, X.  
1541 Huijsdens, S. Schwarz, and E. van Duijkeren, 2013b. 'Resistance phenotypes and genotypes of  
1542 methicillin-resistant *Staphylococcus aureus* isolates from broiler chickens at slaughter and  
1543 abattoir workers', *Journal of Antimicrobial Chemotherapy*, Vol. 68 (11), pp.2458-2463.
- 1544 Wendlandt, S., C. Lozano, K. Kadlec, E. Gomez-Sanz, M. Zarazaga, C. Torres, and S. Schwarz, 2012.  
1545 'The enterococcal ABC transporter gene *Isa(E)* confers combined resistance to lincosamides,  
1546 pleuromutilins and streptogramin A antibiotics in methicillin-susceptible and methicillin-  
1547 resistant *Staphylococcus aureus*', *J Antimicrob Chemother*, Vol.
- 1548 Werckenthin, C., M. Cardoso, J.-L. Martel, and S. Schwarz, 2001. 'Antimicrobial resistance in  
1549 staphylococci from animals with particular reference to bovine *Staphylococcus aureus*, porcine  
1550 *Staphylococcus hyicus*, and canine *Staphylococcus intermedius*', *Veterinary research*, Vol. 32  
1551 (3-4), pp.341-362.
- 1552 WHO, 2003. 'Joint FAO/OIE/WHO Expert Workshop on Non-Human Antimicrobial Usage and  
1553 Antimicrobial Resistance: scientific assessment: 1–5 December 2003, Geneva, Switzerland  
1554 (WHO/CDS/CPE/ZFK/2004.7)',  
1555 [http://apps.who.int/iris/bitstream/handle/10665/68883/WHO\\_CDS\\_CPE\\_ZFK\\_2004.7.pdf;jsess  
1556 ionid=2D03D9861B4F4EB615838D9B0811E5AB?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/68883/WHO_CDS_CPE_ZFK_2004.7.pdf;jsessionid=2D03D9861B4F4EB615838D9B0811E5AB?sequence=1)
- 1557 WHO, 2004. 'Second joint FAO/OIE/WHO expert workshop on non-human antimicrobial usage and  
1558 antimicrobial resistance: Management options. 15–18 March 2004, Oslo, Norway  
1559 (WHO/CDS/CPE/ZFK/2004.8)', 15-18. [http://www.who.int/foodsafety/publications/amr-  
1560 management/en/](http://www.who.int/foodsafety/publications/amr-management/en/)
- 1561 WHO, 2005. 'Critically important antibacterial agents for human medicine for risk management  
1562 strategies of non-human use: report of a WHO working group consultation, 15 - 18 February  
1563 2005. Canberra, Australia.', [http://www.who.int/foodsafety/publications/antibacterial-  
1564 agent/en/](http://www.who.int/foodsafety/publications/antibacterial-agent/en/)
- 1565 WHO, 2007. 'Critically Important Antimicrobials for Human Medicine. Report of the Second WHO Expert  
1566 Meeting Copenhagen, 29–31 May 2007',  
1567 [http://apps.who.int/iris/bitstream/10665/43765/1/9789241595742\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/43765/1/9789241595742_eng.pdf?ua=1)
- 1568 WHO, 2011. 'Critically Important Antimicrobials for Human Medicine (2nd revision)',  
1569 <http://www.who.int/foodsafety/publications/antimicrobials-second/en/>
- 1570 WHO, 2012. 'Critically important antimicrobials for human medicine - 3rd revision 2011',  
1571 31. <http://www.who.int/foodsafety/publications/antimicrobials-third/en/>
- 1572 WHO, 2016. 'Critically Important Antimicrobials for Human Medicine (4th revision) 2013',  
1573 <http://www.who.int/foodsafety/publications/antimicrobials-fourth/en/>
- 1574 WHO, 2017a. 'Critically Important Antimicrobials for Human Medicine (5th revision) 2016',  
1575 <http://www.who.int/foodsafety/publications/antimicrobials-fifth/en/>
- 1576 WHO, 2017b. 'Executive summary: The selection and use of essential medicines 2017. In: Report of  
1577 the 21st WHO Expert Committee on the Selection and Use of Essential Medicines',  
1578 [http://www.who.int/medicines/publications/essentialmedicines/EML\\_2017\\_ExecutiveSummary.  
1579 pdf](http://www.who.int/medicines/publications/essentialmedicines/EML_2017_ExecutiveSummary.pdf)
- 1580 WHO, 2017c. 'Global priority list of antibiotic-resistant bacteria to guide research, discovery, and  
1581 development of new antibiotics', [http://www.who.int/medicines/publications/WHO-PPL-  
1582 Short\\_Summary\\_25Feb-ET\\_NM\\_WHO.pdf](http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf)
- 1583 WHO, 2017d. 'Prioritization of pathogens to guide discovery, research and development of new  
1584 antibiotics for drug-resistant bacterial infections, including tuberculosis.

1585 (WHO/EMP/IAU/2017.12)', [http://www.who.int/medicines/areas/rational\\_use/prioritization-of-](http://www.who.int/medicines/areas/rational_use/prioritization-of-pathogens/en/)  
1586 [pathogens/en/](http://www.who.int/medicines/areas/rational_use/prioritization-of-pathogens/en/)  
1587 WHO, 2017e. 'WHO guidelines on use of medically important antimicrobials in food-producing animals',  
1588 [http://www.who.int/foodsafety/publications/cia\\_guidelines/en/](http://www.who.int/foodsafety/publications/cia_guidelines/en/)  
1589 Wiuff, C., J. Lykkesfeldt, O. Svendsen, and F.M. Aarestrup, 2003. 'The effects of oral and intramuscular  
1590 administration and dose escalation of enrofloxacin on the selection of quinolone resistance  
1591 among Salmonella and coliforms in pigs', *Research in veterinary science*, Vol. 75 (3), pp.185-  
1592 193.  
1593 Zaheer, R., S. Cook, C. Klima, K. Stanford, T. Alexander, E. Topp, R. Read, and T. Mcallister, 2013.  
1594 'Effect of subtherapeutic vs. therapeutic administration of macrolides on antimicrobial  
1595 resistance in Mannheimia haemolytica and enterococci isolated from beef cattle', *Frontiers in*  
1596 *microbiology*, Vol. 4 p.133.  
1597 Zaura, E., B.W. Brandt, M.J.T. de Mattos, M.J. Buijs, M.P. Caspers, M.-U. Rashid, A. Weintraub, C.E.  
1598 Nord, A. Savell, and Y. Hu, 2015. 'Same Exposure but Two Radically Different Responses to  
1599 Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces',  
1600 *mBio*, Vol. 6 (6), pp.e01693-01615.  
1601 Zhang, L., Y. Huang, Y. Zhou, T. Buckley, and H.H. Wang, 2013. 'Antibiotic administration routes  
1602 significantly influence the levels of antibiotic resistance in gut microbiota', *Antimicrobial agents*  
1603 *and chemotherapy*, Vol. 57 (8), pp.3659-3666.  
1604 Zhao, Q., Y. Wang, S. Wang, Z. Wang, X.-d. Du, H. Jiang, X. Xia, Z. Shen, S. Ding, and C. Wu, 2016.  
1605 'Prevalence and abundance of florfenicol and linezolid resistance genes in soils adjacent to  
1606 swine feedlots', *Scientific reports*, Vol. 6 p.32192.  
1607 Zhao, X., and K. Drlica, 2001. 'Restricting the selection of antibiotic-resistant mutants: a general  
1608 strategy derived from fluoroquinolone studies', *Clinical Infectious Diseases*, Vol. 33  
1609 (Supplement\_3), pp.S147-S156.  
1610